In O O
the O O
lymphocytes O O
with O O
a O O
high O O
GR B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
number O O
, O O
dexamethasone O O
inhibited O O
[ O O
3H O O
] O O
-thymidine O O
and O O
[ O O
3H O O
] O O
-acetate O O
incorporation O O
into O O
DNA O O
and O O
cholesterol O O
, O O
respectively O O
, O O
in O O
the O O
same O O
manner O O
as O O
in O O
the O O
control O O
cells O O
. O O

On O O
the O O
other O O
hand O O
, O O
a O O
decreased O O
GR B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
number O O
resulted O O
in O O
a O O
less O O
efficient O O
dexamethasone O O
inhibition O O
of O O
the O O
incorporation O O
of O O
labeled O O
compounds O O
. O O

These O O
data O O
showed O O
that O O
the O O
sensitivity O O
of O O
lymphocytes O O
to O O
glucocorticoids O O
changed O O
only O O
with O O
a O O
decrease O O
of O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
level O O
. O O

[ O O
1 B B_DISEASE_ADJECTIVE[DISEASE]
, I I_DISEASE_ADJECTIVE[DISEASE]
25-Dihydroxyvitamin I I_DISEASE_ADJECTIVE[DISEASE]
D3 I I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DISEASE_ADJECTIVE[DISEASE]
in O O
lymphocytes O O
and O O
T- O O
and O O
B-lymphocyte O O
count O O
in O O
patients O O
with O O
glomerulonephritis O O
] O O

Content O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
hormonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
vitamin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
D3 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
1.25 O B_MEASURE/B_LOCATION
( O O
OH O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O O
constituted O O
27.3 O B_MEASURE/B_ENT
fmole/mg O I_MEASURE/I_ENT
of O O
protein O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BACTERIUM[BIO]
in O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
peripheric O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
children O B_PERSON/B_BIO
with O O
glomerulonephritis O B_DISEASE
. O O

In O O
the O O
patients O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
concentration O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
of O O
total O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ionized O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
form O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
Ca2+ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
decreased O O
down O O
to O O
2.04 O B_MEASURE
mmole/L O I_MEASURE
and O O
1.09 O B_MEASURE/B_LOCATION
mmole/L O I_MEASURE/I_LOCATION
, O O
respectively O O
, O O
while O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
parathormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
PTH O B_PROTEIN[GENE]/B_LOCATION
) O O
by O O
36 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
and O O
a O O
distinct O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decrease O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
25 O B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
OH O O
) O O
D O B_PROTEIN[GENE]
concentration O I_PROTEIN[GENE]
( O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
1.25 O B_MEASURE
ng/ml O I_MEASURE
) O O
was O O
found O O
in O O
blood O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O O
content O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cAMP O B_GENE
was O O
also O O
decreased O O
in O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
33 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
% O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

At O O
the O O
same O B_TIME[MEASURE]/B_LOCATION
time O I_TIME[MEASURE]/I_LOCATION
, O O
total O B_MEASURE/B_ENT
content O I_MEASURE/I_ENT
of O O
T O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lymphocytes O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
decreased O O
1.5-fold O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
peripheric O B_PERSON/B_DISEASE
blood O I_PERSON/I_DISEASE
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
1- O B_MEASURE
( O O
OH O O
) O O
D3 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
normalized O O
also O O
the O O
T O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
lymphocytes O O
content O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
peripheric O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

The O O
data O O
obtained O O
suggest O O
that O O
under O O
conditions O O
of O O
glomerulonephritis O O
only O O
high O O
content O O
of O O
receptors B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
1.25 O O
( O O
OH O O
) O O
2D3 O O
in O O
lymphocytes O O
enabled O O
to O O
perform O O
the O O
cell O O
response O O
to O O
the O O
hormone O O
effect O O
. O O

Tumor O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
serum O O
beta-2-microglobulin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
women O B_PERSON/B_BIO
with O O
breast O B_DISEASE/B_LOCATION
cancer O I_DISEASE/I_LOCATION
. O O

Likewise O O
, O O
beta B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2-M I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
associated O O
with O O
markers O O
of O O
disease O O
extension O O
such O O
as O O
TNM O O
, O O
( O O
UICC O O
, O O
classification O O
of O O
malignant O O
tumors O O
) O O
staging O O
and O O
axillary O O
lymph O O
node O O
involvement O O
or O O
with O O
estrogen O O
, O O
progesterone O O
, O O
and O O
glucocorticoid O O
receptor O O
levels O O
. O O

Although O O
some O O
of O O
the O O
highest O O
values O O
had O O
been O O
obtained O O
in O O
women O O
with O O
larger O O
( O O
T4 O O
) O O
primary O O
tumors O O
, O O
the O O
authors O O
failed O O
to O O
detect O O
any O O
statistical O O
relationship O O
between O O
beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2-M I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
in O O
the O O
tumor O O
with O O
serum O O
levels O O
or O O
between O O
serum B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
beta I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2-M I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
above O O
histologic O O
, O O
laboratory O O
, O O
and O O
clinical O O
factors O O
. O O

In O O
137 O O
cases O O
of O O
childbearing-aged O O
and O O
pregnant O O
women O O
, O O
free B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
( O O
sE B B_LOCATION/B_ORGANIZATION
) O O
in O O
serum O O
were O O
measured O O
by O O
ELISA O O
. O O

Mutation O O
of O O
a O O
kappa B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
B I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
core I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
sequence I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
identified O O
in O O
the O O
IL-2 B B_GENE
promoter I I_GENE
( O O
-206 O O
to O O
-195 O O
) O O
partially O O
inhibits O O
both O O
mitogen- O O
and O O
HTLV-I O O
Tax-mediated O O
activation O O
of O O
this O O
transcription B B_GENE/B_LOCATION
unit I I_GENE/I_LOCATION
and O O
blocks O O
the O O
specific O O
binding O O
of O O
two O O
inducible B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cellular I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
factors I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

The O O
principal O O
distinction O O
of O O
the O O
method O O
is O O
standardization O O
by O O
the O O
lymphocyte O O
count O O
in O O
a O O
sample O O
( O O
1 O O
mln O O
) O O
and O O
the O O
labeled O O
hormone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
concentration O O
. O O

Examinations O O
of O O
70 O O
children O O
aged O O
4 O O
to O O
15 O O
suffering O O
from O O
the O O
nephrotic O O
form O O
of O O
glomerulonephritis O O
have O O
made O O
it O O
possible O O
to O O
distinguish O O
two O O
groups O O
of O O
patients O O
: O O
with O O
relatively O O
high O O
values O O
of O O
specific O O
binding O O
X O O
= O O
6820.1 O O
+/- O O
530.0 O O
( O O
n O O
= O O
30 O O
, O O
p O O
= O O
0.95 O O
, O O
t O O
= O O
2.04 O O
) O O
, O O
this O O
corresponding O O
to O O
a O O
clinical O O
form O O
of O O
hormone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-sensitive O O
glomerulonephritis O O
, O O
and O O
with O O
relatively O O
low O O
values O O
of O O
specific O O
binding O O
X O O
= O O
1815.2 O O
+/- O O
302.8 O O
( O O
n O O
= O O
40 O O
, O O
p O O
= O O
0.95 O O
, O O
t O O
= O O
1.96 O O
) O O
, O O
that O O
corresponds O O
to O O
hormone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
-resistant O O
glomerulonephritis O O
. O O

These O O
results O O
permit O O
regarding O O
the O O
specific O O
binding O O
value O O
as O O
a O O
prognostic O O
criterion O O
in O O
the O O
assessment O O
of O O
corticosteroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O O
; O O
this O O
allows O O
a O O
wide O O
employment O O
of O O
the O O
described O O
method O O
in O O
practical O O
nephrology O O
. O O

Two O O
nuclear B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
bind O O
specifically O O
and O O
with O O
high O O
affinity O O
to O O
the O O
OCTA B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
element I B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
have O O
been O O
identified O O
. O O

Identification O O
of O O
a O O
putative O O
regulator O O
of O O
early B B_DISEASE
T I I_DISEASE
cell I I_DISEASE
activation I I_DISEASE
genes I I_DISEASE
. O O

Separation O O
of O O
bound O O
from O O
free O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
125I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
extracts O O
was O O
achieved O O
using O O
the O O
calcium O O
phosphate O O
matrix O O
, O O
hydroxyapatite O O
at O O
a O O
concentration O O
of O O
0.3 O O
ml O O
of O O
a O O
150 O O
g/l O O
slurry O O
. O O

Under O O
these O O
conditions O O
T3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
nuclear O O
extracts O O
were O O
present O O
at O O
a O O
concentration O O
of O O
22.4 O O
+/- O O
8.6 O O
fmol/mg O O
protein O O
and O O
showed O O
an O O
affinity O O
of O O
( O O
Kd O O
, O O
room O O
temperature O O
) O O
140 O O
+/- O O
10 O O
pmol/l O O
. O O

Calling O O
T3 O B_MEASURE/B_PERSON
100 O I_MEASURE/I_PERSON
, O O
the O O
order O B_MEASURE/B_DISEASE
of O O
potencies O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
observed O O
was O O
: O O
Triac O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
500 O B_MEASURE
; O O
3 O B_NUMBER[MEASURE]
, O O
5-diiodo-3'-isopropylthyronine O B_TIME[MEASURE]
, O O
89 O B_MEASURE
; O O
T4 O B_PROTEIN[GENE]
, O O
32 O B_MEASURE
; O O
3 O B_NUMBER[MEASURE]
, O O
5-dimethyl-3'isopropylthyronine O B_TIME[MEASURE]
2 O I_TIME[MEASURE]
; O O
3 O B_NUMBER[MEASURE]
, O O
5-T2 O B_MEASURE
, O O
0.7 O B_MEASURE
, O O
rT3 O B_MEASURE/B_PROTEIN[GENE]
, O O
0.4 O B_MEASURE
; O O
3'5'-T2 O B_PROTEIN[GENE]/B_MEASURE
, O O
less O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
0.01 O B_MEASURE/B_LOCATION
. O O

These O O
results O O
suggest O O
that O O
the O O
T3 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
present O O
in O O
human O O
IM-9 O O
lymphocyte O O
nuclei O O
and O O
extracts O O
thereof O O
are O O
thyroid B B_DISEASE_ADJECTIVE[DISEASE]
hormone I I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
cells O O
may O O
be O O
a O O
useful O O
tool O O
to O O
increase O O
our O O
understanding O O
of O O
human B B_DISEASE
T3 I I_DISEASE
receptors I I_DISEASE

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
there O O
was O O
a O O
significant O B_MEASURE/B_PERSON
correlation O I_MEASURE/I_PERSON
between O O
the O O
maximum O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
increase O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
polymorphonuclear O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
leukocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O O
the O O
maximum O B_MEASURE
decrease O I_MEASURE
in O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O O
r O B_GENE/B_OTHER
= O O
0.7514 O B_MEASURE
, O O
p O B_MEASURE
less O I_MEASURE
than O O
0.0003 O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

Estradiol O O
receptors O O
in O O
the O O
cytosol O O
of O O
peripheral O O
blood O O
mononuclear O O
cells O O
in O O
hepatitis O O
B O O
virus O O
carriers O O
treated O O
with O O
interferon-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Estradiol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
cytosol O O
of O O
peripheral O O
blood O O
mononuclear O O
cells O O
and O O
the O O
effects O O
of O O
interferon-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IFN-alpha B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
on O O
estradiol B B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptors I I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
studied O O
in O O
asymptomatic O O
hepatitis O O
B O O
virus O O
( O O
HBV O O
) O O
carriers O O
, O O
patients O O
with O O
chronic O O
hepatitis O O
B O O
and O O
normal O O
controls O O
. O O

Tumor-bearing O O
patients O B_PERSON/B_SPECIES[BIO]
with O O
breast O B_DISEASE
cancer O I_DISEASE
were O O
assayed O O
for O O
their O O
natural O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
killer O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
NK O B_PROTEIN[GENE]/B_LOCATION
) O O
cell O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
for O O
the O O
function O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
activated O O
cytotoxic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T-cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
assessed O O
by O O
lectin-dependent O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cellular O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytotoxicity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LDCC O B_DISEASE/B_LOCATION
) O O
. O O

Although O O
the O O
enhanced O O
NK O O
cell O O
activity O O
and O O
LDCC O O
were O O
closely O O
associated O O
with O O
high O O
levels O O
( O O
greater O O
than O O
31 O O
fmol/mg O O
) O O
of O O
estrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ER B B_PROTEIN[GENE]/B_LOCATION
) O O
content O O
in O O
the O O
primary O O
tumor O O
, O O
no O O
other O O
clinical O O
or O O
histologic O O
correlation O O
between O O
the O O
increase O O
in O O
either O O
parameter O O
of O O
cytotoxic O O
effector O O
cell O O
function O O
could O O
be O O
found O O
. O O

Reduced O O
numbers O O
and O O
normal O O
affinity O O
of O O
GR B B_LOCATION/B_ORGANIZATION
were O O
found O O
in O O
the O O
Epstein-Barr O O
virus-transformed O O
lymphocytes O O
from O O
both O O
patients O O
while O O
the O O
son O O
and O O
daughter O O
had O O
normal O O
numbers O O
and O O
affinity O O
of O O
GR B B_PROTEIN[GENE]/B_DISEASE
. O O

The O O
thermal O O
stability O O
of O O
GR B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O O
thermal O O
activation O O
of O O
cytosolic B B_PROTEIN[GENE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_PROTEIN[GENE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
patients O O
were O O
found O O
to O O
be O O
normal O O
. O O

These O O
abnormal O O
properties O O
of O O
GR B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
( O O
reduced O O
numbers O O
of O O
GR B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
) O O
were O O
preserved O O
in O O
the O O
transformed O O
cells O O
from O O
the O O
patients O O
. O O

Octamer O O
transcription O O
factors O O
1 O O
and O O
2 O O
each O O
bind O O
to O O
two O O
different O O
functional B B_LOCATION/B_BIO
elements I I_LOCATION/I_BIO
in O O
the O O
immunoglobulin B B_GENE
heavy-chain I I_GENE
promoter I I_GENE
. O O

The O O
present O O
study O O
demonstrates O O
that O O
both O O
the O O
ubiquitous B B_GENE/B_LOCATION
and I I_GENE/I_LOCATION
lymphoid-cell-specific I I_GENE/I_LOCATION
octamer I I_GENE/I_LOCATION
transcription I I_GENE/I_LOCATION
factors I I_GENE/I_LOCATION
( O O
OTF-1 B B_GENE
and O O
OTF-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
respectively O O
) O O
interact O O
specifically O O
with O O
each O O
of O O
the O O
two O O
conserved B B_GENE/B_LOCATION
sequence I I_GENE/I_LOCATION
elements I I_GENE/I_LOCATION
, O O
forming O O
either O O
homo- B B_LOCATION/B_PERSON
or I I_LOCATION/I_PERSON
heterodimeric I I_LOCATION/I_PERSON
complexes I I_LOCATION/I_PERSON
. O O

Binding O O
of O O
either O O
factor O O
to O O
the O O
octamer B B_LOCATION/B_BIO
element I B_LOCATION/I_BIO
occurred O O
independently O O
. O O

However O O
, O O
OTF B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
interaction O O
with O O
the O O
heptamer B B_GENE/B_LOCATION
sequence I I_GENE/I_LOCATION
appeared O O
to O O
require O O
the O O
presence O O
of O O
an O O
intact O O
octamer O O
motif O O
and O O
occurred O O
with O O
a O O
spacing O O
of O O
either O O
2 B B_LOCATION/B_PERSON
or I I_LOCATION/I_PERSON
14 I I_LOCATION/I_PERSON
base I I_LOCATION/I_PERSON
pairs I I_LOCATION/I_PERSON
between O O
the O O
two O O
elements O O
, O O
suggesting O O
coordinate O O
binding O O
resulting O O
from O O
protein-protein O O
interactions O O
. O O

Possible O O
involvement O O
of O O
an O O
inhibitory B B_PERSON/B_ORGANIZATION
protein I I_PERSON/I_ORGANIZATION
. O O

A O O
complete O O
inhibition O O
of O O
DNA O O
synthesis O O
by O O
dexamethasone O O
( O O
Dx O O
) O O
could O O
be O O
observed O O
when O O
IL O O
2-depleted O O
cultures O O
of O O
CTL O O
were O O
either O O
incubated O O
for O O
6 O O
h O O
with O O
the O O
hormone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prior O O
to O O
the O O
addition O O
of O O
IL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O O
treated O O
simultaneously O O
with O O
Dx O O
and O O
a O O
low O O
concentration O O
of O O
IL B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
action O O
of O O
these O O
hormones B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possibly O O
involves O O
the O O
synthesis O O
of O O
an O O
inhibitory B B_GENE
protein I I_GENE
( O O
s O O
) O O
, O O
since O O
the O O
presence O O
of O O
cycloheximide O O
during O O
the O O
incubation O O
with O O
Dx O O
prevented O O
the O O
inhibition O O
of O O
DNA O O
synthesis O O
. O O

The O O
octamer O O
sequence O O
5'-ATGCAAAT O O
, O O
in O O
either O O
orientation O O
, O O
serves O O
as O O
an O O
upstream B B_GENE/B_PERSON
element I I_GENE/I_PERSON
in O O
a O O
variety O O
of O O
promoters B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
also O O
occurs O O
as O O
a O O
modular B B_GENE/B_PERSON
enhancer I I_GENE/I_PERSON
element I I_GENE/I_PERSON
. O O

We O O
report O O
here O O
the O O
chromatographic O O
separation O O
of O O
ubiquitous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
cell-specific I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
octamer-binding I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
proteins I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

Each O O
of O O
the O O
polypeptides O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
renatured O O
after O O
SDS-PAGE O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
shown O O
to O O
bind O O
to O O
the O O
octamer O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
addition O O
to O O
the O O
ubiquitous B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
B I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
cell-specific I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
octamer-binding I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factors I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
we O O
identified O O
several O O
additional O O
proteins O O
, O O
one O O
of O O
which O O
is O O
B O O
cell O O
-specific O O
, O O
that O O
interact O O
with O O
the O O
kappa B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
. O O

In O O
the O O
cytosol O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cultured O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
skin O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
fibroblasts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
from O O
the O O
patient O B_PERSON/B_BIO
, O O
there O O
was O O
also O O
decreased O O
binding O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capacity O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
thermal O B_MEASURE/B_LOCATION
stability O I_MEASURE/I_LOCATION
and O O
the O O
sedimentation O B_MEASURE
coefficient O I_MEASURE
in O O
a O O
sucrose O B_MEASURE
density O I_MEASURE
gradient O I_MEASURE
of O O
the O O
receptors O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
cytosol O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
cultured O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
skin O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fibroblasts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
the O O
patient O B_PERSON/B_DISEASE
and O O
normal O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
were O O
similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

GR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
complex O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
analyzed O O
by O O
DEAE-cellulose O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
was O O
decreased O O
in O O
the O O
patient O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
results O O
suggest O O
that O O
the O O
patient O O
's O O
glucocorticoid O O
resistance O O
was O O
due O O
to O O
a O O
decrease O O
in O O
the O O
affinity O O
of O O
the O O
receptor O O
for O O
glucocorticoids O O
and O O
a O O
decrease O O
in O O
the O O
binding O O
of O O
the O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
complex I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
DNA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Granulocyte-macrophage B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
colony-stimulating I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
factor I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

In O O
contrast O O
, O O
cells O O
from O O
a O O
HTLV-1 O O
transformed O O
T O O
lymphocyte O O
line O O
( O O
Ab-VDR O O
) O O
established O O
from O O
a O O
patient O O
with O O
vitamin O O
D-resistant O O
rickets O O
type O O
II O O
with O O
undetectable O O
1 B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
25 I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OH I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2D3 I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cellular I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
resistant O O
to O O
the O O
action O O
of O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
. O O

The O O
affinity O B_GENE/B_MEASURE
of O O
these O O
receptors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
to O O
be O O
decreased O O
, O O
by O O
more O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
on O O
average O B_MEASURE/B_SOCIAL_CIRCUMSTANCES
, O O
in O O
the O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
influence O O
of O O
cortisol O O
on O O
thyroid B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discussed O O
here O O
might O O
account O O
for O O
the O O
clinical O O
observations O O
mentioned O O
above O O
. O O

The O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
natural O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
killer O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
NK O B_PROTEIN[GENE]/B_LOCATION
) O O
activity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peripheral O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mononuclear O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PBM O B_LOCATION
) O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
studied O O
in O O
vitro O B_MEASURE/B_LOCATION
using O O
a O O
direct O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
4-h O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
51Cr-release O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
assay O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
K O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
562 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
line O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
as O O
a O O
target O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O O
able O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
minimize O O
the O O
enhancement O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
NK O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cytotoxicity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
obtainable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O O
the O O
presence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
immune O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
interferon O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
IFN-gamma O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Data O O
obtained O O
with O O
the O O
use O O
of O O
antiglucocorticoids O O
and O O
the O O
anti-CBG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
are O O
compatible O O
with O O
a O O
role O O
both O O
of O O
high-affinity O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
of O O
CBG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
mediating O O
cortisol O O
action O O
on O O
the O O
human O O
NK O O
cell O O
activity O O
. O O

Octamer-containing B B_PERSON/B_LOCATION
fragments I I_PERSON/I_LOCATION
have O O
been O O
reported O O
to O O
bind O O
a O O
factor O O
present O O
in O O
nuclear O O
extracts O O
of O O
human O O
cell O O
lines O O
; O O
however O O
, O O
identical O O
binding O O
activity O O
was O O
detected O O
in O O
both O O
B O O
lymphoid O O
and O O
non-lymphoid O O
cells O O
. O O

Mixing O O
of O O
HeLa O B_VIRUS[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
MT-2 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
extracts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O O
the O O
presence O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O O
a O O
LTR-specific O B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulating O I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
MT-2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
extracts O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Trans-acting B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
factors I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O O
mediate O O
B-cell O O
specific O O
transcription O O
of O O
immunoglobulin B B_GENE
genes I I_GENE
have O O
been O O
postulated O O
based O O
on O O
an O O
analysis O O
of O O
the O O
expression O O
of O O
exogenously O O
introduced O O
immunoglobulin B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recombinants I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
lymphoid O O
and O O
non-lymphoid O O
cells O O
. O O

We O O
report O O
here O O
the O O
identification O O
of O O
a O O
human B B_PROTEIN[GENE]/B_MEASURE
B-cell I I_PROTEIN[GENE]/I_MEASURE
nuclear I I_PROTEIN[GENE]/I_MEASURE
factor I I_PROTEIN[GENE]/I_MEASURE
( O O
IgNF-A B B_GENE
) O O
that O O
binds O O
to O O
DNA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sequences I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
upstream B B_LOCATION/B_BIO
regions I I_LOCATION/I_BIO
of O O
both O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
heavy I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
light-chain I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
also O O
to O O
the O O
mouse B B_GENE/B_BIO
heavy-chain I I_GENE/I_BIO
gene I I_GENE/I_BIO
enhancer I I_GENE/I_BIO
. O O

Many O B_PERSON
New O I_PERSON
World O I_PERSON
primate O I_PERSON
species O I_PERSON
have O O
greatly O O
increased O O
plasma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
cortisol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
concentrations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
, O O
decreased O O
plasma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cortisol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding O O
globulin O B_MEASURE/B_LOCATION
capacity O I_MEASURE/I_LOCATION
and O O
affinity O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
marked O B_DISEASE
resistance O I_DISEASE
of O O
the O O
hypothalamic-pituitary-adrenal O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
axis O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
to O O
suppression O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
no O O
biological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
glucocorticoid O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excess O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
glucocorticoid O O
target O O
tissues O O
that O O
have O O
been O O
examined O O
( O O
circulating O O
mononuclear O O
lymphocytes O O
and O O
cultured O O
skin O O
fibroblasts O O
) O O
have O O
normal O O
concentrations O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
decreased O O
affinity O O
for O O
dexamethasone O O
. O O

The O O
receptor O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
these O O
cells O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O O
a O O
low O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affinity O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

The O O
molecular O B_MEASURE/B_LOCATION
weight O I_MEASURE/I_LOCATION
of O O
the O O
receptor O B_GENE
, O O
determined O O
by O O
SDS-PAGE O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
is O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
that O O
of O O
Old O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
World O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
primates O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
approximately O O
92 O B_MEASURE
, O O
000 O B_MEASURE
) O O
and O O
the O O
activation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pattern O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
per O O
se O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
examined O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
heating O O
cytosol O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
performing O O
phosphocellulose O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chromatography O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
appears O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
that O O
of O O
human O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controls O I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
ratios O O
of O O
nuclear O O
to O O
cytosolic B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
hormone-receptor-complexes I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
of O O
cytosolic O O
activated O O
to O O
unactivated B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
complexes I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
in O O
intact O O
cells O O
are O O
similar O O
to O O
Old O O
World O O
primates O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
mixing O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O O
not O O
support O O
the O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
a O O
binding O B_DISEASE_ADJECTIVE[DISEASE]
inhibitor O I_DISEASE_ADJECTIVE[DISEASE]
( O O
s O O
) O O
or O O
a O O
deficient O B_ENZYME[GENE]/B_MEASURE
cytosolic O I_ENZYME[GENE]/I_MEASURE
positive O I_ENZYME[GENE]/I_MEASURE
modifier O I_ENZYME[GENE]/I_MEASURE
( O O
s O B_DISEASE/B_PROTEIN[GENE]
) O O
of O O
binding O B_GENE/B_DISEASE
underlies O O
the O O
findings O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
these O O
primates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O O

Erythroid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Kruppel-like I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EKLF B B_LOCATION/B_DISEASE
) O O
is O O
a O O
red B B_GENE
cell-specific I I_GENE
transcriptional I I_GENE
activator I I_GENE
that O O
is O O
crucial O O
for O O
consolidating O O
the O O
switch O O
to O O
high O O
levels O O
of O O
adult O O
beta-globin O O
expression O O
during O O
erythroid O O
ontogeny O O
. O O

However O O
, O O
its O O
interactions O O
with O O
these O O
histone B B_GENE/B_LOCATION
acetyltransferases I I_GENE/I_LOCATION
are O O
not O O
equivalent O O
, O O
as O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
P/CAF B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
utilize O O
EKLF B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
as O O
a O O
substrate O O
for O O
in O O
vitro O O
acetylation O O
within O O
its O O
trans-activation O O
region O O
. O O

Recognition O O
of O O
herpes B B_DISEASE
simplex I I_DISEASE
virus I I_DISEASE
type I I_DISEASE
2 I I_DISEASE
tegument I I_DISEASE
proteins I I_DISEASE
by O O
CD4 O O
T O O
cells O O
infiltrating O O
human O O
genital O O
herpes O O
lesions O O
. O O

The O O
antiviral O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
functions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
infiltrating O O
CD4-bearing O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
include O O
cytotoxicity O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
viral O B_DISEASE_ADJECTIVE[DISEASE]
growth O I_DISEASE_ADJECTIVE[DISEASE]
, O O
lymphokine O B_DISEASE_ADJECTIVE[DISEASE]
secretion O I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
support O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
humoral O B_GENE
and O O
CD8 O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
responses O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Expression O O
cloning O O
with O O
this O O
region O O
of O O
DNA O O
now O O
shows O O
that O O
tegument B B_GENE/B_VIRUS[BIO]
protein I B_GENE/I_VIRUS[BIO]
VP22 B B_GENE/I_VIRUS[BIO]
and O O
the O O
viral B B_GENE
dUTPase I I_GENE
, O O
encoded O O
by O O
genes B B_GENE/B_PERSON
UL49 I I_GENE/I_PERSON
and I I_GENE/I_PERSON
UL50 I I_GENE/I_PERSON
, O O
respectively O O
, O O
are O O
T-cell B B_DISEASE_ADJECTIVE[DISEASE]
antigens I I_DISEASE_ADJECTIVE[DISEASE]
. O O

Three O O
new O O
epitopes O O
were O O
identified O O
in O O
VP16 B B_GENE/B_SPECIES[BIO]
, O O
a O O
tegument B B_PROTEIN[GENE]/B_LOCATION
protein I I_PROTEIN[GENE]/I_LOCATION
associated O O
with O O
VP22 B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
results O O
suggest O O
that O O
herpes B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simplex I I_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tegument I I_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I I_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
processed O O
for O O
antigen O O
presentation O O
in O O
vivo O O
and O O
are O O
possible O O
candidate O O
compounds O O
for O O
herpes O O
simplex O O
vaccines O O
. O O

Mononuclear O O
phagocytes O O
are O O
exposed O O
to O O
fibrinous O O
provisional O O
matrix O O
throughout O O
migration O O
into O O
inflammatory O O
foci O O
, O O
so O O
this O O
study O O
was O O
undertaken O O
to O O
determine O O
whether O O
fibrinogen O O
triggers O O
activation O O
of O O
NF-kappa B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
B I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
conclude O O
that O O
contact O O
with O O
fibrinogen-derived B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
contribute O O
to O O
mononuclear O O
phagocyte O O
activation O O
by O O
signaling O O
through O O
CD11b/CD18 B B_GENE
, O O
resulting O O
in O O
selective O O
activation O O
of O O
transcriptional B B_GENE
regulatory I I_GENE
factors I I_GENE
, O O
including O O
NF-kappa B B_GENE
B I I_GENE
. O O

T O B_PERSON/B_LOCATION
cells O I_PERSON/I_LOCATION
were O O
separated O O
into O O
CD4 O B_GENE
and O O
CD8 O B_GENE
. O O

Partial O O
sequences O O
from O O
exons B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
1-8 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
nearly O O
identical O O
to O O
the O O
published O O
sequence O O
of O O
the O O
human B B_GENE/B_BIO
ER I I_GENE/I_BIO
mRNA I I_GENE/I_BIO
. O O

Variant O O
receptor O O
transcripts O O
lacking O O
exon B B_GENE
5 I I_GENE
or O O
exon B B_MEASURE/B_LOCATION
7 I I_MEASURE/I_LOCATION
, O O
which O O
encodes O O
the O O
hormone B B_GENE
binding I I_GENE
domain I I_GENE
, O O
were O O
identified O O
in O O
the O O
majority O O
of O O
the O O
cells O O
. O O

Precise O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
deletion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
of O O
the O O
exons O B_GENE
suggests O O
that O O
they O O
are O O
alternatively O O
spliced O O
transcripts O B_LOCATION/B_GENE
. O O

A O O
nondegradable B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mutant I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
I B B_GENE
kappa I I_GENE
B I I_GENE
blocked O O
both O O
FasL B B_GENE
expression O O
and O O
apoptosis O O
induced O O
by O O
DNA O O
damage O O
but O O
not O O
Fas O O
ligation O O
. O O

These O O
stimuli O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
induced O O
the O O
stress-activated O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SAPK/JNK O B_GENE/B_LOCATION
) O O
, O O
which O O
was O O
required O O
for O O
the O O
maximal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
apoptosis O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
a O O
small O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
molecule O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
can O O
activate O O
a O O
receptor O B_ENZYME[GENE]/B_LOCATION
that O O
normally O O
binds O O
a O O
relatively O O
large O B_DISEASE_ADJECTIVE[DISEASE]
protein O I_DISEASE_ADJECTIVE[DISEASE]
ligand O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Eight O B_TIME[MEASURE]/B_PERSON
patients O B_TIME[MEASURE]/I_PERSON
in O O
long-term O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
LT O B_PERSON/B_LOCATION
; O O
3 O B_NUMBER[MEASURE]/B_LOCATION
to O O
15 O B_TIME[MEASURE]
years O I_TIME[MEASURE]
) O O
and O O
15 O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
in O O
short-term O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
ST O B_PROTEIN[GENE]/B_DISEASE
; O O
up O O
to O O
3 O B_MEASURE/B_ENT
years O I_MEASURE/I_ENT
) O O
remission O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
were O O
studied O O
. O O

Although O O
all O O
MRD-positive O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
in O O
LT O B_DISEASE/B_LOCATION
remission O B_DISEASE/I_LOCATION
are O O
still O O
until O O
now O O
event-free O B_DISEASE_ADJECTIVE[DISEASE]
, O O
3 O B_NUMBER[MEASURE]
of O O
the O O
7 O B_NUMBER[MEASURE]
MRD-positive O I_NUMBER[MEASURE]
( O O
MRD+ O B_PROTEIN[GENE]/B_LOCATION
) O O
patients O B_PERSON/B_LOCATION
in O O
ST O B_MEASURE/B_DISEASE
remission O I_MEASURE/I_DISEASE
soon O O
relapsed O O
. O O

Basically O O
, O O
the O O
total O B_MEASURE/B_PERSON
percentage O I_MEASURE/I_PERSON
of O O
the O O
CD4+ O B_GENE
, O O
CD8+ O B_GENE
and O O
CD56+ O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
populations O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
BM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
was O O
increased O O
and O O
in O O
the O O
following O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
order O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
: O O
MRD-/LT O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
, O O
normal O B_PERSON/B_PROTEIN[GENE]
volunteers O B_PERSON/I_PROTEIN[GENE]
, O O
MRD+/LT O B_DISEASE/B_PROTEIN[GENE]
patients O B_DISEASE/I_PROTEIN[GENE]
and O O
MRD+ O B_PROTEIN[GENE]/B_LOCATION
or O O
-/ST O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
patients O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

Thus O O
, O O
the O O
difference O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
possible O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
T/NK-cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phenotype O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
BM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
may O O
strongly O O
influence O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
molecular O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
remission O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
major O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
goal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
determine O O
whether O O
the O O
mycobacterial O B_DISEASE_ADJECTIVE[DISEASE]
cell O I_DISEASE_ADJECTIVE[DISEASE]
wall O I_DISEASE_ADJECTIVE[DISEASE]
component O I_DISEASE_ADJECTIVE[DISEASE]
mannose-capped O O
lipoarabinomannan O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
ManLAM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
of O O
Mycobacterium O B_DISEASE
tuberculosis O I_DISEASE
( O O
M. O B_OTHER/B_PROTEIN[GENE]
tuberculosis O O
) O B_DISEASE/B_PROTEIN[GENE]
could O O
activate O O
transcription O O
of O B_GENE
HIV-1 O O
in O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
T O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
with O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
the O O
use O O
of O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
an O O
in O O
vitro O O
cell O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
M. O B_OTHER/B_PROTEIN[GENE]
tuberculosis O O
can O B_DISEASE/B_BACTERIUM[BIO]
upregulate O O
HIV-1 O O
expression O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
could O O
thus O O
have O O
the O O
potential O O
to O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
influence O O
the O O
pathogenesis O O
of O B_DISEASE_ADJECTIVE[DISEASE]
HIV-1 O O
infection O B_DISEASE
. O I_DISEASE

Human B B_PERSON
immunodeficiency I I_PERSON
virus I I_PERSON
type I I_PERSON
1 I I_PERSON
long I I_PERSON
terminal I I_PERSON
repeat I I_PERSON
quasispecies O O
differ O O
in O O
basal O O
transcription O O
and O O
nuclear O O
factor O O
recruitment O O
in O O
human O O
glial O O
cells O O
and O O
lymphocytes O O
. O O

The O O
generation O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
genomic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
diversity O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O O
the O O
course O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O O
infection O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O O
the O O
potential O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
affect O O
all O O
aspects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
HIV-1 O O
replication O B_TIME[MEASURE]/B_DISEASE
, O O
including O O
expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
the O O
proviral O B_GENE
genome O I_GENE
. O O

Sequence O O
analysis O O
of O O
nineteen O O
LTRs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cloned O O
from O O
2 O O
adult O O
and O O
3 O O
pediatric O O
patients O O
revealed O O
an O O
average O O
of O O
33 O O
nucleotide O O
changes O O
( O O
with O O
respect O O
to O O
the O O
sequence O O
of O O
the O O
LAI B B_LOCATION/B_GENE
LTR I I_LOCATION/I_GENE
) O O
within O O
the O O
455-bp B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
U3 I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
region I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Transient O O
expression O O
analyses O O
in O O
cells O O
of O O
neuroglial O O
and O O
lymphocytic O O
origin O O
demonstrated O O
that O O
some O O
of O O
these O O
LTRs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
had O O
activities O O
which O O
varied O O
significantly O O
from O O
the O O
LAI B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
LTR I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
U-373 O O
MG O O
cells O O
( O O
an O O
astrocytoma O O
cell O O
line O O
) O O
as O O
well O O
as O O
in O O
Jurkat O O
cells O O
( O O
a O O
CD4-positive O O
lymphocyte O O
cell O O
line O O
) O O
. O O

While O O
LTRs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O O
demonstrated O O
the O O
highest O O
activities O O
in O O
U-373 O O
MG O O
cells O O
also O O
yielded O O
high O O
activities O O
in O O
Jurkat O O
cells O O
, O O
the O O
LTRs B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
were O O
generally O O
more O O
active O O
in O O
Jurkat O O
cells O O
when O O
compared O O
to O O
the O O
LAI B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LTR I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Differences O O
in O O
LTR B B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
sequence I I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
also O O
resulted O O
in O O
differences O O
in O O
transcription O O
factor O O
recruitment O O
to O O
cis-acting B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
sites I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
within O O
the O O
U3 B B_LOCATION/B_MEASURE
region I I_LOCATION/I_MEASURE
of O O
the O O
LTR B B_GENE/B_DISEASE
, O O
as O O
demonstrated O O
by O O
electrophoretic O O
mobility O O
shift O O
assays O O
. O O

In O O
particular O O
, O O
naturally O O
occurring O O
sequence O O
variation O O
impacted O O
transcription B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
binding O O
to O O
an O O
activating B B_GENE
transcription I I_GENE
factor I I_GENE
/ O O
cAMP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ATF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
CREB B B_LOCATION/B_ORGANIZATION
) O O
binding O O
site O O
( O O
located O O
between O O
the O O
LEF-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
distal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappaB I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
that O O
we O O
identified O O
in O O
previous O O
studies O O
of O O
the O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
LTR I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

HMG B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
box I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcription I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
lymphocyte O O
differentiation O O
. O O

Sox-4 B B_GENE
is O O
important O O
for O O
very O O
early O O
B-cell O O
differentiation O O
, O O
while O O
TCF-1 B B_LOCATION/B_ORGANIZATION
/ O O
LEF-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
play O O
a O O
crucial O O
role O O
in O O
early O O
thymocyte O O
development O O
. O O

TCF/LEF B B_PERSON
proteins I I_PERSON
have O O
recently O O
been O O
found O O
to O O
constitute O O
a O O
downstream O O
component O O
of O O
the O O
Wingless/Wnt O O
signal O O
transduction O O
pathway O O
. O O

Deregulation O B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
pathway O B_GENE/B_DISEASE
occurs O O
in O O
several O B_DISEASE
human O I_DISEASE
tumors O I_DISEASE
. O O

These O O
insights O O
in O O
the O O
molecular O O
events O O
that O O
are O O
involved O O
in O O
TCF/LEF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
function O O
in O O
these O O
organisms O O
may O O
eventually O O
lead O O
to O O
the O O
understanding O O
of O O
the O O
function O O
of O O
these O O
HMG B B_GENE
box I I_GENE
proteins I I_GENE
in O O
lymphoid O O
development O O

Transcriptional O O
regulation O O
by O O
C/EBP B B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DISEASE_ADJECTIVE[DISEASE]
and I I_DISEASE_ADJECTIVE[DISEASE]
-beta I I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
expression O O
of O O
the O O
gene O O
for O O
the O O
MRP14 B B_GENE
myeloid I I_GENE
calcium I I_GENE
binding I I_GENE
protein I I_GENE
. O O

On O O
the O O
other O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
hand O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
gene O B_GENE/B_MEASURE
was O O
expressed O O
in O O
monocytic O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
THP-1 O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
in O O
the O O
HL-60 O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
treated O O
with O O
1 O B_MEASURE
, O O
25-dihydroxyvitamin O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D3 O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
VD3 O B_PROTEIN[GENE]/B_MEASURE
) O O
. O O

Among O O
several O O
known O O
transcription B B_GENE/B_MEASURE
factor I I_GENE/I_MEASURE
binding I I_GENE/I_MEASURE
motifs I I_GENE/I_MEASURE
, O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
s I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
VD3-treated O O
HL-60 O O
cells O O
and O O
THP-1 O O
cells O O
bound O O
to O O
the O O
CCAAT/enhancer B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
protein I I_GENE/I_LOCATION
( I I_GENE/I_LOCATION
C/EBP I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
-binding I I_GENE/I_LOCATION
motif I I_GENE/I_LOCATION
that O O
was O O
located O O
in O O
the O O
upstream B B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
region I I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
MRP14 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
( O O
-81 O O
) O O
, O O
as O O
evidenced O O
by O O
the O O
competitive O O
gel O O
mobility-shift O O
assay O O
. O O

An O O
antibody O O
for O O
C/EBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
super-shifted O O
the O O
nucleoprotein B B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I B_GENE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
THP-1 O O
cells O O
but O O
not O O
in O O
the O O
VD3-treated O O
HL-60 O O
cells O O
, O O
whereas O O
an O O
antibody O O
for O O
C/EBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocked O O
the O O
formation O O
of O O
the O O
complex O O
with O O
the O O
nuclear B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
HL-60 O O
cells O O
but O O
not O O
with O O
that O O
of O O
THP-1 O O
cells O O
. O O

An O O
anti-C/EBP B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
delta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
had O O
no O O
effect O O
on O O
the O O
complex O O
in O O
either O O
cell O O
. O O

Thus O O
, O O
it O O
was O O
concluded O O
that O O
C/EBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-beta I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
able O O
to O O
bind O O
to O O
the O O
C/EBP B B_GENE
motif I I_GENE
, O O
and O O
that O O
C/EBP B B_GENE/B_MEASURE
alpha I I_GENE/I_MEASURE
bound O O
to O O
the O O
motif O O
in O O
THP-1 O O
cells O O
and O O
C/EBP B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bound O O
to O O
that O O
in O O
the O O
VD3-treated O O
HL-60 O O
cells O O
. O O

Using O O
the O O
human O B_GENE
androgen-receptor O I_GENE
( O O
HUMARA O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
assay O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
we O O
analysed O O
the O O
clonal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
patterns O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
highly O O
purified O B_TIME[MEASURE]/B_GENE
immature O I_TIME[MEASURE]/I_GENE
CD34+ O I_TIME[MEASURE]/I_GENE
38- O I_TIME[MEASURE]/I_GENE
and O O
committed O O
CD34+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
38+ O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
marrow-derived O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
CD16+ O B_GENE/B_TIME[MEASURE]
14- O I_GENE/I_TIME[MEASURE]
granulocytes O I_GENE/I_TIME[MEASURE]
, O O
CD14+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
CD3+ O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
CD19+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
B O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
from O O
peripheral O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Steroid O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
metabolism O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
investigated O O
in O O
cultured O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
B-lymphoblastoid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
B-LCL O B_DISEASE
) O O
, O O
and O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Gene O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
examined O O
by O O
reverse-transcription O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polymerase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
amplification O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
RT-PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Appropriate O O
sized O O
transcripts B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
detected O O
in O O
both O O
cultured O O
and O O
fresh O O
peripheral O O
lymphocytes O O
for O O
CYP11A B B_GENE/B_LOCATION
, O O
CYP17 B B_GENE
, O O
HSD11L B B_GENE/B_DISEASE
( O O
11beta-hydroxysteroid B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
I I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
HSD17B1 B B_GENE/B_DISEASE
( O O
17beta-hydroxysteroid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
SRD5A1 B B_GENE/B_DISEASE
( O O
5alpha-reductase B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Human O O
white O O
blood O O
cells O O
and O O
hair O O
follicles O O
are O O
good O O
sources O O
of O O
mRNA B B_GENE
for O O
the O O
pterin B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carbinolamine I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dehydratase/dimerization I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cofactor I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
HNF1 B B_GENE
for O O
mutation O O
detection O O
. O O

It O O
is O O
a O O
pterin B B_ENZYME[GENE]
4alpha-carbinolamine I I_ENZYME[GENE]
dehydratase I I_ENZYME[GENE]
that O O
is O O
involved O O
in O O
the O O
regeneration O O
of O O
the O O
cofactor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tetrahydrobiopterin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
the O O
phenylalanine O O
hydroxylase- O O
catalyzed O O
hydroxylation O O
of O O
phenylalanine O O
. O O

Taking O O
advantage O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
finding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
, O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
convenient O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
screening O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
mutations O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
occurring O O
in O O
the O O
coding O B_LOCATION/B_PERSON
region O I_LOCATION/I_PERSON
of O O
this O O
gene O B_GENE/B_LOCATION
has O O
been O O
described O O
. O O

The O O
NF-Y B B_GENE
complex I I_GENE
derived O O
from O O
class O O
II+ O O
mature O O
B-cells O O
bound O O
with O O
high O O
affinity O O
to O O
anion B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
exchangers I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
eluted O O
as O O
an O O
intact O O
trimeric B B_LOCATION
complex I I_LOCATION
, O O
whereas O O
, O O
NF-Y B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derived O O
from O O
class O O
II- O O
plasma O O
B-cells O O
, O O
and O O
from O O
bare O O
lymphocyte O O
syndrome O O
group O O
II O O
cell O O
lines O O
, O O
RJ2.2.5 O O
and O O
RM3 O O
, O O
dissociated O O
into O O
discrete O O
NF-YA B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
NF-YB B B_PROTEIN[GENE]
: I I_PROTEIN[GENE]
C I I_PROTEIN[GENE]
subunit B I_PROTEIN[GENE]
fractions I I_PROTEIN[GENE]
. O O

Recombination O O
of O O
the O O
MPC11 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plasma I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B-cell I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derived I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NF-Y I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
low O O
molecular O O
mass O O
protein O O
fraction O O
, O O
NF-Y-associated B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
factors I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
YAFs B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
derived O O
from O O
mature O O
A20 O O
B-cell O O
nuclei O O
, O O
conferred O O
high O O
affinity O O
anion O O
exchange O O
binding O O
to O O
NF-Y B B_GENE
as O O
an O O
intact B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trimeric I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
complex I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Interaction O O
between O O
PC4 B B_GENE
and O O
NF-Y B B_GENE
was O O
mapped O O
to O O
the O O
C-terminal B B_LOCATION/B_BIO
region I I_LOCATION/I_BIO
of O O
PC4 B B_GENE
, O O
and O O
the O O
subunit B B_LOCATION/B_MEASURE
interaction I I_LOCATION/I_MEASURE
subdomain I I_LOCATION/I_MEASURE
of O O
the O O
highly B B_PROTEIN[GENE]
conserved I I_PROTEIN[GENE]
DNA I I_PROTEIN[GENE]
binding-subunit I I_PROTEIN[GENE]
interaction I I_PROTEIN[GENE]
domain I I_PROTEIN[GENE]
( O O
DBD B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
of O O
NF-YA B B_GENE
. O O

Arrest O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
B O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocyte O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
terminal O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
differentiation O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
CD40 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
mechanism O B_DISEASE_ADJECTIVE[DISEASE]
for O O
lack O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
antibody-secreting O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
germinal O B_BIO/B_DISEASE
centers O I_BIO/I_DISEASE
. O O

Furthermore O O
, O O
the O O
inhibition O O
of O O
B O O
cell O O
differentiation O O
by O O
CD40 B B_GENE
engagement O O
could O O
not O O
be O O
overcome O O
by O O
either O O
mitogens B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
could O O
be O O
reversed O O
by O O
antibodies O O
that O O
interfere O O
with O O
the O O
CD40 B B_GENE
/ O O
gp39 B B_GENE/B_LOCATION
interaction O O
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
secretory O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunoglobulin O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
not O O
produced O O
by O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
are O O
actively O O
engaged O O
by O O
gp39-expressing O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

alpha-Lipoic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
LA O B_LOCATION/B_ORGANIZATION
) O O
is O O
taken O O
up O O
by O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
and O O
reduced O O
to O O
its O O
potent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
dithiol O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
form O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
dihydrolipoate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
DHLA O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
, O O
much O B_MEASURE/B_LOCATION
of O O
which O O
is O O
rapidly O O
effluxed O O
out O O
from O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

At O O
5 O B_GENE
microM O I_GENE
LA-Plus O I_GENE
, O O
but O O
not O O
LA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
protected O O
against O O
both O O
spontaneous O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
etoposide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O O
apoptosis O B_DISEASE
in O O
rat O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
thymocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

METHODOLOGY O O
: O O
A O O
polymerase O O
chain O O
reaction-based O O
method O O
was O O
used O O
to O O
amplify O O
a O O
polymorphic O O
CAG B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
repeat I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
the O O
first B B_GENE/B_LOCATION
exon I I_GENE/I_LOCATION
of O O
the O O
androgen B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
after O O
selective O O
digestion O O
of O O
the O O
active B B_GENE
X I I_GENE
chromosome I I_GENE
with O O
a O O
methylation-sensitive B B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzyme I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
HpaII B B_TIME[MEASURE]/B_BACTERIUM[BIO]
to O O
distinguish O O
between O O
the O O
paternal B B_GENE/B_PERSON
and I I_GENE/I_PERSON
maternal I I_GENE/I_PERSON
alleles I I_GENE/I_PERSON
and O O
to O O
identify O O
their O O
methylation O O
status O O
. O O

As O O
anticipated O O
, O O
NRXI O O
could O O
be O O
demonstrated O O
in O O
all O O
lymphoid O O
cells O O
studied O O
from O O
obligate O O
carriers O O
of O O
XSCID O O
and O O
an O O
obligate O O
carrier O O
of O O
XLH O O
but O O
not O O
on O O
a O O
carrier O O
of O O
X-linked O O
immunodeficiency O O
with O O
hyper-IgM B B_DISEASE
. O O

We O O
addressed O O
the O O
role O O
of O O
hyperglycemia O O
in O O
leukocyte-endothelium O O
interaction O O
under O O
flow O O
conditions O O
by O O
exposing O O
human O O
umbilical O O
vein O O
endothelial O O
cells O O
for O O
24 O O
h O O
to O O
normal O O
( O O
5 O O
mM O O
) O O
, O O
high O O
concentration O O
of O O
glucose O O
( O O
30 O O
mM O O
) O O
, O O
advanced O O
glycosylation O O
end O O
product-albumin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
100 O O
microg/ml O O
) O O
, O O
or O O
hyperglycemic O O
( O O
174-316 O O
mg/dl O O
) O O
sera O O
from O O
patients O O
with O O
diabetes O O
and O O
abnormal O O
hemoglobin O O
A1c O O
( O O
8.1+/-1.4 O O
% O O
) O O
. O O

The O O
distance O B_MEASURE/B_LOCATION
travelled O O
by O O
leukocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
before O O
arrest O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
30 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
on O O
IL-1beta-treated O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
endothelial O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
was O O
significantly O O
( O O
P O B_TIME[MEASURE]/B_LOCATION
< O I_TIME[MEASURE]/I_LOCATION
0.01 O I_TIME[MEASURE]/I_LOCATION
) O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
that O O
observed O O
for O O
leukocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
adhering O O
on O O
control O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
endothelium O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
30 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mM O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
glucose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
: O O
76.7+/-3.5 O B_MEASURE
; O O
IL1beta O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
69.7+/-4 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mM O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
21.5+/-5 O B_MEASURE
microm O I_MEASURE
) O O
. O O

Treatment O O
of O O
HUVEC O O
exposed O O
to O O
high O O
glucose O O
with O O
the O O
NF-kB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pyrrolidinedithiocarbamate O O
( O O
100 O O
microM O O
) O O
and O O
tosyl-phe-chloromethylketone O O
( O O
25 O O
microM O O
) O O
significantly O O
reduced O O
( O O
P O O
< O O
0.05 O O
) O O
leukocyte O O
adhesion O O
in O O
respect O O
to O O
HUVEC O O
treated O O
with O O
glucose O O
alone O O
. O O

Advanced O O
glycosylation O O
end O O
product-albumin B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
significantly O O
increased O O
the O O
number O O
of O O
adhering O O
leukocytes O O
in O O
respect O O
to O O
native B B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
albumin I I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
used O O
as O O
control O O
( O O
110+/-16 O O
versus O O
66+/-7 O O
, O O
P O O
< O O
0.01 O O
) O O
. O O

Ikaros B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
in O O
hemopoietic O O
lineage O O
determination O O
and O O
homeostasis O O
. O O

In O O
addition O O
a O O
comparative O O
analysis O O
of O O
the O O
hemopoietic O O
stem O O
cell O O
and O O
precursor O O
compartment O O
resulting O O
from O O
the O O
two O O
Ikaros B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reveals O O
a O O
profound O O
yet O O
not O O
absolute O O
requirement O O
for O O
Ikaros B B_DISEASE/B_GENE

Induction O O
of O O
early B B_DISEASE/B_VIRUS[BIO]
B I B_DISEASE/I_VIRUS[BIO]
cell I B_DISEASE/I_VIRUS[BIO]
factor I B_DISEASE/I_VIRUS[BIO]
( O O
EBF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
multiple B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lineage I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
the O O
basic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
helix-loop-helix I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
transcription I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
E12 B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Moreover O O
, O O
we O O
show O O
that O O
ectopic O O
expression O O
of O O
the O O
E2A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein O O
E12 B B_GENE/B_MEASURE
in O O
this O O
macrophage O O
line O O
results O O
in O O
the O O
induction O O
of O O
many B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lineage I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
EBF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IL7Ralpha B B_GENE
, O O
lambda5 B B_GENE
, O O
and O O
Rag-1 O O
, O O
and O O
the O O
ability O O
to O O
induce O O
kappa B B_GENE/B_DISEASE
light I I_GENE/I_DISEASE
chain I I_GENE/I_DISEASE
in O O
response O O
to O O
mitogen O O
. O O

Our O O
data O O
demonstrate O O
that O O
, O O
in O O
the O O
context O O
of O O
this O O
macrophage O O
line O O
, O O
E12 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O O
expression O O
of O O
EBF B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
together O O
these O O
transcription B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I B_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coordinately O O
regulate O O
numerous O O
B B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lineage-associated I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Nucleotide O O
sequence O O
analysis O O
identified O O
the O O
5 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
end I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
this O O
RNA B B_GENE/B_BIO
as O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
retinoid I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
RXRalpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Here O O
, O O
we O O
report O O
the O O
nucleotide O O
sequence O O
of O O
3.6 B B_DISEASE/B_GENE
kilobases I B_DISEASE/I_GENE
of O O
this O O
RNA O O
, O O
which O O
represents O O
the O O
3 B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
RXRalpha B B_GENE
mRNA I I_GENE
, O O
the O O
sequence O O
of O O
which O O
has O O
not O O
been O O
previously O O
described O O
. O O

Important O O
in O O
the O O
development O O
of O O
HIV-associated O O
NHL O O
are O O
cytokines B B_DISEASE
and O O
other O O
factors O O
that O O
induce O O
B-cell O O
proliferation O O
and O O
increase O O
the O O
likelihood O O
of O O
mutations O O
of O O
c-myc B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
bcl-6 B B_GENE
, O O
and O O
other O O
tumor-suppressor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
carcinogenic O O
potential O O
. O O

Specific O O
forms O O
of O O
HIV-associated O O
NHL O O
are O O
linked O O
to O O
expression O O
of O O
Epstein-Barr B B_DISEASE/B_VIRUS[BIO]
virus I B_DISEASE/I_VIRUS[BIO]
( I B_DISEASE/I_VIRUS[BIO]
EBV I B_DISEASE/I_VIRUS[BIO]
) I B_DISEASE/I_VIRUS[BIO]
-latent I B_DISEASE/I_VIRUS[BIO]
proteins I B_DISEASE/I_VIRUS[BIO]
; O O
the O O
newly O O
described O O
DNA O O
virus O O
, O O
Karposi O O
's O O
sarcoma-associated O O
herpesvirus/human O O
herpesvirus-8 O O
( O O
KSHV/HHV-8 O O
) O O
; O O
and O O
perhaps O O
HIV O O
. O O

There O O
is O O
increased O O
activity O O
of O O
the O O
proinflammatory B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytokine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
TNF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
in O O
alcoholic O O
liver O O
disease O O
( O O
ALD O O
) O O
. O O

Patients O O
with O O
ALD O O
also O O
have O O
decreased O O
protective B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
cellular O O
oxidative O O
injury O O
. O O

The O O
objectives O O
of O O
these O O
studies O O
were O O
to O O
investigate O O
mechanisms O O
for O O
induction O O
of O O
an O O
injurious B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IL-8 B B_GENE/B_LOCATION
) O O
and O O
a O O
protective B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
( O O
MnSOD B B_GENE/B_LOCATION
) O O
in O O
the O O
HepG2 O O
human O O
hepatoma O O
cell O O
line O O
. O O

In O O
the O O
first O O
set O O
of O O
experiments O O
, O O
IL-8 B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
reporter I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
constructs I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
were O O
used O O
to O O
transiently O O
transfect O O
a O O
derivative O O
( O O
MVh2E1-9 O O
) O O
of O O
the O O
HepG2 O O
cell O O
line O O
which O O
expresses O O
P-4502E1 B B_GENE/B_DISEASE
and O O
metabolizes O O
ethanol O O
. O O

Both O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ethanol O O
increased O O
HepG2 O O
cell O O
MnSOD B B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
in O O
short-term O O
( O O
72 O O
hr O O
) O O
cultures O O
with O O
ethanol O O
. O O

However O O
, O O
after O O
long-term O O
( O O
10 O O
weeks O O
) O O
culture O O
with O O
ethanol O O
, O O
there O O
was O O
no O O
induction O O
of O O
MnSOD B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
ethanol O O
and O O
there O O
was O O
a O O
diminished O O
induction O O
of O O
MnSOD B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
response O O
to O O
TNF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

We O O
conclude O O
that O O
transfected O O
liver O O
cell O O
lines O O
can O O
be O O
used O O
to O O
evaluate O O
mechanisms O O
for O O
increased O O
injurious B B_DISEASE/B_GENE
factors I I_DISEASE/I_GENE
and O O
decreased O O
protective B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
alcoholic O O
liver O O
injury O O
. O O

Tissue O O
factor O O
transcription O O
driven O O
by O O
Egr-1 B B_GENE
is O O
a O O
critical O O
mechanism O O
of O O
murine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pulmonary I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fibrin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
deposition O O
in O O
hypoxia O O
. O O

We O O
have O O
demonstrated O O
previously O O
that O O
in O O
a O O
murine O O
model O O
of O O
normobaric O O
hypoxia O O
pulmonary O O
fibrin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
deposition O O
is O O
a O O
result O O
of O O
expression O O
of O O
tissue B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
especially O O
in O O
oxygen-deprived B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
mononuclear I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
phagocytes I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MPs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
. O O

MPs B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
HeLa O O
cells O O
subjected O O
to O O
hypoxia O O
( O O
pO2 O O
approximately O O
13 O O
torr O O
) O O
had O O
increased O O
levels O O
of O O
tissue B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
approximately O O
18-fold O O
) O O
and O O
an O O
increased O O
rate O O
of O O
transcription O O
( O O
approximately O O
15-fold O O
) O O
, O O
based O O
on O O
nuclear O O
run-on O O
analysis O O
. O O

Gel-shift O O
analysis O O
of O O
nuclear O O
extracts O O
from O O
hypoxic B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
MPs I B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
HeLa O O
cells O O
demonstrated O O
increased O O
DNA-binding O O
activity O O
at O O
the O O
serum B B_LOCATION
response I I_LOCATION
region I I_LOCATION
( O O
SRR O O
; O O
-111/+14 O O
bp O O
) O O
of O O
the O O
tissue B B_GENE
factor I I_GENE
promoter I I_GENE
at O O
Egr-1 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
motifs I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
central O O
role O O
for O O
Egr-1 B B_GENE
in O O
hypoxia-mediated O O
tissue O O
factor O O
expression O O
was O O
confirmed O O
by O O
experiments O O
with O O
homozygous O O
Egr-1 B B_GENE/B_DISEASE
null O O
mice O O
; O O
wild-type O O
mice O O
subjected O O
to O O
oxygen B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
deprivation I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
expressed I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tissue I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
factor I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
showed O O
fibrin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
deposition O O
, O O
but O O
hypoxic O O
homozygous O O
Egr-1 B B_GENE/B_DISEASE
null O O
mice O O
displayed O O
neither O O
tissue B B_DISEASE/B_GENE
factor I B_DISEASE/I_GENE
nor O O
fibrin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O

These O O
data O O
delineate O O
a O O
novel O O
biology O O
for O O
hypoxia-induced O O
fibrin B B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deposition O O
, O O
in O O
which O O
oxygen O O
deprivation-induced O O
activation O O
of O O
Egr-1 B B_GENE
, O O
resulting O O
in O O
expression O O
of O O
tissue B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
has O O
an O O
unexpected O O
and O O
central O O
role O O
. O O

Here O O
we O O
have O O
analysed O O
the O O
kinetics O O
and O O
nature O O
of O O
cytokine O O
production O O
in O O
human O O
peripheral O O
blood-derived O O
T O O
lymphoblasts O O
stimulated O O
with O O
anti-CD3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
Lens B B_GENE/B_SPECIES[BIO]
culinaris I I_GENE/I_SPECIES[BIO]
lectin I I_GENE/I_SPECIES[BIO]
( O O
LCL B B_DISEASE/B_PROTEIN[GENE]
) O O
. O O

T O O
cells O O
were O O
purified O O
from O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMC O O
) O O
and O O
primarily O O
activated O O
with O O
anti-CD3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
cultured O O
in O O
the O O
presence O O
of O O
interleukin-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IL-2 B B_GENE
) O O
. O O

Oxidized O B_LOCATION/B_ORGANIZATION
LDL O I_LOCATION/I_ORGANIZATION
( O O
oxLDL O B_GENE
) O O
is O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
atherosclerotic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lesions O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
is O O
believed O O
to O O
play O O
a O O
key O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
atherogenesis O B_DISEASE
. O O

Injection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
LDL O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
enriched O O
with O O
the O O
antioxidant O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
probucol O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O O
in O O
arterial O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
accumulation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
apolipoprotein O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
the O O
expression O B_GENE/B_MEASURE
of O O
oxLDL-specific O B_GENE
epitopes O I_GENE
was O O
reduced O O
at O O
24 O B_TIME[MEASURE]/B_SPORT[ENT]
hours O I_TIME[MEASURE]/I_SPORT[ENT]
. O O

Sequence O O
analysis O O
demonstrated O O
that O O
two O O
NF-kappaB-like B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
1 O O
and O O
2 O O
) O O
were O O
present O O
in O O
the O O
regulatory B B_LOCATION/B_BIO
region I B_LOCATION/I_BIO
. O O

Both O O
NF-kappaB-like B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
elements I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
able O O
to O O
bind O O
to O O
NF-kappaB B B_GENE/B_DISEASE
or O O
its O O
related O O
factor O O
( O O
s O O
) O O
in O O
a O O
Tax B B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-dependent O O
manner O O
. O O

Chloramphenicol B B_GENE
acetyltransferase I I_GENE
assays O O
indicated O O
that O O
NF-kappaB-like B B_GENE
element I I_GENE
1 I I_GENE
was O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
-responsive O O
, O O
although O O
the O O
activity O O
was O O
lower O O
than O O
that O O
the O O
native B B_GENE/B_MEASURE
promoter I I_GENE/I_MEASURE
. O O

beta-Amyloid B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
fibrils I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
activate O O
parallel O O
mitogen-activated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathways O O
in O O
microglia O O
and O O
THP1 O O
monocytes O O
. O O

The O O
senile O O
plaques O O
of O O
Alzheimer O O
's O O
disease O O
are O O
foci O O
of O O
local O O
inflammatory O O
responses O O
, O O
as O O
evidenced O O
by O O
the O O
presence O O
of O O
acute B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phase I B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
proteins I B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
oxidative O O
damage O O
. O O

Fibrillar B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
forms I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
beta-amyloid B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Abeta B B_PROTEIN[GENE]/B_DISEASE
) O O
, O O
which O O
are O O
the O O
primary O O
constituents O O
of O O
senile O O
plaques O O
, O O
have O O
been O O
shown O O
to O O
activate O O
tyrosine O O
kinase-dependent O O
signal O O
transduction O O
cascades O O
, O O
resulting O O
in O O
inflammatory O O
responses O O
in O O
microglia O O
. O O

However O O
, O O
the O O
downstream O O
signaling O O
pathways O O
mediating O O
Abeta B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
inflammatory O O
events O O
are O O
not O O
well O O
characterized O O
. O O

We O O
report O O
that O O
exposure O O
of O O
primary O O
rat O O
microglia O O
and O O
human O O
THP1 O O
monocytes O O
to O O
fibrillar B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Abeta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
results O O
in O O
the O O
tyrosine B B_GENE
kinase I I_GENE
-dependent O O
activation O O
of O O
two O O
parallel O O
signal O O
transduction O O
cascades O O
involving O O
members O O
of O O
the O O
mitogen-activated B B_GENE/B_PERSON
protein I I_GENE/I_PERSON
kinase I I_GENE/I_PERSON
( I I_GENE/I_PERSON
MAPK I I_GENE/I_PERSON
) I I_GENE/I_PERSON
superfamily I I_GENE/I_PERSON
. O O

Whereas O O
CRABP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
ubiquitously O O
expressed O O
, O O
CRABP B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
II I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O O
mainly O O
detected O O
in O O
various O O
cell O O
types O O
of O O
the O O
skin O O
. O O

Adherence O O
, O O
which O O
is O O
important O O
for O O
MO O O
differentiation O O
, O O
induced O O
CRABP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O O
, O O
but O O
the O O
addition O O
of O O
10 O O
( O O
-7 O O
) O O
M O O
retinoic O O
acid O O
inhibited O O
the O O
upregulation O O
of O O
CRABP B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
II I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
expression O O
during O O
MO/MAC O O
differentiation O O
. O O

From O O
these O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O O
conclude O O
( O O
1 O B_SEQUENCE[MEASURE]
) O O
that O O
the O O
availability O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O O
the O O
metabolism O B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
retinoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
MAC O B_DISEASE/B_PROTEIN[GENE]
compared O O
to O O
MO O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O O
dendritic O B_LOCATION/B_PERSON
cells O I_LOCATION/I_PERSON
and O O
( O O
2 O B_SEQUENCE[MEASURE]
) O O
that O O
this O O
may O O
influence O O
differentiation O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
activation O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
those O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
. O O

Transcription B B_GENE
factor I I_GENE
B-cell-specific I I_GENE
activator I I_GENE
protein I I_GENE
( O O
BSAP B B_LOCATION/B_ORGANIZATION
) O O
is O O
differentially O O
expressed O O
in O O
B O O
cells O O
and O O
in O O
subsets O O
of O O
B-cell O O
lymphomas O O
. O O

All O O
of O O
the O O
13 O B_MEASURE
( O O
100 O B_MEASURE
% O I_MEASURE
) O O
B-cell O B_DISEASE_ADJECTIVE[DISEASE]
chronic O I_DISEASE_ADJECTIVE[DISEASE]
lymphocytic O I_DISEASE_ADJECTIVE[DISEASE]
leukemias O I_DISEASE_ADJECTIVE[DISEASE]
( O O
B-CLLs O B_DISEASE/B_LOCATION
) O O
, O O
21 O B_MEASURE
of O O
( O O
100 O B_MEASURE
% O I_MEASURE
) O O
mantle O B_DISEASE
cells O I_DISEASE
( O O
MCLs O B_DISEASE/B_PROTEIN[GENE]
) O O
, O O
and O O
20 O B_NUMBER[MEASURE]
of O O
21 O B_NUMBER[MEASURE]
( O O
95 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
follicular O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphomas O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
FLs O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
were O O
positive O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Moderate O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
staining O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intensities O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
found O O
in O O
most O B_DISEASE/B_PROTEIN[GENE]
B-CLL O B_DISEASE/I_PROTEIN[GENE]
and O O
FL O B_LOCATION/B_ORGANIZATION
cases O I_LOCATION/I_ORGANIZATION
, O O
whereas O O
most O B_NUMBER[MEASURE]/B_PERSON
MCLs O B_NUMBER[MEASURE]/I_PERSON
showed O O
strong O B_DISEASE_ADJECTIVE[DISEASE]
reactions O I_DISEASE_ADJECTIVE[DISEASE]
, O O
paralleling O O
the O O
strong O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactivity O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
nonmalignant O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mantle O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

None O O
of O O
the O O
23 O O
T- O O
and O O
null-cell O O
lymphomas O O
reacted O O
with O O
the O O
BSAP B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
antisera O O
, O O
whereas O O
in O O
Hodgkin O O
's O O
disease O O
, O O
2 O O
of O O
4 O O
( O O
50 O O
% O O
) O O
nodular O O
lymphocytic O O
predominance O O
and O O
5 O O
of O O
14 O O
( O O
36 O O
% O O
) O O
classical O O
cases O O
showed O O
weak O O
nuclear O O
or O O
nucleolar O O
BSAP B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions O O
in O O
a O O
fraction O O
of O O
the O O
tumor O O
cells O O
. O O

A O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
human B B_GENE
STAT6 I I_GENE
recognizes O O
an O O
approximately O O
100 B B_PROTEIN[GENE]/B_LOCATION
kDa I I_PROTEIN[GENE]/I_LOCATION
molecule I I_PROTEIN[GENE]/I_LOCATION
that O O
becomes O O
activated O O
and O O
translocates O O
to O O
the O O
nucleus O O
upon O O
both O O
growth O O
factor O O
and O O
mitogen O O
stimulation O O
of O O
catfish O O
leukocytes O O
. O O

This O O
presumed O O
catfish B B_LOCATION
STAT I I_LOCATION
binds O O
the O O
mammalian B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon-gamma I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
known O O
motif O O
of O O
mammalian O O
STAT O O
binding O O
, O O
as O O
shown O O
by O O
electromobility O O
shift O O
assays O O
. O O

Purification O O
of O O
the O O
proteins O O
present O O
in O O
these O O
DNA B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
confirms O O
that O O
the O O
catfish O O
reactive O O
molecule O O
binds O O
to O O
the O O
interferon-gamma B B_GENE
activation I I_GENE
site I I_GENE
sequence I I_GENE
. O O

NF-kappaB O B_GENE/B_PERSON
activation O I_GENE/I_PERSON
was O O
also O O
inhibited O O
by O O
CS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Transcription O B_GENE
increases O I_MEASURE
DNA O I_MEASURE
repair O I_MEASURE
efficiency O I_MEASURE
and O O
modulates O O
the O O
distribution O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
certain O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
types O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
DNA O B_DISEASE/B_GENE
damage O I_DISEASE/I_GENE
. O O

We O O
first O O
developed O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
thymidine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
tk O B_PROTEIN[GENE]/B_DISEASE
) O O
inducible O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
human O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cell O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lines O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O O
the O O
Gal4-Estrogen O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
system O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Tk B B_DISEASE/B_ORGANISM_FUNCTION
mRNA I I_DISEASE/I_ORGANISM_FUNCTION
is O O
induced O O
following O O
treatment O O
with O O
estrogen O O
. O O

Spontaneous O B_GENE
mutation O I_GENE
rate O I_GENE
was O O
significantly O O
decreased O O
in O O
human O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
lines O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
after O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
in O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
report O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O O
yeast O B_SPECIES[BIO]
. O O

Thus O O
, O O
humans O B_PERSON/B_BIO
may O O
have O O
evolved O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
or O O
additional O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
to O O
deal O O
with O O
transcription O B_GENE/B_DISEASE
related O O
spontaneous O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutagenesis O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
mutations O O
are O O
linked O O
to O O
transcription O O
initiation O O
, O O
but O O
non-Ig B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
promoters I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
permissible O O
for O O
the O O
mutation O O
process O O
; O O
thus O O
, O O
other O O
genes O O
expressed O O
in O O
mutating O O
B O O
cells O O
may O O
also O O
be O O
subject O O
to O O
somatic O O
hypermutation O O
. O O

CD28-mediated O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
activation O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
CD45RA+ O B_GENE
and O O
CD45RO+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
: O O
enhanced O O
levels O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
reactive O B_GENE/B_BACTERIUM[BIO]
oxygen O I_GENE/I_BACTERIUM[BIO]
intermediates O I_GENE/I_BACTERIUM[BIO]
and O O
c-Rel O B_DISEASE/B_GENE
nuclear O I_DISEASE/I_GENE
translocation O I_DISEASE/I_GENE
in O O
CD45RA+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
further O O
emphasize O O
the O O
differences O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O O
CD45RA+ O B_GENE
and O O
CD45RO+ O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
ROI-dependent O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
signaling O O
pathways O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Biochemical O O
characterization O O
of O O
MIP-1 B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
alpha I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
nuclear I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

In O O
TF-1 O O
cells O O
, O O
an O O
erythroleukemia O O
cell O O
line O O
, O O
granulocyte-macrophage B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
colony-stimulating I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GM-CSF B B_GENE/B_LOCATION
) O O
and O O
erythropoietin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
Epo B B_GENE/B_LOCATION
) O O
greatly O O
enhanced O O
Bcl-3 B B_GENE
expression O O
at O O
both O O
the O O
protein O O
and O O
mRNA O O
levels O O
in O O
association O O
with O O
stimulation O O
of O O
proliferation O O
. O O

Bcl-3 B B_GENE
in O O
nuclear O O
extracts O O
of O O
TF-1 O O
cells O O
bound O O
to O O
a O O
kappaB B B_GENE/B_LOCATION
enhancer I B_GENE/I_LOCATION
in O O
the O O
c-myb B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
together O O
with O O
NF-kappaB2/p52 B B_GENE
and O O
this O O
binding O O
activity O O
was O O
enhanced O O
by O O
GM-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
stimulation O O
. O O

These O O
findings O O
suggest O O
that O O
Bcl-3 B B_GENE
may O O
participate O O
in O O
the O O
transcriptional O O
regulation O O
of O O
certain O O
kappaB-containing B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
involved O O
in O O
hematopoiesis O O
, O O
including O O
c-myb B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Additionally O O
, O O
our O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
molecular O B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
determinants O B_LOCATION/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
govern O O
5-lipoxygenase O B_GENE
and O O
NF-kappaB O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
redistribution O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
the O O
nucleus O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
may O O
be O O
coordinately O O
controlled O O
in O O
granulocytic O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Since O O
scrape O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loading O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
relies O O
on O O
adherent O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
human O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
( O O
PB-T O B_PROTEIN[GENE]/B_MEASURE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
immobilized O O
on O O
the O O
nonspecific O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
cell O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
attachment O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
factor O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
poly-L-lysine O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
. O O

Transient O O
transfection O O
analysis O O
further O O
confirmed O O
the O O
Tax B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transactivation O O
of O O
the O O
TR3/nur77 B B_GENE/B_LOCATION
promoter O O
but O O
not O O
the O O
NOR-1 B B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoter I I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
different O O
cell O O
types O O
. O O

Long-range O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transcriptional O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
regulation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cytokine O B_GENE
gene O I_GENE
expression O I_GENE
. O O

Recent O O
work O O
has O O
identified O O
distal B B_LOCATION/B_BIO
elements I I_LOCATION/I_BIO
that O O
mediate O O
long-range O O
cytokine O O
gene O O
regulation O O
and O O
has O O
implicated O O
chromatin O O
reorganization O O
in O O
regulation O O
of O O
cytokine B B_GENE
gene I I_GENE
loci I I_GENE
. O O

Unlike O O
antioxidants O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
hypoxia O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
did O O
not O O
inhibit O O
nuclear O B_GENE
factor O I_GENE
KB O I_GENE
mobilization O I_GENE
. O O

Stem B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SCF B B_GENE/B_LOCATION
) O O
and O O
erythropoietin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
EPO B B_LOCATION/B_ORGANIZATION
) O O
work O O
synergistically O O
to O O
support O O
erythropoiesis O O
, O O
but O O
the O O
mechanism O O
for O O
this O O
synergism O O
is O O
unknown O O
. O O

By O O
using O O
purified O O
human O O
erythroid O O
colony-forming O O
cells O O
( O O
ECFC O O
) O O
, O O
we O O
have O O
found O O
that O O
SCF B B_GENE/B_BIO
and O O
EPO B B_LOCATION/B_ORGANIZATION
synergistically O O
activate O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MAPK B B_GENE
, O O
ERK1/2 B B_GENE
) O O
, O O
which O O
correlates O O
with O O
the O O
cell O O
growth O O
and O O
thus O O
may O O
be O O
responsible O O
for O O
the O O
synergistic O O
effects O O
. O O

Furthermore O O
, O O
EPO B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
not O O
SCF B B_GENE/B_BIO
, O O
led O O
to O O
activation O O
of O O
STAT5 B B_GENE
, O O
whereas O O
SCF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O O
wortmannin O O
had O O
no O O
effect O O
on O O
the O O
EPO B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
STAT5 B B_GENE
activation O O
, O O
suggesting O O
that O O
STAT5 B B_GENE
is O O
not O O
involved O O
in O O
the O O
synergistic O O
action O O
of O O
SCF B B_GENE/B_LOCATION
and O O
EPO B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

All O O
but O O
one O B_NUMBER[MEASURE]/B_PERSON
PCNSL O I_NUMBER[MEASURE]/I_PERSON
expressed O O
hMSH2 O B_GENE
, O O
which O O
among O O
mature O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
selectively O O
stains O O
GC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Antioxidant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
phorbol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ester-induced O O
adhesion O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
Jurkat O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
T-cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
to O O
endothelial O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Regulation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
adhesion O B_GENE/B_ORGANISM_FUNCTION
molecule O B_GENE/I_ORGANISM_FUNCTION
expression O B_GENE/I_ORGANISM_FUNCTION
and O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
reactive O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxygen O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
redox O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sensitive O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
have O O
been O O
reported O O
. O O

The O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O O
clinically O O
safe O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antioxidants O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
regulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
adhesion O B_GENE
molecule O I_GENE
expression O I_GENE
in O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
endothelial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ECV O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
, O O
and O O
adherence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
Jurkat O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
ECV O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
investigated O O
. O O

The O O
thiol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antioxidant O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
alpha-lipoate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
at O O
clinically O O
relevant O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
doses O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
down-regulated O O
phorbol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12-myristate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
13-acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PMA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
-induced O O
adhesion O B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
molecule O B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
expression O B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O O
cell-cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
adhesion O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

Inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
PMA-induced O B_GENE/B_LOCATION
ICAM-1 O I_GENE/I_LOCATION
and O O
VCAM-1 O O
expression O B_GENE
as O O
well O O
as O O
PMA-induced O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
adhesion O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Jurkat O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
T-cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
to O O
ECV O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
alpha-lipoate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
dose O B_DISEASE_ADJECTIVE[DISEASE]
dependent O I_DISEASE_ADJECTIVE[DISEASE]
( O O
50-250 O B_MEASURE
microM O I_MEASURE
) O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
demonstrate O O
that O O
HIV-1 B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
envelope I B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
glycoproteins I B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
both O O
T-cell-tropic O O
and O O
macrophagetropic O O
strains O O
rapidly O O
activate O O
the O O
ERK/mitogen-activated O O
protein O O
( O O
MAP O O
) O O
kinase O O
pathway O O
and O O
the O O
binding O O
of O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AP-1 B B_GENE
, O O
NF-kappaB B B_GENE
, O O
and O O
C/EBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
stimulate O O
expression O O
of O O
cytokine B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemokine I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Cytosolic B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GR B B_LOCATION/B_ORGANIZATION
) O O
binding O O
studies O O
on O O
immune O O
tissues O O
demonstrate O O
that O O
the O O
thymus O O
exhibits O O
three O O
to O O
four O O
times O O
higher O O
levels O O
of O O
GR B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
than O O
the O O
spleen O O
. O O

High O O
levels O O
of O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
consistent O O
with O O
the O O
exquisite O O
sensitivity O O
of O O
the O O
thymus O O
to O O
glucocorticoid O O
exposure O O
. O O

Nevertheless O O
, O O
whole O O
cell O O
binding O O
studies O O
reveal O O
similar O O
levels O O
of O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
immature O O
thymic O O
T O O
lymphocytes O O
and O O
more O O
mature O O
, O O
splenic O O
T O O
lymphocytes O O
. O O

Moreover O O
, O O
whole O O
cell O O
binding O O
techniques O O
indicate O O
that O O
neutrophils O O
( O O
which O O
represent O O
roughly O O
30 O O
% O O
of O O
splenic O O
leukocytes O O
) O O
exhibit O O
higher O O
GR B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
than O O
both O O
T O O
and O O
B O O
lymphocytes O O
, O O
further O O
contradicting O O
results O O
from O O
cytosolic O O
binding O O
studies O O
. O O

In O O
addition O O
, O O
neutrophils O O
were O O
found O O
to O O
have O O
fewer O O
GR B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
than O O
lymphocytes O O
and O O
monocytes O O
. O O

Functional O O
replacement O O
of O O
the O O
mouse B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
E2A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
a O O
human B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
HEB I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
cDNA I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
understand O O
the O O
molecular O O
basis O O
of O O
the O O
functional O O
specificity O O
between O O
E2A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
HEB B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
E2-2 B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mammalian O O
development O O
, O O
we O O
generated O O
and O O
tested O O
a O O
panel O O
of O O
E2A B B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
knockin O O
mutations O O
including O O
subtle O O
mutations O O
in O O
the O O
E12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E47 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exons I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
substitution O O
of O O
both O O
E12 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E47 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
exons I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
a O O
human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
HEB I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cDNA I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Finally O O
, O O
the O O
postnatal O O
lethality O O
associated O O
with O O
E2A B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
disruption O O
is O O
fully O O
rescued O O
by O O
the O O
addition O O
of O O
HEB B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
signals O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O O
by O O
ligation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
TCR O B_GENE
, O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
need O O
additional O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O O
co-stimulatory O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
be O O
activated O O
. O O

Duplication O O
of O O
at O O
least O O
a O O
portion O O
of O O
the O O
DR3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
the O O
extracellular B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
transmembrane I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
regions I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
but O O
not O O
the O O
cytoplasmic B B_GENE
domain I I_GENE
, O O
was O O
demonstrated O O
by O O
both O O
fluorescence O O
in O O
situ O O
hybridization O O
and O O
genomic O O
Southern O O
blotting O O
. O O

The O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cycloheximide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
granulocyte/macrophage O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
progenitors O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
CFU-GM O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
) O O
after O O
in O O
vitro O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
Ara-C O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BIO
exposure O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BIO
was O O
examined O O
using O O
normal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
human O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
bone O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
marrow O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
, O O
malignant O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
patients O B_PERSON/B_BIO
with O O
chronic O B_DISEASE
myelogenous O I_DISEASE
leukemia O I_DISEASE
( O O
CML O B_LOCATION/B_ORGANIZATION
) O O
, O O
and O O
clonogenic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
the O O
human O B_DISEASE/B_BIO
acute O I_DISEASE/I_BIO
nonlymphocytic O I_DISEASE/I_BIO
leukemia O I_DISEASE/I_BIO
cell O I_DISEASE/I_BIO
lines O I_DISEASE/I_BIO
HL-60 O O
and O O
KG-1 O B_GENE/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Using O O
whole O O
cell O O
assays O O
, O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
patients O O
were O O
found O O
to O O
have O O
reduced O O
total O O
binding O O
capacity O O
. O O

We O O
conclude O O
that O O
these O O
two O O
patients O O
, O O
members O O
of O O
the O O
same O O
family O O
, O O
have O O
primary O O
cortisol O O
resistance O O
accompanied O O
by O O
a O O
reduced O O
number O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

[ O O
Glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
response O O
to O O
polychemotherapy O O
in O O
acute O O
lymphatic O O
leukemia O O
] O O

Glucocorticoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GR B B_LOCATION/B_ORGANIZATION
) O O
levels O O
were O O
quantified O O
in O O
leukemic O O
blasts O O
from O O
peripheral O O
blood O O
of O O
86 O O
patients O O
with O O
acute O O
lymphoblastic O O
leukemia O O
. O O

We O O
have O O
examined O O
mononuclear O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparations O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
patients O B_PERSON/B_BIO
with O O
chronic O B_DISEASE
myeloid O I_DISEASE
leukemia O I_DISEASE
[ O I_DISEASE
CML O I_DISEASE
] O O
for O O
binding O O
of O O
and O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
1 O B_NUMBER[MEASURE]
, O O
25-dihydroxycholecalciferol O B_MEASURE
[ O I_MEASURE
1 O I_MEASURE
, O O
25- O B_MEASURE
( O O
OH O B_LOCATION/B_MEASURE
) O O
2D3 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
cytosols O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
prepared O O
from O O
a O O
mixture O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
CML O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
and O O
1 O B_NUMBER[MEASURE]
, O O
25- O B_MEASURE
( O O
OH O B_MEASURE/B_PROTEIN[GENE]
) O O
2D3 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor-positive O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
T47D O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
human O B_DISEASE/B_LOCATION
breast O I_DISEASE/I_LOCATION
cancer O I_DISEASE/I_LOCATION
) O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
had O O
less O B_MEASURE
than O O
10 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
the O O
binding O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
measured O O
in O O
T47D O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cytosol O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
alone O O
. O O

Thus O O
, O O
CML O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
appear O O
to O O
contain O O
both O O
the O O
receptor O B_GENE
for O O
1 O B_MEASURE
, O O
25- O B_MEASURE
( O O
OH O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
an O O
unknown O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
substance O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
which O O
prevents O O
its O O
detection O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
following O O
the O O
preparation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cytosol O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

We O O
conclude O O
that O O
the O O
differentiation-induction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
1 O B_MEASURE
, O O
25- O B_MEASURE
( O O
OH O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
is O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
depend O O
on O O
adequate O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
receptor O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
that O O
intact O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
rather O O
than O O
cytosol O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
preparations O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
should O O
be O O
studied O O
before O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
a O O
particular O B_DISEASE/B_MEASURE
tissue O I_DISEASE/I_MEASURE
are O O
designated O O
as O O
receptor O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
negative O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
increase O O
was O O
specific O O
for O O
glucocorticoid B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
receptor I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
ligands O O
. O O

As O O
compared O O
to O O
the O O
reference O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
compound O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
dexamethasone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O O
relative O B_TIME[MEASURE]/B_LOCATION
receptor O I_TIME[MEASURE]/I_LOCATION
binding O I_TIME[MEASURE]/I_LOCATION
affinity O I_TIME[MEASURE]/I_LOCATION
defined O O
as O O
100 O B_MEASURE
% O I_MEASURE
) O O
, O O
two O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potent O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthetic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
progestins O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
a O O
pregnane-type O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
megestrol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
medroxyprogesterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
were O O
found O O
to O O
display O O
a O O
considerable O B_MEASURE
binding O I_MEASURE
affinity O I_MEASURE
towards O O
the O O
receptor O B_GENE
( O O
46 O B_MEASURE
and O O
42 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
respectively O O
) O O
. O O

The O O
relative O B_MEASURE/B_DISEASE
binding O I_MEASURE/I_DISEASE
affinity O I_MEASURE/I_DISEASE
of O O
the O O
naturally O O
occurring O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
to O O
the O O
receptor O B_GENE
was O O
clearly O O
lower O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
25 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
. O O

These O O
included O O
inhibition O O
of O O
the O O
proliferative O O
responses O O
to O O
the O O
T-cell B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mitogens I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concanavalin B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
phytohaemagglutinin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O O
an O O
enhanced O O
accumulation O O
of O O
immunoglobulin O O
secreting O O
cells O O
in O O
pokeweed O O
mitogen-stimulated O O
cultures O O
. O O

Human O O
chronic O O
lymphocytic O O
leukemia O O
( O O
CLL O O
) O O
cells O O
like O O
prothymocytes O O
and O O
immunoactivated O O
T-lymphocytes O O
are O O
readily O O
lysed O O
in O O
vitro O O
by O O
pharmacological O O
concentrations O O
of O O
glucocorticoids O O
such O O
as O O
cortisol O O
, O O
whereas O O
peripheral O O
blood O O
lymphocytes O O
and O O
thymocytes O O
are O O
unaffected O O
by O O
the O O
hormone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Ultrastructural O O
studies O O
demonstrated O O
sequential O O
changes O O
in O O
the O O
cytoplasm O O
, O O
including O O
swelling O O
of O O
mitochondria O O
and O O
cytoplasmic O O
decompartmentalization O O
, O O
followed O O
by O O
loss O O
of O O
surface O O
microvilli O O
with O O
the O O
appearance O O
of O O
`` O O
holes O O
'' O O
in O O
the O O
cell O O
membrane O O
, O O
and O O
subsequent O O
condensation O O
of O O
nuclear B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
chromatin I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
large O O
holes O O
in O O
the O O
membrane O O
appearing O O
after O O
6 O O
hr O O
of O O
incubation O O
with O O
the O O
hormone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
be O O
the O O
cause O O
for O O
the O O
penetration O O
of O O
the O O
viable O O
stain O O
into O O
the O O
dead O O
cells O O
, O O
as O O
seen O O
by O O
light O O
microscopy O O
. O O

Glucocorticoid B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
lymphoid O O
tumors O O
. O O

All O O
clinical O O
specimens O O
from O O
patients O O
with O O
lymphatic O O
leukemia O O
have O O
some O O
measurable O O
level O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
; O O
therefore O O
, O O
the O O
resistance O O
seen O O
in O O
vivo O O
can O O
not O O
be O O
explained O O
by O O
the O O
lack O O
of O O
receptors O O
. O O

On O O
the O O
basis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
it O O
is O O
proposed O O
that O O
perhaps O O
the O O
high O B_DISEASE/B_PERSON
receptor O I_DISEASE/I_PERSON
cell O I_DISEASE/I_PERSON
lines O I_DISEASE/I_PERSON
( O O
i.e. O O
, O O
common O B_LOCATION/B_MEASURE
ALL O O
of O O
childhood O B_PERSON/B_DISEASE
) O O
have O O
relative O B_MEASURE
stability O I_MEASURE
of O O
their O O
genetic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
material O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
making O O
glucocorticoid-resistant O B_DISEASE
mutations O I_DISEASE
less O O
likely O B_DISEASE_ADJECTIVE[DISEASE]
to O O
occur O O
in O O
patients O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
these O O
cells O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
than O O
in O O
low-receptor O B_DISEASE/B_PERSON
cell O I_DISEASE/I_PERSON
lines O I_DISEASE/I_PERSON
( O O
i.e. O O
, O O
T-cell O B_DISEASE/B_PERSON
leukemia O I_DISEASE/I_PERSON
) O O
. O O

[ O O
Tumor O O
histology O O
and O O
steroid B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
receptors I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
breast O O
carcinoma O O
] O O

In O O
Specimens O O
of O O
115 O O
patients O O
with O O
breast O O
cancer O O
4 O O
tumorparameters O O
( O O
tumorsize O O
, O O
tumorboder O O
, O O
nucleargrade O O
, O O
lymphocytic O O
stromal O O
reaction O O
) O O
3 O O
features O O
of O O
regional O O
lymphnodes O O
( O O
sinushistiocytosis O O
, O O
T-cellreaction O O
, O O
lymphnode O O
metastases O O
) O O
and O O
estrogen B B_DISEASE
and I I_DISEASE
progesteron I I_DISEASE
receptors I I_DISEASE
were O O
determined O O
. O O

We O O
have O O
investigated O O
this O O
syndrome O O
for O O
the O O
possibility O O
of O O
abnormal B B_DISEASE_ADJECTIVE[DISEASE]
Type I I_DISEASE_ADJECTIVE[DISEASE]
I I I_DISEASE_ADJECTIVE[DISEASE]
or O O
`` B B_MEASURE/B_PROTEIN[GENE]
mineralocorticoid-like I I_MEASURE/I_PROTEIN[GENE]
'' I I_MEASURE/I_PROTEIN[GENE]
receptors I I_MEASURE/I_PROTEIN[GENE]
, O O
which O O
have O O
intrinsic O O
steroid O O
specificity O O
indistinguishable O O
from O O
that O O
of O O
renal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mineralocorticoid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
are O O
found O O
in O O
many O O
tissues O O
and O O
cells O O
, O O
including O O
mononuclear O O
leukocytes O O
. O O

Percoll-separated O B_MEASURE/B_GENE
control O I_MEASURE/I_GENE
monocytes O I_MEASURE/I_GENE
bound O O
[ O O
3H O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
aldosterone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
affinity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
Kd O B_PROTEIN[GENE]/B_MEASURE
approximately O O
3 O B_MEASURE/B_COLOR
nM O I_MEASURE/I_COLOR
) O O
and O O
limited O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
capacity O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
150 O B_MEASURE/B_LOCATION
to O O
600 O B_MEASURE/B_ENT
sites O I_MEASURE/I_ENT
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
) O O
. O O

Two O B_MEASURE/B_LOCATION
human O I_MEASURE/I_LOCATION
lymphoblast O I_MEASURE/I_LOCATION
cell O I_MEASURE/I_LOCATION
lines O I_MEASURE/I_LOCATION
, O O
LICR-LON-HMy2 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
( O O
HMy2 O B_GENE
cells O I_GENE
) O O
and O O
GM4672A O B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
are O O
moderately O O
growth O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibited O O
by O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
1 O B_MEASURE
, O O
4-pregnadien-9-fluoro-16 O B_TIME[MEASURE]
alpha-methyl-11 O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
17 O B_MEASURE/B_PERSON
alpha O I_MEASURE/I_PERSON
, O O
21-triol-3 O B_MEASURE
, O O
20-dione O B_MEASURE
) O O
( O O
Dex O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Both O O
cell O O
types O O
secrete O O
a O O
urokinase B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
UK I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
-like I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
plasminogen I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PA B B_LOCATION/B_ORGANIZATION
) O O
. O O

HMy2 O O
cell O O
PA B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
is O O
fully O O
suppressible O O
by O O
Dex O O
, O O
whereas O O
up O O
to O O
one O O
third O O
of O O
the O O
activator O O
expressed O O
by O O
GM4672A O O
cells O O
is O O
resistant O O
to O O
glucocorticoid O O
inhibition O O
. O O

Mixing O O
experiments O O
using O O
a O O
UK O O
standard O O
and O O
conditioned O O
media O O
from O O
Dex-treated O O
cells O O
suggest O O
an O O
absence O O
of O O
glucocorticoid-inducible B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
UK B B_GENE
or O O
plasmin B B_LOCATION
in O O
both O O
cell O O
types O O
. O O

Thus O O
, O O
low O O
levels O O
of O O
glucocorticoid-inducible B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
contribute O O
to O O
, O O
but O O
can O O
not O O
fully O O
account O O
for O O
, O O
Dex O O
inhibition O O
of O O
GM4672A B B_GENE
PA I I_GENE
activity O O
. O O

Thus O O
, O O
regulation O O
of O O
UK-like B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PAs I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
HMy2 O O
and O O
GM4672A O O
cells O O
differs O O
with O O
respect O O
to O O
the O O
extent O O
to O O
which O O
glucocorticoids O O
inhibit O O
constitutively B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expressed I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O O
, O O
as O O
well O O
as O O
the O O
possible O O
contribution O O
of O O
glucocorticoid-inducible B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
regulatory O O
process O O
in O O
GM4672A O O
cells O O
. O O

Characterization O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
aldosterone O B_GENE
binding O I_GENE
sites O I_GENE
in O O
circulating O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
mononuclear O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
leukocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

Aldosterone O B_GENE/B_PERSON
binding O I_GENE
sites O B_LOCATION/B_ENT
in O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
mononuclear O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
leukocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
were O O
characterized O O
after O O
separation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
blood O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
a O O
Percoll O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gradient O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Aldosterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
binds O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
a O O
single O B_MEASURE/B_LOCATION
class O B_MEASURE/I_LOCATION
of O O
receptors O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
an O O
affinity O B_MEASURE
of O O
2.7 O B_MEASURE
+/- O I_MEASURE
0.5 O I_MEASURE
nM O I_MEASURE
( O O
means O B_MEASURE/B_LOCATION
+/- O O
SD O B_MEASURE/B_DISEASE
, O O
n O O
= O O
14 O B_MEASURE
) O O
and O O
a O O
capacity O B_MEASURE/B_LOCATION
of O O
290 O B_MEASURE
+/- O O
108 O B_MEASURE
sites/cell O I_MEASURE
( O O
n O B_MEASURE/B_LOCATION
= O O
14 O B_MEASURE
) O O
. O O

Mineralocorticoid B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
circulating O O
mononuclear O O
leukocytes O O
of O O
patients O O
with O O
primary O O
hyperaldosteronism O O
. O O

The O O
affinity O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
aldosterone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O O
the O O
receptor O B_GENE
was O O
found O O
to O O
be O O
not O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
that O O
of O O
healthy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
control O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
subjects O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Estrogens O O
stimulate O O
some O O
aspects O O
of O O
macrophage O O
activity O O
and O O
, O O
depending O O
on O O
dose O O
and O O
mitogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
inhibit O O
or O O
stimulate O O
lymphocyte O O
proliferative O O
response O O
in O O
vitro O O
. O O

Lymphocytes O O
from O O
adult O O
, O O
neonatally O O
DES-treated O O
female O O
mice O O
have O O
a O O
reduced O O
mitogen O O
response O O
to O O
ConA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
LPS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
T B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mitogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
the O O
delayed O O
type O O
hypersensitivity O O
response O O
is O O
depressed O O
. O O

The O O
activity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Natural O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
Killer O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
permanently O O
reduced O O
and O O
this O O
functional O B_DISEASE_ADJECTIVE[DISEASE]
impairment O I_DISEASE_ADJECTIVE[DISEASE]
is O O
related O O
to O O
a O O
decreased O O
number O B_MEASURE
of O O
these O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
in O O
turn O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
determined O O
at O O
the O O
bone O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
marrow O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
level O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
. O O

Natural O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
killer O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O O
NK O B_PROTEIN[GENE]/B_LOCATION
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
form O O
an O O
antitumor O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
surveillance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
system O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
appear O O
to O O
be O O
vital O B_DISEASE_ADJECTIVE[DISEASE]
in O O
preventing O O
tumor O B_DISEASE
growth O I_DISEASE
and O O
metastasis O B_DISEASE/B_ORGANISM_FUNCTION
in O O
animal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

Serum O O
sex O O
steroid O O
and O O
peptide O O
hormone O O
concentrations O O
, O O
and O O
endometrial O O
estrogen O O
and O O
progestin O O
receptor O O
levels O O
during O O
administration O O
of O O
human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
leukocyte I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interferon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Five O O
normally O O
cycling O O
healthy O O
women O O
were O O
given O O
daily O O
subcutaneous O O
injections O O
of O O
human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
leukocyte I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interferon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
3 O O
X O O
10 O O
( O O
6 O O
) O O
units/day O O
) O O
from O O
the O O
3rd O O
through O O
23rd O O
day O O
of O O
the O O
menstrual O O
cycle O O
, O O
and O O
serum O O
steroid O O
and O O
peptide O O
hormone O O
concentrations O O
monitored O O
at O O
3-day O O
intervals O O
during O O
the O O
treatment O O
and O O
the O O
preceding O O
control O O
cycle O O
. O O

Concentrations O O
of O O
cytosol B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nuclear I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
estrogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
ERC B B_LOCATION/B_ORGANIZATION
and O O
ERN B B_LOCATION/B_ORGANIZATION
, O O
respectively O O
) O O
and O O
progestin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PRC B B_LOCATION
and O O
PRN B B_LOCATION/B_ORGANIZATION
) O O
were O O
also O O
measured O O
from O O
endometrial O O
biopsies O O
taken O O
on O O
the O O
24th O O
day O O
of O O
the O O
control O O
and O O
treatment O O
cycle O O
. O O

No O O
significant O O
changes O O
were O O
observed O O
in O O
the O O
serum O O
peptide O O
hormone O O
concentrations O O
measured O O
( O O
FSH O O
, O O
LH O O
, O O
prolactin O O
, O O
insulin O O
, O O
growth O O
hormone O O
and O O
TSH O O
) O O
; O O
neither O O
were O O
the O O
levels O O
of O O
endometrial B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ERC I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ERN I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
PRC I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
PRN I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
affected O O
by O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administration O O
. O O

As O O
expected O O
, O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O O
resulted O O
in O O
decreased O O
leukocyte O O
counts O O
. O O

Moreover O O
, O O
an O O
increasing O O
tendency O O
in O O
the O O
activities O O
of O O
serum B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
alkaline I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
gamma-glutamyltransferase B B_GENE
during O O
the O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O O
shows O O
that O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
may O O
slightly O O
interfere O O
with O O
the O O
liver O O
function O O
. O O

But O O
in O O
the O O
patients O O
with O O
acute O O
pancreatitis O O
the O O
decrease O O
in O O
content O O
of O O
leukocyte B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
not O O
observed O O
although O O
there O O
was O O
an O O
increase O O
in O O
cortisol O O
concentration O O
in O O
blood O O
. O O

The O O
role O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
immunological O O
processes O O
under O O
conditions O O
of O O
purulent O O
complications O O
and O O
possibility O O
to O O
regulate O O
the O O
metabolism O O
in O O
leukocytes O O

Therapeutic O O
concentrations O O
of O O
glucocorticoids O O
suppress O O
the O O
antimicrobial O O
activity O O
of O O
human O O
macrophages O O
without O O
impairing O O
their O O
responsiveness O O
to O O
gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Proliferating O O
lymphocytes O O
and O O
gamma-interferon B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thus O O
increased O O
the O O
antimicrobial O O
activity O O
of O O
phagocytes O O
exposed O O
to O O
glucocorticoids O O
over O O
that O O
of O O
control O O
cells O O
. O O

Macrophage O O
activation O O
and O O
correction O O
of O O
the O O
dexamethasone O O
effect O O
by O O
gamma-interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
however O O
, O O
was O O
dependent O O
on O O
the O O
pathogen O O
. O O

Suppression O O
of O O
macrophage O O
antimicrobial O O
activity O O
should O O
thus O O
be O O
considered O O
when O O
treating O O
patients O O
with O O
glucocorticoids O O
; O O
its O O
prevention O O
by O O
gamma-interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O O
be O O
beneficial O O
for O O
some O O
but O O
not O O
all O O
pathogens O O
. O O

Using O O
anti-Tac B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
a O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
recognizes O O
the O O
IL-2 B B_GENE
receptor I I_GENE
, O O
the O O
receptor O O
has O O
been O O
purified O O
and O O
shown O O
to O O
be O O
a O O
Mr O O
33 O O
, O O
000 O O
peptide O O
that O O
is O O
posttranslationally O O
glycosylated O O
to O O
a O O
Mr O O
55 O O
, O O
000 O O
mature O O
form O O
. O O

Two O O
patients O O
with O O
Tac-positive O O
adult O O
T-cell O O
leukemia O O
have O O
been O O
treated O O
with O O
the O O
anti-Tac B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

One O O
of O O
the O O
patients O O
had O O
6- O O
and O O
3-mo O O
remissions O O
of O O
his O O
leukemia O O
following O O
two O O
courses O O
of O O
therapy O O
with O O
this O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
directed O O
toward O O
this O O
growth B B_PROTEIN[GENE]/B_DISEASE
factor I I_PROTEIN[GENE]/I_DISEASE
receptor I I_PROTEIN[GENE]/I_DISEASE
. O O

In O O
intact O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
receptor O B_MEASURE/B_LOCATION
number O I_MEASURE/I_LOCATION
, O O
affinity O B_GENE/B_MEASURE
and O O
activity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
can O O
change O O
in O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
factors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
bind O O
to O O
the O O
receptor O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
or O O
that O O
act O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indirectly O O
through O O
ill-defined O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O O
may O O
include O O
resumption O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
arrest O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
cycling O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O O
variations O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
intracellular O B_MEASURE/B_DISEASE
calcium O I_MEASURE/I_DISEASE
ion O I_MEASURE/I_DISEASE
concentrations O I_MEASURE/I_DISEASE
. O O

Some O O
of O O
these O O
factors O O
appear O O
to O O
exert O O
their O O
effect O O
by O O
controlling O O
critical O O
receptor O O
properties O O
such O O
as O O
ATP-dependent O O
phosphorylation O O
, O O
integrity O O
of O O
thiol B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
exposure O O
of O O
key B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
amino I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
residues I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
agonists O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
promote O O
the O O
'transformation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
' O O
of O O
the O O
receptor O B_GENE
into O O
the O O
DNA-binding O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
state O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
which O O
is O O
competent O B_DISEASE_ADJECTIVE[DISEASE]
for O O
modulating O O
gene O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Glucocorticoid O O
antagonists O O
are O O
steroids O O
that O O
interact O O
with O O
the O O
receptor O O
but O O
either O O
fail O O
to O O
produce O O
a O O
stable B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
complex I B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
or O O
produce O O
a O O
stable B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
but I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inefficient I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Most O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O O
receptor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
accommodated O O
by O O
postulating O O
the O O
existence O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
an O O
intracellular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
involves O O
five O B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
states O I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
the O O
receptor O B_GENE
. O O

The O O
active O B_GENE
free O I_GENE
receptor O I_GENE
is O O
phosphorylated O O
, O O
reduced O O
, O O
and O O
presumably O O
oligomeric O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
( O O
state O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Following O O
binding O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
an O O
agonist O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
state O B_LOCATION/B_MEASURE
B O I_LOCATION/I_MEASURE
) O O
, O O
it O O
can O O
become O O
transformed O O
by O O
dissociation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
into O O
its O O
subunits O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
dephosphorylation O B_ENZYME[GENE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
state O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

The O O
transformed B B_GENE
receptor I I_GENE
then O O
interacts O O
with O O
chromatin B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
state O O
D O O
) O O
. O O

Dissociation O O
of O O
the O O
steroid O O
and O O
oxidation O O
of O O
receptor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thiol I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
s O O
) O O
lead O O
to O O
the O O
inactive O O
receptor O O
form O O
( O O
state O O
E O O
) O O
. O O

Reduction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
rephosphorylation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
the O O
receptor O B_GENE
enable O O
it O O
to O O
bind O O
steroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
again O O
so O O
that O O
the O O
cycle O B_TIME[MEASURE]/B_LOCATION
is O O
closed O O
. O O

The O O
thermodynamics O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
interaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
with O O
their O O
receptor O B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
studied O O
in O O
cytosol O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
from O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoblastoid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Few O O
but O O
significant O O
numbers O O
of O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2700/cell O O
) O O
and O O
no O O
insulin B B_GENE
receptors I I_GENE
( O O
-1/cell O O
) O O
were O O
found O O
in O O
the O O
resting O O
( O O
G0 O O
) O O
phase O O
. O O

As O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
entered O O
the O O
G1a O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
the O O
specific O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
increased O O
and O O
of O O
insulin O B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
took O O
place O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
cortico-sensitivity O O
in O O
a O O
human O O
clonal O O
monocytic O O
cell O O
line O O
, O O
CM-SM O O
. O O

Untreated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
CM-SM O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
contain O O
single O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
class O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
high-affinity O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
( O O
KD O B_DISEASE/B_PROTEIN[GENE]
= O O
4.0 O B_MEASURE/B_LOCATION
X O I_MEASURE/I_LOCATION
10 O I_MEASURE/I_LOCATION
( O O
-9 O O
) O O
M O B_OTHER/B_MEASURE
) O O
glucocorticoid-specific O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
approximately O O
60 O B_MEASURE
, O O
000 O B_MEASURE
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
) O O
, O O
as O O
measured O O
by O O
a O O
whole O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
at O O
37 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
, O O
using O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triamcinolone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

TA-receptor O B_GENE
sites O I_GENE
rapidly O O
decreased O O
( O O
about O O
70 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
after O O
DEX O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
without O O
any O O
apparent O B_DISEASE_ADJECTIVE[DISEASE]
change O I_DISEASE_ADJECTIVE[DISEASE]
in O O
steroid O B_MEASURE/B_LOCATION
specificity O I_MEASURE/I_LOCATION
and O O
affinity O B_GENE/B_MEASURE
. O O

DEX O O
almost O O
completely O O
inhibited O O
TPA O O
activation O O
of O O
the O O
following O O
macrophage O O
functions O O
: O O
adherency O O
to O O
the O O
culture O O
plate O O
, O O
expression O O
of O O
lysosomal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enzymes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
Fc B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
and I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
C3 I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
receptors I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
, O O
and O O
stimulation O O
of O O
phagocytosis O O
. O O

Disease-free O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
survival O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
DFS O B_DISEASE
) O O
in O O
childhood O B_PERSON/B_MEASURE
ALL O O
is O O
60 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
and O O
survival O B_MEASURE/B_DISEASE
in O O
good O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
average O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
poor O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
prognostic O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
groups O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
defined O O
by O O
initial O B_MEASURE/B_PERSON
WBC O B_MEASURE/I_PERSON
and O O
age O B_GENE
is O O
90 O B_MEASURE
, O O
60 O B_MEASURE
, O O
and O O
45 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
respectively O O
. O O

Glucocorticoid B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
vitro O O
sensitivity O O
to O O
steroid O O
hormones O O
in O O
human O O
lymphoproliferative O O
diseases O O
and O O
myeloid O O
leukemia O O
. O O

Within O O
the O O
lymphoproliferative O O
diseases O O
, O O
ALL O O
cells O O
exhibited O O
the O O
highest O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentration O O
( O O
regardless O O
of O O
the O O
method O O
used O O
) O O
and O O
the O O
highest O O
in O O
vitro O O
inhibition O O
of O O
spontaneous O O
[ O O
3H O O
] O O
thymidine O O
( O O
[ O O
3H O O
] O O
TdR O O
) O O
uptake O O
by O O
glucocorticoids O O
. O O

A O O
significant O O
relationship O O
between O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentration O O
( O O
whole-cell O O
assay O O
) O O
and O O
in O O
vitro O O
sensitivity O O
to O O
dexamethasone O O
was O O
also O O
found O O
. O O

Concerning O O
myeloid O O
leukemia O O
, O O
ANLL O O
patients O O
had O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentrations O O
slightly O O
higher O O
than O O
those O O
found O O
in O O
the O O
ALL O O
group O O
but O O
exhibited O O
the O O
lowest O O
degree O O
of O O
inhibition O O
of O O
spontaneous O O
[ O O
3H O O
] O O
TdR O O
uptake O O
by O O
dexamethasone O O
( O O
stimulatory O O
effects O O
occurred O O
in O O
some O O
cases O O
) O O
. O O

Glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
vitro O O
corticosensitivity O O
of O O
peanut-positive O O
and O O
peanut-negative O O
human O O
thymocyte O O
subpopulations O O
. O O

The O O
unagglutinated O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
thymocytes O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
( O O
peanut O B_DISEASE_ADJECTIVE[DISEASE]
negative O I_DISEASE_ADJECTIVE[DISEASE]
) O O
contained O O
about O O
2 O B_MEASURE/B_ORGANIZATION
times O I_MEASURE/I_ORGANIZATION
more O I_MEASURE/I_ORGANIZATION
receptor O I_MEASURE/I_ORGANIZATION
sites O I_MEASURE/I_ORGANIZATION
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
than O O
agglutinated O O
( O O
peanut O B_DISEASE_ADJECTIVE[DISEASE]
positive O I_DISEASE_ADJECTIVE[DISEASE]
) O O
ones O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
7650 O B_PROTEIN[GENE]/B_LOCATION
+/- O I_PROTEIN[GENE]/I_LOCATION
1550 O I_PROTEIN[GENE]/I_LOCATION
S.D. O O
verus O B_MEASURE/B_PERSON
3195 O I_MEASURE/I_PERSON
+/- O O
896 O B_MEASURE
S.D. O O
) O O
. O O

The O O
affinity O B_GENE/B_MEASURE
for O O
steroid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
both O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
subsets O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
as O O
was O O
the O O
stereospecificity O B_MEASURE
for O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
time-course O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
steroid-receptor O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
association O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
cytoplasmic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
to O O
nuclear O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
translocation O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
studied O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
six O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
from O O
four O B_LOCATION/B_ENT
different O I_LOCATION/I_ENT
kindreds O I_LOCATION/I_ENT
with O O
the O O
syndrome O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hereditary O B_DISEASE
end-organ O I_DISEASE
resistance O I_DISEASE
to O O
1 O B_MEASURE
, O O
25 O B_MEASURE
( O O
OH O O
) O O
2D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
the O O
so-called O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
vitamin O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
D-dependent O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
rickets O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
type O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
II O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
) O O
. O O

Moreover O O
, O O
in O O
contrast O O
to O O
normal O O
lymphocytes O O
, O O
the O O
mitogenic O O
stimulation O O
of O O
these O O
patients O O
' O O
lymphocytes O O
by O O
phytohemagglutinin B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
concanavalin O O
A O O
was O O
not O O
inhibited O O
by O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
. O O

Glucocorticoid B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
receptors I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
mononuclear O O
leukocytes O O
from O O
myasthenia O O
gravis O O
patients O O
. O O

The O O
present O O
study O O
was O O
performed O O
to O O
analyse O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
GR B B_LOCATION/B_ORGANIZATION
) O O
binding O O
in O O
peripheral O O
blood O O
mononuclear O O
leukocytes O O
( O O
MNL O O
) O O
from O O
39 O O
myasthenia O O
gravis O O
( O O
MG O O
) O O
patients O O
( O O
unoperated O O
patients O O
( O O
n O O
= O O
13 O O
) O O
, O O
thymectomized O O
patients O O
( O O
n O O
= O O
14 O O
) O O
and O O
patients O O
receiving O O
glucocorticoids O O
: O O
thymectomized O O
( O O
n O O
= O O
11 O O
) O O
and O O
unoperated O O
( O O
n O O
= O O
6 O O
] O O
. O O

GR B B_PERSON
mean O O
values O O
were O O
significantly O O
higher O O
in O O
the O O
MNL O O
of O O
MG O O
patients O O
( O O
thymectomized O O
or O O
not O O
) O O
not O O
receiving O O
glucocorticoid O O
than O O
in O O
the O O
MNL O O
of O O
healthy O O
donors O O
. O O

Affinity O B_GENE/B_TIME[MEASURE]
was O O
within O O
the O O
normal O B_MEASURE/B_LOCATION
range O B_MEASURE/I_LOCATION
. O O

Reduced O O
synthesis O B_MEASURE/B_GENE
of O O
B- O O
as O O
well O O
as O O
T-lymphocytes O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O O
be O O
seen O O
. O O

Reduced O O
T-cell O O
function O O
indicated O O
by O O
impaired O O
stimulation O O
by O O
PHA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
porkweed B B_DISEASE/B_GENE
as O O
well O O
as O O
by O O
impaired O O
lymphokinin O O
effects O O
on O O
leukocyte O O
migration O O
inhibition O O
has O O
been O O
reported O O
. O O

Identification O O
of O O
human B B_GENE/B_LOCATION
leukemic I I_GENE/I_LOCATION
glucocorticoid I I_GENE/I_LOCATION
receptors I I_GENE/I_LOCATION
using O O
affinity O O
labeling O O
and O O
anti-human B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
presence O O
of O O
anti-human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
verified O O
by O O
: O O
( O O
a O O
) O O
adsorption O O
of O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
3H I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
] I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
TA-receptor-antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
Protein B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
( O O
b O O
) O O
a O O
shift O O
to O O
higher O O
apparent O O
molecular O O
weight O O
in O O
the O O
elution O O
position O O
from O O
Sephacryl O O
S300 O O
of O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
3H I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
] I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
TA-receptor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
complexes I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
incubated O O
with O O
immune O O
serum O O
; O O
and O O
( O O
c O O
) O O
the O O
ability O O
of O O
immune O O
serum O O
to O O
displace O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
3H I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
] I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
TA-receptor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
complexes I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
on O O
sucrose O O
gradients O O
. O O

These O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
recognized O O
rat O O
liver O O
and O O
murine B B_BODY_PART_OR_ORGAN_COMPONENT/B_PROTEIN[GENE]
S49 I I_BODY_PART_OR_ORGAN_COMPONENT/I_PROTEIN[GENE]
cell I I_BODY_PART_OR_ORGAN_COMPONENT/I_PROTEIN[GENE]
glucocorticoid I I_BODY_PART_OR_ORGAN_COMPONENT/I_PROTEIN[GENE]
receptors I I_BODY_PART_OR_ORGAN_COMPONENT/I_PROTEIN[GENE]
. O O

Thus O O
, O O
the O O
combination O O
of O O
affinity O O
labeling O O
and O O
anti-human B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
capable O O
of O O
providing O O
direct O O
physical O O
identification O O
of O O
human B B_GENE
lymphoid I I_GENE
glucocorticoid I I_GENE
receptors I I_GENE
. O O

Incubation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
with O O
thymosin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fraction O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
( O O
TMS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
F5 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O O
300 O B_MEASURE/B_LOCATION
micrograms/ml O I_MEASURE/I_LOCATION
) O O
a O O
partially O O
purified O O
thymic O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor O B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
reduced O O
the O O
steroid O B_MEASURE/B_DISEASE
binding O I_MEASURE/I_DISEASE
activity O I_MEASURE/I_DISEASE
of O O
human O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
infant O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
thymocytes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
9.6 O B_MEASURE
+/- O O
2.1 O B_MEASURE
fmole/ml O I_MEASURE
to O O
5.0 O B_MEASURE
+/- O I_MEASURE
2.0 O I_MEASURE
fmole/ml O I_MEASURE
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
show O O
that O O
thymosin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O O
induce O O
changes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
consistent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O O
differentiation O B_PROTEIN[GENE]/B_DISEASE
in O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
thymocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
a O O
physiological O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
thymosin O B_GENE
in O O
intrathymic O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
T O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
maturation O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O O
man O B_SPECIES[BIO]
. O O

Human O B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
peripheral O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
monocytes O I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
have O O
high O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affinity O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
1 O B_MEASURE
, O O
25- O B_MEASURE
( O O
OH O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
Kd O B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0.14 O I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nM O I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
sedimentation O B_MEASURE/B_LOCATION
coefficient O I_MEASURE/I_LOCATION
3.7S O I_MEASURE/I_LOCATION
) O O
. O O

The O O
receptor O B_GENE
in O O
activated O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
has O O
a O O
sedimentation O B_MEASURE/B_LOCATION
coefficient O I_MEASURE/I_LOCATION
of O O
3.7S O B_MEASURE
and O O
a O O
high O B_LOCATION/B_MEASURE
affinity O B_LOCATION/I_MEASURE
( O O
Kd O B_LOCATION/B_MEASURE
0.10 O I_LOCATION/I_MEASURE
nM O I_LOCATION/I_MEASURE
) O O
for O O
the O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
binding O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indicated O O
that O O
increased O O
binding O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O B_PERSON/B_BIO
treated O O
with O O
prednisone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
due O O
to O O
an O O
ncrease O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
receptor O B_MEASURE/B_BIO
concentration O B_MEASURE/I_BIO
, O O
whereas O O
in O O
patients O B_PERSON/B_BIO
with O O
adrenocortical O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hyperfunction O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
was O O
due O O
to O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
receptor O B_MEASURE
affinity O I_MEASURE
. O O

Reduced O O
level O O
of O O
cellular B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucocorticoid I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
patients O O
with O O
anorexia O O
nervosa O O
. O O

Using O O
a O O
competitive O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
binding O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
whole O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cell O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
we O O
have O O
examined O O
the O O
binding O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
-dexamethasone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O O
24 O B_MEASURE
and O O
37 O B_MEASURE/B_LOCATION
degrees O I_MEASURE/I_LOCATION
C O I_MEASURE/I_LOCATION
in O O
untreated O B_PERSON/B_BIO
normal O I_PERSON/I_BIO
subjects O I_PERSON/I_BIO
and O O
in O O
healthy O B_PERSON/B_BIO
subjects O I_PERSON/I_BIO
taking O O
various O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
preparations O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Using O O
direct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imunofluorescence O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
lesions O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O O
266 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
human O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
breast O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specimens O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
studied O O
for O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
IgA O B_GENE
, O O
IgM O B_GENE/B_DISEASE
, O O
or O O
IgG O B_GENE
localization O I_GENE
. O O

A O O
detailed O O
histopathologic O O
review O O
of O O
50 O O
primary O O
breast O O
cancer O O
tumors O O
analyzed O O
for O O
estrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ER B B_PROTEIN[GENE]/B_LOCATION
) O O
level O O
was O O
carried O O
out O O
and O O
a O O
variety O O
of O O
morphologic O O
features O O
correlated O O
with O O
ER B B_LOCATION/B_GENE
results O O
to O O
identify O O
any O O
factors O O
that O O
will O O
improve O O
the O O
management O O
and O O
prognosis O O
for O O
breast O O
cancer O O
. O O

Breast O O
carcinomas O O
were O O
examined O O
by O O
the O O
immunoperoxidase O O
technique O O
using O O
antisera O O
specific O O
for O O
lymphocyte O O
subsets O O
, O O
monocytes O O
, O O
NK O O
cells O O
and O O
major B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histocompatibility I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antigens I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HLA-A B B_GENE
, O O
-B B B_PROTEIN[GENE]/B_LOCATION
, O O
-C O O
; O O
Ia-like B B_DISEASE/B_PERSON
) O O
. O O

Only O O
a O O
few O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
mononuclear O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
infiltrating O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
had O O
receptors O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
transferrin O B_GENE
. O O

Some O O
of O O
the O O
antisera O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
specific O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
lymphocyte O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
subsets O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
also O O
stained O O
the O O
breast O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
carcinoma O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
case O O
of O O
male O O
pseudohermaphroditism O O
with O O
normal O O
androgen B B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
receptor I I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
binding O O
and O O
47 O O
, O O
XYY O O
karyotype O O
. O O

Physiologic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
concentrations O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
1 O B_MEASURE
, O O
25- O B_MEASURE
( O O
OH O O
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
0.01 O B_MEASURE/B_LOCATION
to O O
0.1 O B_MEASURE
nm O I_MEASURE
) O O
inhibited O O
the O O
antigen-induced O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
secretion O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
of O O
IL O B_GENE
2 O I_GENE
by O O
several O B_NUMBER[MEASURE]/B_BIO
of O O
these O O
T O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hybridomas O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
the O O
T O B_DISEASE/B_PROTEIN[GENE]
hybridoma O B_DISEASE/I_PROTEIN[GENE]
but O O
not O O
the O O
TA3 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
stimulator O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
with O O
1 O B_MEASURE
, O O
25- O B_MEASURE
( O O
OH O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
resulted O O
in O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
activation O B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

These O O
results O O
are O O
consistent O O
with O O
the O O
finding O O
that O O
specific O O
1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
25- I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
OH I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2D3 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
present O O
on O O
the O O
T O O
cell O O
hybridomas O O
but O O
are O O
lacking O O
in O O
TA3 O O
cells O O
. O O

These O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
1 O B_MEASURE
, O O
25- O B_MEASURE
( O O
OH O O
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
may O O
be O O
interfering O O
with O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
events O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
antigen-induced O B_DISEASE
T O I_DISEASE
cell O I_DISEASE
activation O I_DISEASE
, O O
perhaps O O
by O O
hindering O O
T O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
recognition O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
relevant O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigen O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
stimulator O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
surfaces O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Given O O
these O O
facts O O
, O O
over O O
the O O
last O O
10 O O
years O O
, O O
several O O
investigators O O
have O O
measured O O
the O O
number O O
of O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
normal O O
and O O
neoplastic O O
lymphoid O O
tissue O O
to O O
see O O
whether O O
their O O
number O O
correlated O O
with O O
glucocorticoid O O
responsiveness O O
in O O
vitro O O
or O O
in O O
vivo O O
. O O

[ O O
Glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
normal O O
human O O
lymphocytes O O
] O O

Glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
GC O B_PROTEIN[GENE]/B_DISEASE
) O O
receptors O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
studied O O
in O O
intact O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
11 O B_PERSON/B_BIO
donors O B_PERSON/I_BIO
. O O

The O O
binding O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
estrogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
preparations O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
of O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
mononuclear O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
well O O
as O O
by O O
splenic O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
thymic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
demonstrated O O
by O O
three O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
different O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
approaches O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Dextran-coated O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
charcoal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whole O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
gel O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
filtration O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
a O O
sepharose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
4B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
column O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Physicochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
properties O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
binder O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
binding O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capacity O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
steroid O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
specificity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
are O O
quite O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
those O O
reported O O
for O O
the O O
thymus O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
small O B_SPECIES[BIO]
mammalian O I_SPECIES[BIO]
species O I_SPECIES[BIO]
or O O
human O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
thymoma O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Administration O O
of O O
fibroblast B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
patients O O
with O O
advanced O O
breast O O
cancer O O
: O O
possible O O
effects O O
on O O
skin O O
metastasis O O
and O O
on O O
hormone B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Eleven O O
patients O O
with O O
metastasized O O
breast O O
cancer O O
received O O
8 O O
intramuscular O O
injections O O
of O O
6 O O
x O O
10 O O
( O O
6 O O
) O O
units O O
of O O
human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fibroblast I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
interferon I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
over O O
a O O
period O O
of O O
40 O O
days O O
. O O

Lymphocytes O O
from O O
patients O O
with O O
untreated O O
adrenal O O
insufficiency O O
had O O
fewer O O
binding B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
3364 O O
+/-322 O O
) O O
and O O
a O O
2-fold O O
increase O O
in O O
binding O O
affinity O O
( O O
5.4 O O
+/- O O
0.9 O O
mM O O
) O O
. O O

No O O
correlation O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
found O O
between O O
activities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
enzymes O B_ENZYME[GENE]
and O O
remission O B_DISEASE
or O O
survival O B_DISEASE_ADJECTIVE[DISEASE]
rate O I_DISEASE_ADJECTIVE[DISEASE]
. O O

On O O
DEAE-cellulose O O
chromatography O O
, O O
[ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CVZ-receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
a O O
shift O O
from O O
high O O
( O O
0.25 O O
M O O
KP O O
) O O
to O O
low O O
salt O O
( O O
0.09 O O
M O O
KP O O
) O O
eluting O O
forms O O
upon O O
activation O O
. O O

In O O
contrast O B_MEASURE
, O O
the O O
binding O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
DEX O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
C7 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cytosol O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
revealed O O
a O O
single O B_MEASURE
class O I_MEASURE
of O O
binding O O
sites O B_LOCATION/B_ENT
( O O
Kd O B_PROTEIN[GENE]/B_LOCATION
= O O
1.9 O B_MEASURE/B_COLOR
nM O I_MEASURE/I_COLOR
; O O
receptor O B_MEASURE/B_LOCATION
concentration O I_MEASURE/I_LOCATION
, O O
0.46 O B_MEASURE/B_LOCATION
pmol/mg O I_MEASURE/I_LOCATION
protein O I_MEASURE/I_LOCATION
) O O
. O O

Examination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
binding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CVZ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
using O O
10 O B_NUMBER[MEASURE]/B_LOCATION
( O O
-5 O O
) O O
M O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DEX O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
the O O
competing O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
DEX O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binds O O
only O O
to O O
the O O
low O B_PROTEIN[GENE]/B_LOCATION
affinity O I_PROTEIN[GENE]/I_LOCATION
site O I_PROTEIN[GENE]/I_LOCATION
detected O O
by O O
[ O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
CVZ O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

An O O
assay O O
for O O
the O O
quantitation O O
of O O
cytoplasmic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
lymphoid O O
tissue O O
has O O
been O O
developed O O
using O O
controlled O O
pore O O
glass O O
( O O
CPG O O
) O O
beads O O
. O O

Soluble O O
receptor B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
-- I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
3H-steroid I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
cytosol O O
or O O
nuclear O O
extract O O
) O O
is O O
adsorbed O O
quantitatively O O
within O O
the O O
crevasses O O
of O O
porous O O
glass O O
beads O O
. O O

Previous O O
studies O O
, O O
however O O
, O O
have O O
not O O
revealed O O
any O O
consistent O O
relationship O O
between O O
clinical O O
responsiveness O O
and O O
the O O
cellular O O
or O O
cytosolic O O
concentration O O
of O O
glucocorticoid-binding B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sites I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Mean O B_MEASURE/B_LOCATION
and O O
median O B_MEASURE
cytosolic O I_MEASURE
receptor O I_MEASURE
concentrations O I_MEASURE
in O O
12 O B_MEASURE/B_DISEASE
acute O I_MEASURE/I_DISEASE
lymphoblastic O I_MEASURE/I_DISEASE
leukemia O I_MEASURE/I_DISEASE
specimens O I_MEASURE/I_DISEASE
lacking O O
the O O
standard O B_GENE
B-cell O I_GENE
or O O
T-cell O B_GENE
markers O I_GENE
( O O
`` O B_PROTEIN[GENE]/B_LOCATION
null O I_PROTEIN[GENE]/I_LOCATION
cells O O
'' O O
) O O
were O O
approximately O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
4-fold O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
higher O O
than O O
in O B_PERSON/B_BIO
23 O I_PERSON/I_BIO
other O I_PERSON/I_BIO
leukemic O I_PERSON/I_BIO
cell O I_PERSON/I_BIO
specimens O O

They O O
had O O
Stokes O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radii O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
Rs O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
of O O
8.1 O B_MEASURE
+/- O O
0.5 O B_MEASURE
( O O
S.D. O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
nm O O
( O B_MEASURE/B_LOCATION
n O O
= O B_OTHER/B_MEASURE
50 O O
) O B_MEASURE
, O O
sedimentation O O
coefficients O B_MEASURE
of O I_MEASURE
9.5 O O
+/- O B_MEASURE
0.3S O I_MEASURE
( O I_MEASURE
n O O
= O B_OTHER/B_MEASURE
40 O O
) O B_MEASURE
, O O
molecular O O
weights O B_MEASURE/B_LOCATION
of O I_MEASURE/I_LOCATION
approximately O O
330 O O
, O B_MEASURE
000 O O
, O B_MEASURE
and O O
axial O O
ratios O B_MEASURE
( O I_MEASURE
a/b O O
) O B_PROTEIN[GENE]/B_LOCATION
of O O
approximately O O
12 O O
. O B_NUMBER[MEASURE]/B_LOCATION

In O O
hypertonic O O
, O O
molybdate-free O O
buffer O O
, O O
these O O
oligomeric B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
dissociated O O
into O O
subunits O O
with O O
Rs O O
of O O
5.9 O O
+/- O O
0.3 O O
nm O O
( O O
n O O
= O O
12 O O
) O O
and O O
a/b O O
of O O
11 O O
to O O
12 O O
, O O
as O O
observed O O
previously O O
for O O
other O O
receptors O O
. O O

We O O
conclude O O
that O O
intrinsic O B_DISEASE_ADJECTIVE[DISEASE]
structural O I_DISEASE_ADJECTIVE[DISEASE]
defects O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
receptors O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
unlikely O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
explanations O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
unresponsiveness O B_DISEASE_ADJECTIVE[DISEASE]
of O O
some O O
types O B_PERSON/B_LOCATION
of O O
leukemia O B_DISEASE
to O O
steroid O O
therapy O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
order O O
to O O
elucidate O O
the O O
relationship O O
between O O
cell O O
water O O
content O O
and O O
number O O
of O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
eleven O O
normal O O
and O O
malignant O O
lymphoid O O
or O O
myelomonocytic O O
cell O O
types O O
originating O O
from O O
mouse O O
, O O
rat O O
and O O
man O O
were O O
investigated O O
. O O

When O O
intact O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
thymocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
are O O
treated O O
with O O
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dexamethasone-21-mesylate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
an O O
Mr O B_PROTEIN[GENE]/B_MEASURE
approximately O O
equal O B_MEASURE
to O O
95 O B_MEASURE
, O O
000 O B_MEASURE/B_PERSON
moiety O I_MEASURE/I_PERSON
is O O
also O O
labeled O O
covalently O O
. O O

Approximately O O
35 O O
% O O
of O O
the O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
labeled O O
covalently O O
when O O
intact O O
thymocytes O O
are O O
treated O O
with O O
100 O O
nM O O
[ O O
3H O O
] O O
dexamethasone-21-mesylate O O
for O O
30 O O
min O O
at O O
4 O O
degrees O O
. O O

In O O
all O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
an O O
Mr O B_PROTEIN[GENE]/B_MEASURE
approximately O O
equal O B_MEASURE
to O O
95 O B_MEASURE
, O O
000 O B_MEASURE/B_PERSON
moiety O I_MEASURE/I_PERSON
was O O
labeled O O
covalently O O
; O O
labeling O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
inhibited O O
by O O
excess O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glucocorticoid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Smaller B B_NUMBER[MEASURE]/B_PERSON
moieties I I_NUMBER[MEASURE]/I_PERSON
were O O
also O O
identified O O
by O O
competition O O
experiments O O
; O O
these O O
may O O
represent O O
proteolytic B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
fragments I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
Mr O O
approximately O O
equal O O
to O O
95 O O
, O O
000 O O
receptor O O
. O O

The O O
association O O
of O O
cytosol O O
oestrogen B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
progesterone I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
histological O O
features O O
of O O
breast O O
cancer O O
and O O
early O O
recurrence O O
of O O
disease O O
. O O

The O O
value O O
of O O
REc B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
RPc B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O O
as O O
an O O
indicator O O
of O O
prognosis O O
was O O
examined O O
in O O
a O O
sub-group O O
of O O
175 O O
patients O O
receiving O O
no O O
additional O O
treatment O O
following O O
mastectomy O O
. O O

Overall O O
relapse-free O O
survival O O
( O O
RFS O O
) O O
was O O
no O O
different O O
for O O
those O O
patients O O
with O O
receptors O O
compared O O
to O O
those O O
without O O
them O O
( O O
REc B B_LOCATION
P O O
= O O
0.11 O O
, O O
RPc O O
P O O
= O O
0.7 O O
) O O
. O O

Similar O O
glucocorticoid B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
be O O
detected O O
in O O
lymphoid O O
cells O O
from O O
patients O O
with O O
acute O O
lymphoblastic O O
leukemia O O
( O O
ALL O O
) O O
. O O

The O O
level O B_MEASURE/B_LOCATION
of O O
receptor O B_GENE
shows O O
a O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlation O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O O
increasing O O
aggressiveness O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
the O O
tumor O B_DISEASE/B_PERSON
( O O
null-cell O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
leukemia O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
greater O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O O
T-cell O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
leukemia O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
greater O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O O
Burkitt O B_DISEASE
's O I_DISEASE
lymphoma O I_DISEASE
) O O
. O O

Intracytoplasmic B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
corticosteroid-specific I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
receptors I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
appear O O
to O O
be O O
an O O
important O O
common O O
pathway O O
for O O
steroid-induced O O
changes O O
, O O
but O O
variations O O
of O O
receptor O O
parameters O O
do O O
not O O
account O O
for O O
the O O
multifaceted O O
effects O O
on O O
the O O
immune O O
system O O
. O O

Because O O
the O O
CD28 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
costimulus O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
to O O
induce O O
the O O
production O B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
reactive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
oxygen O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
intermediates O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
( O O
ROIs O B_GENE/B_DISEASE
) O O
, O O
the O O
intracellular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ROI O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
CD45RA+ O B_GENE/B_DISEASE
and O O
CD45RO+ O B_GENE/B_BIO
cells O I_GENE/I_BIO
were O O
compared O O
by O O
flow O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytometry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
further O O
emphasize O O
the O O
differences O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O O
CD45RA+ O B_GENE
and O O
CD45RO+ O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
ROI-dependent O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
signaling O O
pathways O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Ikaros B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
in O O
hemopoietic O O
lineage O O
determination O O
and O O
homeostasis O O
. O O

In O O
addition O O
a O O
comparative O O
analysis O O
of O O
the O O
hemopoietic O O
stem O O
cell O O
and O O
precursor O O
compartment O O
resulting O O
from O O
the O O
two O O
Ikaros B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutations O O
reveals O O
a O O
profound O O
yet O O
not O O
absolute O O
requirement O O
for O O
Ikaros B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
production O O
and O O
differentiation O O
of O O
these O O
populations O O
. O O

BACKGROUND O O
: O O
Antigen-receptor O O
interactions O O
on O O
lymphocytes O O
result O O
in O O
local O O
clustering O O
of O O
actin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O O
receptors O O
and O O
signaling O O
molecules O O
into O O
an O O
asymmetric O O
membrane O O
structure O O
termed O O
a O O
cap O O
. O O

Although O O
actin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerization O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
to O O
be O O
required O O
, O O
the O O
mechanisms O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
underlying O O
cap O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
formation O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
unclear O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
vav-/- O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
deficient O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
interleukin-2 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
IL-2 O B_GENE/B_MEASURE
) O O
production O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
proliferation O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
, O O
and O O
the O O
peak O B_MEASURE
of O O
Ca2+ O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mobilization O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
reduced O O
although O O
of O O
normal O B_TIME[MEASURE]
duration O I_TIME[MEASURE]
. O O

Treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
with O O
cytochalasin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
D O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
blocks O O
actin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
polymerization O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
inhibited O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cap O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formation O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
produced O O
defects O B_DISEASE_ADJECTIVE[DISEASE]
in O O
signaling O O
and O O
IL-2 O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
transcriptional O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
induction O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O O
response O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
antigen-receptor O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signaling O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
were O O
nearly O O
identical O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
those O O
seen O O
in O O
vav-/- O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

E-selectin O B_DISEASE_ADJECTIVE[DISEASE]
expression O I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
B. O B_PROTEIN[GENE]/B_DISEASE
fragilis O O
outer O B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
membranes O I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
was O I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
not O O
blocked O O
by O O
polymixin O O
B O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

In O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
E-selectin O B_DISEASE_ADJECTIVE[DISEASE]
expression O I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
outer O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
membrane O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
fractions O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
purified O O
from O O
E. O B_OTHER/B_PERSON
coli O O
was O B_BACTERIUM[BIO]/B_PERSON
competitively O O
inhibited O O
by O O
polymixin O O
B O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]

Two O O
different O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
directed O O
against O O
human B B_GENE
CD14 I I_GENE
completely O O
inhibited O O
B. O O
fragilis O O
outer O O
membrane-induced O O
NF-kappa B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
B I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
activation O O
, O O
E-selectin O O
transcription O O
, O O
and O O
E-selectin O O
surface O O
expression O O
. O O

Recently O O
, O O
NF-kappaB O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
induction O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
shown O O
to O O
play O O
a O O
role O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
protecting O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
programmed O O
cell O B_DISEASE
death O I_DISEASE
. O O

As O O
was O O
observed O O
for O O
the O O
U9-IIIB O O
cells O O
, O O
TNFalpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
treatment O O
also O O
induced O O
a O O
marked O O
decrease O O
in O O
Bcl-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
in O O
TD-IkappaB O O
expressing O O
cells O O
. O O

These O O
experiments O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O O
that O O
apoptotic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
perturbed O O
in O O
HIV-1-infected O B_DISEASE
U9-IIIB O I_DISEASE
cells O I_DISEASE
and O O
indicate O O
that O O
NF-kappaB O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O O
play O O
an O O
additional O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protective O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
HIV-1-induced O B_DISEASE/B_GENE
apoptosis O I_DISEASE/I_GENE
in O O
myeloid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
. O O

Ku B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
DNA-targeting B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
component I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
the O O
large O O
catalytic B B_LOCATION/B_PERSON
sub-unit I I_LOCATION/I_PERSON
of O O
the O O
DNA-dependent B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
complex I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DNA-PK B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CS I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
that O O
plays O O
a O O
critical O O
role O O
in O O
mammalian O O
double-strand O O
break O O
repair O O
and O O
lymphoid O O
V O O
( O O
D O O
) O O
J O O
recombination O O
. O O

By O O
using O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
we O O
demonstrated O O
that O O
in O O
addition O O
to O O
the O O
major B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ku I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
x I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
usually O O
detected O O
in O O
cell O O
line O O
extracts O O
, O O
a O O
second O O
complex O O
with O O
faster O O
electrophoretic O O
mobility O O
was O O
observed O O
in O O
normal O O
peripheral O O
blood O O
lymphocytes O O
( O O
PBL O O
) O O
extracts O O
. O O

Although O O
the O O
heterodimer B B_GENE
Ku70/variant-Ku86 I I_GENE
binds O O
to O O
DNA-ends B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
this O O
altered O O
form O O
of O O
the O O
Ku B B_GENE
heterodimer I I_GENE
has O O
a O O
decreased O O
ability O O
to O O
recruit O O
the O O
catalytic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
component I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
the O O
complex O O
, O O
DNA-PK B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CS I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
contributes O O
to O O
an O O
absence O O
of O O
detectable O O
DNA-PK O O
activity O O
in O O
B O O
cells O O
. O O

Interestingly O O
, O O
inhibiting O O
PKC O B_GENE
signaling O O
with O O
calphostin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
C O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
further O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
increased O O
P-CREB O B_DISEASE/B_GENE
levels O I_DISEASE/I_GENE
3-fold O I_DISEASE/I_GENE
over O O
that O O
observed O O
in O O
IL-2/CD3 O B_GENE/B_PERSON
co-stimulated O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
not O O
pretreated O O
with O O
a O O
PKC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

HIV-1 O O
infection O B_GENE/B_DISEASE
induces O O
a O O
selective O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduction O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
STAT5 O B_DISEASE/B_GENE
protein O B_DISEASE/I_GENE
expression O B_DISEASE/I_GENE
. O O

HIV-1 O O
infection O B_DISEASE/B_GENE
is O O
accompanied O O
by O O
qualitative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
quantitative O B_DISEASE_ADJECTIVE[DISEASE]
defects O I_DISEASE_ADJECTIVE[DISEASE]
in O O
CD4+ O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Conversely O O
, O O
LKLF-deficient O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
produced O O
by O O
gene O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
targeting O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
showed O O
increased O O
proliferation O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
, O O
increased O O
cell O B_MEASURE
size O I_MEASURE
and O O
enhanced O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
surface O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
markers O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

LKLF B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O O
to O O
function O O
, O O
at O O
least O O
in O O
part O O
, O O
by O O
decreasing O O
expression O O
of O O
the O O
proto-oncogene B B_GENE
encoding O O
c-Myc B B_GENE
. O O

This O O
study O O
demonstrated O O
that O O
p12 B B_GENE
( I I_GENE
I I I_GENE
) I I_GENE
binds O O
to O O
the O O
cytoplasmic B B_LOCATION/B_PERSON
domain I I_LOCATION/I_PERSON
of O O
the O O
interleukin-2 B B_GENE
receptor I I_GENE
( I I_GENE
IL-2R I I_GENE
) I I_GENE
beta I I_GENE
chain I I_GENE
that O O
is O O
involved O O
in O O
the O O
recruitment O O
of O O
the O O
Jak1 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
Jak3 I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
kinases I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

However O O
, O O
p12 B B_GENE/B_PERSON
( I I_GENE/I_PERSON
I I I_GENE/I_PERSON
) I I_GENE/I_PERSON
could O O
increase O O
proliferation O O
of O O
human O O
PBMCs O O
only O O
after O O
stimulation O O
of O O
T-cell B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
treatment O O
of O O
cells O O
with O O
low O O
concentrations O O
of O O
alphaCD3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alphaCD28 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Single O O
dose O O
intranasal O O
administration O O
of O O
retinal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
autoantigen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
generates O O
a O O
rapid O O
accumulation O O
and O O
cell O O
activation O O
in O O
draining O O
lymph O O
node O O
and O O
spleen O O
: O O
implications O O
for O O
tolerance O O
therapy O O
. O O

BACKGROUND/AIMS O O
: O O
A O O
single O O
intranasal O O
delivery O O
of O O
retinal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
autoantigen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
suppresses O O
effectively O O
experimental O O
autoimmune O O
uveoretinitis O O
( O O
EAU O O
) O O
. O O

METHODS O O
: O O
Flow O O
cytometry O O
, O O
cell O O
proliferation O O
assays O O
, O O
and O O
microscopy O O
were O O
used O O
to O O
track O O
antigen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
following O O
a O O
single O O
, O O
intranasal O O
dose O O
of O O
Alexa-488 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
labelled I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
retinal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antigen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

RESULTS O O
: O O
A O O
rapid O O
accumulation O O
of O O
antigen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O O
both O O
superficial O O
cervical O O
lymph O O
nodes O O
( O O
SCLN O O
) O O
and O O
spleen O O
was O O
observed O O
after O O
30 O O
minutes O O
. O O

CONCLUSIONS O O
: O O
The O O
results O O
provide O O
novel O O
evidence O O
that O O
following O O
a O O
single O O
intranasal O O
application O O
rapid O O
transfer O O
of O O
antigen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
occurs O O
. O O

Resulting O O
T O B_DISEASE
cell O I_DISEASE
proliferation O I_DISEASE
develops O O
consequent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O O
differential O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
signalling O O
in O O
SCLN O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
spleen O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-18 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
been O O
well O O
characterized O O
as O O
a O O
costimulatory B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
induction O O
of O O
IL-12-mediated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
interferon I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IFN I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
production O O
by O O
T O O
helper O O
( O O
Th O O
) O O
1 O O
cells O O
, O O
but O O
also O O
can O O
induce O O
IL-4 O O
production O O
and O O
thus O O
facilitate O O
the O O
differentiation O O
of O O
Th2 O O
cells O O
. O O

Thus O O
, O O
positive/negative O O
regulation O O
of O O
the O O
IL-18Ralpha B B_GENE
by O O
the O O
major O O
inductive O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IL-12 B B_GENE
and O O
IL-4 B B_GENE
) O O
determines O O
the O O
capacity O O
of O O
IL-18 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
to O O
polarize O O
an O O
immune O O
response O O
. O O

Glucocorticoid-regulated B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
transcription I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factors I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Histone O O
acetylation O O
is O O
regulated O O
by O O
a O O
balance O O
between O O
the O O
activity O O
of O O
histone B B_ENZYME[GENE]
acetyltransferases I I_ENZYME[GENE]
( O O
HATs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
and O O
histone B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deacetylases I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
HDACs B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acts O O
as O O
a O O
direct O O
inhibitor O O
of O O
NF-kappa O O
B-induced O O
HAT O O
activity O O
and O O
also O O
by O O
recruiting O O
HDAC2 B B_GENE
to O O
the O O
NF-kappa B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
B/HAT I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
complex I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

This O O
suggests O O
that O O
pharmacological O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
manipulation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
specific O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
histone O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetylation O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
status O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
a O O
potentially O O
useful O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
approach O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
for O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
inflammatory O B_DISEASE
diseases O I_DISEASE
. O O

Ultraviolet-B-induced O B_DISEASE/B_GENE
DNA O B_DISEASE/I_GENE
damage O B_DISEASE/I_GENE
is O O
repaired O O
by O O
the O O
nucleotide O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
excision O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
repair O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
mechanism O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
very O O
efficiently O O
. O O

Nucleotide O B_DISEASE/B_GENE
excision O B_DISEASE/I_GENE
repair O B_DISEASE/I_GENE
comprises O O
two O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
subpathways O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
: O O
transcription-coupled O B_GENE/B_LOCATION
and O O
global O B_GENE
genome O I_GENE
repair O I_GENE
. O O

XPA O B_PERSON/B_BIO
mice O I_PERSON/I_BIO
carry O O
a O O
total O B_DISEASE/B_GENE
nucleotide O I_DISEASE/I_GENE
excision O I_DISEASE/I_GENE
repair O I_DISEASE/I_GENE
defect O I_DISEASE/I_GENE
, O O
whereas O O
XPC O B_LOCATION/B_PERSON
and O O
CSB O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
mice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
only O O
lack O O
global O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genome O B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
transcription-coupled O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
nucleotide O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
excision O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repair O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
respectively O O
. O O

Our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O O
that O O
cellular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
immune O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
parameters O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
XPA O B_DISEASE/B_PROTEIN[GENE]
, O O
XPC O B_LOCATION/B_PERSON
, O O
and O O
CSB O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
mice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
are O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O O
with O O
their O O
wild-type O B_GENE/B_PERSON
( O O
control O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
littermates O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
both O O
global O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
genome O I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repair O I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
transcription-coupled O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
repair O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O O
needed O O
to O O
prevent O O
immunomodulation O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
ultraviolet O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whereas O O
transcription-coupled O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
repair O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
the O O
major O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
DNA O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
repair O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
subpathway O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
nucleotide O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
excision O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repair O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
that O O
prevents O O
the O O
acute O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ultraviolet-B-induced O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
erythema O B_DISEASE
. O O

Previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O O
suggested O O
that O O
biomechanical O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strain O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulates O O
macrophage O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phenotype O I_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
tested O O
the O O
hypothesis O O
that O O
biomechanical O O
strain O O
can O O
induce O O
expression O O
of O O
the O O
class B B_GENE
A I I_GENE
scavenger I I_GENE
receptor I I_GENE
( O O
SRA B B_LOCATION/B_ORGANIZATION
) O O
, O O
an O O
important O O
lipoprotein B B_GENE/B_PERSON
receptor I I_GENE/I_PERSON
in O O
atherogenesis O O
. O O

To O O
evaluate O O
this O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
apolipoprotein O B_GENE
E O I_GENE
( O O
-/- O B_PERSON/B_PROTEIN[GENE]
) O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
randomly O O
assigned O O
to O O
receive O O
standard O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
chow O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
a O O
high-cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
diet O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
or O O
a O O
high-cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diet O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
hypertension O B_DISEASE
induced O O
by O O
angiotensin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
II O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
infusion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O O
8 O B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks O I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

High O B_DISEASE/B_GENE
glucose O B_DISEASE/I_GENE
induces O O
MCP-1 O O
expression O B_GENE
partly O O
via O O
tyrosine O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase-AP-1 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
peritoneal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
mesothelial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

MCP-1 B B_DISEASE_ADJECTIVE[DISEASE]
protein I I_DISEASE_ADJECTIVE[DISEASE]
in O O
cell O O
culture O O
supernant O O
was O O
also O O
increased O O
. O O

Signal O B_ORGANIZATION/B_TIME[MEASURE]
thresholds O B_ORGANIZATION/I_TIME[MEASURE]
and O O
modular O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
synergy O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
during O O
expression O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
costimulatory O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
B O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Our O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
distinct O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
signal O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
transducer O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
requirements O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
with O O
the O O
added O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consequences O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cross-talk O B_DISEASE/B_GENE
, O O
offers O O
an O O
explanation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
variable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
modulation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
costimulatory O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecule O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
response O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
diverse O B_DISEASE
physiological O I_DISEASE
stimuli O I_DISEASE
. O O

In O O
the O O
process O O
of O O
neoplastic O O
transformation O O
, O O
the O O
EBV-encoded B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
latent I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
membrane I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
1 I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
LMP1 I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
oncogene I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
represents O O
the O O
major O O
driving O O
force O O
. O O

LMP1 B B_GENE
acts O O
like O O
a O O
constitutively B B_GENE/B_PERSON
activated I I_GENE/I_PERSON
receptor I I_GENE/I_PERSON
of O O
the O O
tumor B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
necrosis I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
family I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
allows O O
the O O
amplification O O
or O O
bypassing O O
of O O
physiological O O
regulatory O O
signals O O
through O O
direct O O
and O O
indirect O O
interactions O O
with O O
proteins O O
of O O
the O O
tumor B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
necrosis I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
factor I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
receptor-associated I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
factor I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
( I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
TRAF I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
) I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
family I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
. O O

The O O
carboxy B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
terminus I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
LMP1 B B_GENE
is O O
also O O
a O O
reliable O O
marker O O
for O O
individual O O
EBV O O
strain O O
identification O O
and O O
thus O O
offers O O
new O O
possibilities O O
in O O
tracing O O
the O O
molecular O O
events O O
leading O O
to O O
posttransplant O O
lymphoproliferative O O
disorders O O
( O O
PTLDs O O
) O O
. O O

Cytotoxic O O
T O O
lymphocytes O O
directed O O
against O O
well-characterized O O
epitopes O O
of O O
EBV B B_DISEASE/B_VIRUS[BIO]
latency I B_DISEASE/I_VIRUS[BIO]
genes I B_DISEASE/I_VIRUS[BIO]
represent O O
an O O
already O O
successful O O
and O O
promising O O
therapeutic O O
approach O O
to O O
EBV-associated O O
lymphomas O O
, O O
in O O
particular O O
PTLDs O O

The O O
ability O O
of O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
( I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
IFN I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
) I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
-alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
to O O
induce O O
autoimmunity O O
and O O
exacerbate O O
Th1 O O
diseases O O
is O O
well O O
known O O
. O O

However O O
, O O
addition O O
of O O
IFN-alpha B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
anti-CD3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
results O O
in O O
enhanced O O
Th1 O O
response O O
and O O
crypt O O
cell O O
hyperplasia O O
. O O

Together O O
these O O
data O O
indicate O O
that O O
IFN-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
facilitate O O
activation O O
of O O
Th1-reactive O O
cells O O
in O O
the O O
gut O O
and O O
drive O O
immunopathology O O
. O O

METHODS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
stimulated O O
with O O
Escherichia O B_GENE/B_BACTERIUM[BIO]
coli O I_GENE/I_BACTERIUM[BIO]
LPS O I_GENE/I_BACTERIUM[BIO]
( O O
100 O B_LOCATION/B_MEASURE
ng/ml O I_LOCATION/I_MEASURE
) O O
with O O
and O O
without O O
forskolin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
FSK O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
50 O B_NUMBER[MEASURE]/B_LOCATION
microM O I_NUMBER[MEASURE]/I_LOCATION
) O O
or O O
dibutyryl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cyclic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
AMP O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
dbcAMP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
100 O B_NUMBER[MEASURE]/B_LOCATION
microM O I_NUMBER[MEASURE]/I_LOCATION
) O O
. O O

Neutralization O O
of O O
IL-10 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O O
a O O
specific O O
antibody B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
attenuate O O
the O O
effect O O
of O O
cAMP-elevating O O
agents O O
on O O
TNF-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
production O O
. O O

Activation O O
of O O
the O O
p21 B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
CIP1/WAF1 I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
by O O
bone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
morphogenetic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein-2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
mouse O O
B O O
lineage O O
cells O O
. O O

BMPs B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exert O O
a O O
negative O O
growth O O
effect O O
on O O
various O O
types O O
of O O
cells O O
. O O

In O O
the O O
present O O
study O O
, O O
we O O
demonstrated O O
that O O
BMP-2 B B_GENE
activated O O
the O O
mouse O O
p21 B B_GENE/B_LOCATION
( I I_GENE/I_LOCATION
CIP1/WAF1 I I_GENE/I_LOCATION
) I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
in O O
HS-72 O O
cells O O
, O O
and O O
that O O
a O O
29-base B B_MEASURE/B_LOCATION
pair I I_MEASURE/I_LOCATION
( I I_MEASURE/I_LOCATION
b I I_MEASURE/I_LOCATION
) I I_MEASURE/I_LOCATION
region I I_MEASURE/I_LOCATION
of O O
the O O
promoter O O
( O O
-1928/-1900 O O
relative O O
to O O
the O O
TATA B B_GENE/B_MEASURE
box I I_GENE/I_MEASURE
) O O
, O O
conserved O O
between O O
mice O O
and O O
humans O O
, O O
was O O
responsive O O
to O O
BMP-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O O
well O O
as O O
expression O O
of O O
Smad1 B B_GENE
, O O
Smad4 B B_GENE
, O O
and O O
constitutively O O
active O O
mutants O O
of O O
BMP B B_GENE
type I I_GENE
I I I_GENE
receptors I I_GENE
. O O

These O O
results O O
suggested O O
that O O
BMP-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
might O O
activate O O
p21 O O
( O O
CIP1/WAF1 O O
) O O
transcription O O
by O O
inducing O O
a O O
binding O O
of O O
Smad4 B B_GENE
and O O
Smad1 B B_GENE/B_MEASURE
to O O
the O O
29-b B B_LOCATION/B_BIO
region I B_LOCATION/I_BIO
in O O
HS-72 O O
cells O O
. O O

Dendritic O O
cells O O
( O O
DCs O O
) O O
are O O
professional O O
antigen-presenting O O
cells O O
which O O
both O O
initiate O O
adaptive O O
immune O O
responses O O
and O O
control O O
tolerance O O
to O O
self-antigens B B_DISEASE/B_BIO
. O O

Here O O
we O O
summarize O O
our O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
both O O
CD8 O B_GENE
alpha+ O I_GENE
and O O
CD8 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
alpha- O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
DCs O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
can O O
arise O O
from O O
clonogenic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
common O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
myeloid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CMPs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
in O O
both O O
thymus O B_BODY_PART_OR_ORGAN_COMPONENT
and O O
spleen O O
. O O

The O O
smallest O B_MEASURE/B_PERSON
unit O I_MEASURE/I_PERSON
of O O
bacterial O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
peptidoglycans O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
known O O
to O O
be O O
endowed O O
with O O
biological O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activities O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
muramyl O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dipeptide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
MDP O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

A O O
clinically O O
acceptable O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
synthetic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
derivative O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
MDP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
namely O O
murabutide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MB O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
has O O
been O O
found O O
to O O
present O O
interesting O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pharmacological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
properties O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
to O O
suppress O O
HIV-1 O B_DISEASE_ADJECTIVE[DISEASE]
replication O I_DISEASE_ADJECTIVE[DISEASE]
in O O
monocyte-derived O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MDM O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
. O O

We O O
also O O
examined O O
whether O O
signaling O O
by O O
muramyl O O
peptides O O
involves O O
the O O
use O O
of O O
cell B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
surface I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
CD14 B B_GENE
and O O
Toll-like B B_GENE/B_MEASURE
receptor I I_GENE/I_MEASURE
2 I I_GENE/I_MEASURE
( O O
TLR2 B B_GENE
) O O
or O O
TLR4 B B_GENE/B_PERSON
that O O
are O O
known O O
to O O
be O O
signal-transducing B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
other O O
bacterial O O
cell O O
wall O O
components O O
. O O

Treatment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O O
peritoneal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
fluid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
from O O
healthy O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controls O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
down-regulated O O
PPAR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transactivation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
this O O
report O O
, O O
we O O
show O O
that O O
Ush B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
expressed O O
in O O
hemocyte O O
precursors O O
and O O
plasmatocytes O O
throughout O O
embryogenesis O O
and O O
larval O O
development O O
, O O
and O O
the O O
GATA B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
Serpent I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
is O O
essential O O
for O O
Ush B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
embryonic O O
expression O O
. O O

This O O
interaction O O
is O O
mediated O O
by O O
the O O
C-terminal B B_LOCATION/B_PROTEIN[GENE]
part O O
of O O
Siah-1 B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
by O O
residues O O
in O O
the O O
N-terminus B B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
OBF-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
partly O O
distinct O O
from O O
the O O
residues O O
required O O
for O O
formation O O
of O O
a O O
complex O O
with O O
the O O
Oct B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
POU I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domains I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
DNA O O
. O O

The O O
beta-catenin O B_GENE
-- O O
TCF-1 O O
pathway O B_LOCATION
ensures O O
CD4 O B_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
CD8 O B_GENE
( O O
+ O B_DISEASE/B_PROTEIN[GENE]
) O O
thymocyte O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
survival O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

This O O
domain O B_LOCATION/B_GENE
is O O
necessary O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
mediate O O
the O O
survival O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
immature O B_GENE
CD4 O I_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
CD8 O B_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
double-positive O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
DP O B_PROTEIN[GENE]/B_DISEASE
) O O
thymocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

TRAIL/Apo2L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
also O O
overcame O O
the O O
survival O O
effect O O
of O O
interleukin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
6 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
MM O O
cells O O
and O O
did O O
not O O
affect O O
the O O
survival O O
of O O
peripheral O O
blood O O
and O O
bone O O
marrow O O
mononuclear O O
cells O O
and O O
purified O O
B O O
cells O O
from O O
healthy O O
donors O O
. O O

Nuclear O O
factor O O
( O O
NF O O
) O O
-kappaB O O
inhibitors O O
, O O
such O O
as O O
SN50 O O
( O O
a O O
cell-permeable O O
inhibitor O O
of O O
the O O
nuclear O O
translocation O O
and O O
transcriptional O O
activity O O
of O O
NF-kappaB B B_GENE
) O O
or O O
the O O
proteasome O O
inhibitor O O
PS-341 O O
, O O
enhanced O O
the O O
proapoptotic O O
activity O O
of O O
TRAIL/Apo2L B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
against O O
TRAIL-sensitive O O
MM O O
cells O O
, O O
whereas O O
SN50 O O
reversed O O
the O O
TRAIL O O
resistance O O
of O O
ARH-77 O O
and O O
IM-9 O O
MM O O
cells O O
. O O

These O O
preclinical O O
studies O O
suggest O O
that O O
TRAIL/Apo2L B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
overcome O O
conventional O O
drug O O
resistance O O
and O O
provide O O
the O O
basis O O
for O O
clinical O O
trials O O
of O O
TRAIL B B_GENE
-based O O
treatment O O
regimens O O
to O O
improve O O
outcome O O
in O O
patients O O
with O O
MM O O
. O O

The O O
activation O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
resting O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
for O O
the O O
acquisition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
various O B_DISEASE_ADJECTIVE[DISEASE]
functions O I_DISEASE_ADJECTIVE[DISEASE]
depends O O
on O O
whether O O
CD28 O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
costimulatory O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
provided O O
upon O O
T O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
cell O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
receptor O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
. O O

Importantly O O
, O O
STAT6 O B_GENE/B_DISEASE
phosphorylation O I_GENE/I_DISEASE
following O O
IL-4 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
was O O
not O O
decreased O O
in O O
anti-CD28-uncostimulated O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

These O O
resutls O O
indicate O O
that O O
CD28 O O
costimulation O O
not O O
only O O
contributes O O
to O O
up-regulating O O
IL-12R B B_GENE
expression O O
but O O
is O O
also O O
required O O
to O O
render O O
JAKs/STAT4 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
responsive O O
to O O
IL-12 B B_GENE
stimulation O O
. O O

Recent O O
data O O
from O O
mice O O
deficient O O
for O O
phosphatase B B_GENE/B_DISEASE
and O O
tensin B B_GENE/B_LOCATION
homologue I I_GENE/I_LOCATION
deleted O O
from O O
chromosome B B_GENE
10 I I_GENE
or O O
src B B_MEASURE
homology I I_MEASURE
2 I I_MEASURE
domain-containing I I_MEASURE
5 I I_MEASURE
' I I_MEASURE
inositol I I_MEASURE
phosphatase I I_MEASURE
, O O
phosphatases B B_ENZYME[GENE]/B_BIO
that O O
negatively O O
regulate O O
the O O
phosphatidylinositol B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
3-kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PI3K B B_GENE/B_LOCATION
) O O
pathway O O
, O O
revealed O O
an O O
increased O O
number O O
of O O
macrophages O O
in O O
these O O
animals O O
, O O
suggesting O O
an O O
essential O O
role O O
for O O
the O O
PI3K B B_GENE
pathway O O
for O O
macro-phage O O
survival O O
. O O

However O O
, O O
after O O
inhibition O O
of O O
the O O
PI3K B B_GENE
/ O O
Akt-1 B B_GENE
pathway O O
, O O
a O O
marked O O
decrease O O
in O O
the O O
expression O O
of O O
the O O
antiapoptotic B B_GENE
molecule I I_GENE
Mcl-1 B I_GENE
, O O
but O O
not O O
other O O
Bcl-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
members I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
observed O O
, O O
and O O
Mcl-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
rescued O O
macrophages O O
from O O
LY294002-induced O O
cell O O
death O O
. O O

GRbeta O B_GENE
expression O I_GENE
in O O
nasal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
polyp O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
inflammatory O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cells O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
its O O
relationship O B_PERSON
to O O
the O O
anti-inflammatory O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
intranasal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluticasone O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
anti-inflammatory O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
FP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
examined O O
in O O
relation O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
pretreatment O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
GRbeta O B_GENE
expression O I_GENE
. O O

Galectin-10 B B_GENE
( O O
gal-10 B B_GENE/B_DISEASE
, O O
also O O
known O O
as O O
Charcot-Leyden B B_GENE/B_DISEASE
crystal I I_GENE/I_DISEASE
protein I I_GENE/I_DISEASE
) O O
is O O
a O O
member O O
of O O
the O O
galectin B B_PERSON/B_BIO
family I I_PERSON/I_BIO
of O O
beta-galactoside B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
is O O
expressed O O
uniquely O O
in O O
eosinophilic O O
and O O
basophilic O O
leukocytes O O
. O O

Analysis O O
of O O
the O O
minimal B B_GENE/B_LOCATION
promoter I B_GENE/I_LOCATION
revealed O O
nine O O
consensus-binding B B_LOCATION/B_PERSON
sites I I_LOCATION/I_PERSON
for O O
transcription B B_GENE/B_MEASURE
factors I I_GENE/I_MEASURE
, O O
including O O
several O O
that O O
are O O
also O O
found O O
in O O
the O O
minimal B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
promoters I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
galectins B B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
-1 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
-2 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
-3 I I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
decrease O O
in O O
gal-10 O O
promoter O O
activity O O
after O O
disruption O O
of O O
either O O
the O O
GC B B_GENE
box I I_GENE
( O O
-44 O O
to O O
-50 O O
) O O
or O O
the O O
Oct B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
-255 O O
to O O
-261 O O
) O O
suggests O O
that O O
these O O
sites O O
, O O
along O O
with O O
the O O
previously O O
characterized O O
GATA B B_LOCATION/B_ORGANIZATION
and I I_LOCATION/I_ORGANIZATION
EoTF I I_LOCATION/I_ORGANIZATION
sites I I_LOCATION/I_ORGANIZATION
, O O
are O O
necessary O O
for O O
full O O
promoter O O
activity O O
. O O

Mammary O B_DISEASE_ADJECTIVE[DISEASE]
development O I_DISEASE_ADJECTIVE[DISEASE]
depends O O
on O O
branching O O
morphogenesis O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O O
namely O O
the O O
bifurcation O B_DISEASE/B_ORGANIZATION
and O O
extension O B_TIME[MEASURE]/B_DISEASE
of O O
ductal O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
points O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
end O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
buds O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
secretory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
lobules O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
into O O
a O O
more O O
or O O
less O O
fatty O B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
stroma O I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
. O O

Evidence O O
is O O
presented O O
that O O
if O O
they O O
are O O
to O O
grow O O
, O O
end O O
buds O O
must O O
condition O O
proximal O O
fatty O O
stroma O O
by O O
recruiting O O
white O O
blood O O
cells O O
as O O
well O O
as O O
inducing O O
stromal O O
cell O O
division O O
and O O
, O O
possibly O O
, O O
estrogen B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
agreement O O
with O O
the O O
evidence O O
of O O
a O O
coordinate O O
transcription O O
of O O
the O O
HLA-D B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
these O O
cell O O
lines O O
, O O
we O O
have O O
shown O O
the O O
constitutive O O
expression O O
of O O
CIITA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transactivator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
CIITA B B_TIME[MEASURE]/B_LOCATION
being O O
known O O
as O O
the O O
master O O
switch O O
of O O
MHC O O
class O O
II O O
expression O O
. O O

Truncated B B_DISEASE/B_MEASURE
Cn I I_DISEASE/I_MEASURE
A I I_DISEASE/I_MEASURE
was O O
associated O O
with O O
enhanced O O
phosphatase O O
activity O O
and O O
reduced O O
calmodulin O O
sensitivity O O
. O O

Maturation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
human O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dendritic O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
sulfasalazine O B_DISEASE_ADJECTIVE[DISEASE]
target O I_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
determine O O
whether O O
dendritic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
could O O
be O O
a O O
possible O B_PERSON/B_LOCATION
target O I_PERSON/I_LOCATION
of O O
the O O
drug O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
studied O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sulfasalazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
metabolites O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
aminosalicylate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
sulfapyridine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
on O O
in O O
vitro O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
maturation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
( O O
terminal O B_DISEASE/B_LOCATION
differentiation O B_DISEASE/I_LOCATION
) O O
of O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
myeloid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
dendritic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

From O O
concentration-dependent O B_DISEASE_ADJECTIVE[DISEASE]
changes O I_DISEASE_ADJECTIVE[DISEASE]
in O O
CD83 O B_GENE/B_MEASURE
expression O B_GENE/I_MEASURE
, O O
we O O
found O O
an O O
apparent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ID50 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1.5 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
micromol/L O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfasalazine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Thus O O
, O O
dendritic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
maturation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
sulfasalazine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Type O O
1 O O
diabetes O O
( O O
also O O
known O O
as O O
insulin-dependent O O
diabetes O O
mellitus O O
or O O
juvenile-onset O O
diabetes O O
) O O
is O O
usually O O
caused O O
by O O
T O O
cell-mediated O O
autoimmunity O O
, O O
with O O
a O O
prediabetic O O
state O O
characterized O O
by O O
the O O
production O O
of O O
autoantibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
specific O O
for O O
proteins O O
expressed O O
by O O
pancreatic O O
beta O O
cells O O
. O O

The O O
nonobese O O
patient O O
with O O
diabetes O O
( O O
NOD O O
) O O
mouse O O
is O O
a O O
spontaneous O O
model O O
of O O
type O O
1 O O
diabetes O O
with O O
a O O
strong O O
genetic O O
component O O
that O O
maps O O
to O O
the O O
major B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
histocompatibility I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
complex I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
MHC I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
) I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
region I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O O
the O O
genome B B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

A O O
specific O O
proteasome B B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
defect O O
has O O
been O O
identified O O
in O O
NOD O O
mouse O O
in O O
select O O
lymphocytic O O
and O O
monocytic O O
lineages O O
that O O
results O O
from O O
down-regulation O O
of O O
expression O O
of O O
the O O
proteasome B B_GENE/B_MEASURE
subunit I I_GENE/I_MEASURE
LMP2 I I_GENE/I_MEASURE
, O O
which O O
is O O
encoded O O
by O O
a O O
gene O O
in O O
the O O
MHC B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
genomic I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
region I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
defect O O
prevents O O
the O O
proteolytic O O
processing O O
required O O
for O O
the O O
production O O
and O O
activation O O
of O O
the O O
transcription B B_GENE
factor I I_GENE
nuclear I I_GENE
factor-kappaB I I_GENE
( O O
NF-kappaB B B_GENE
) O O
, O O
which O O
plays O O
important O O
roles O O
in O O
immune O O
and O O
inflammatory O O
responses O O
, O O
as O O
well O O
as O O
increases O O
the O O
susceptibility O O
of O O
the O O
affected O O
cells O O
to O O
apoptosis O O
induced O O
by O O
tumor B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
necrosis I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor-alpha I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

Down-regulation O O
of O O
TDT O O
transcription O O
in O O
CD4 O O
( O O
+ O O
) O O
CD8 O O
( O O
+ O O
) O O
thymocytes O O
by O O
Ikaros B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
direct O O
competition O O
with O O
an O O
Ets B B_GENE/B_LOCATION
activator I I_GENE/I_LOCATION
. O O

Reduced O O
access O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
restriction O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enzyme O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cleavage O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
suggested O O
that O O
chromatin O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alterations O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accompany O O
down-regulation O B_DISEASE
. O O

Rather O O
, O O
the O O
small O O
isoform B B_GENE
assembled O O
into O O
multimeric B B_LOCATION/B_BIO
complexes I I_LOCATION/I_BIO
with O O
DNA-bound B B_GENE
Ikaros I I_GENE
at O O
the O O
pericentromeric O O
foci O O
. O O

Type B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferons I I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
IL-12 B B_GENE/B_BIO
: O O
convergence O O
and O O
cross-regulation O O
among O O
mediators O O
of O O
cellular O O
immunity O O
. O O

Therapeutic O O
use O O
of O O
type B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
IFN I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IFN-alpha/beta B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
has O O
become O O
common O O
. O O

It O O
is O O
thus O O
notable O O
that O O
the O O
pleiotropic O O
effects O O
of O O
type B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IFN I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
CMI O O
remain O O
poorly O O
understood O O
. O O

We O O
characterized O O
the O O
effects O O
of O O
type B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
IFN I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
the O O
production O O
of O O
IL-12 B B_GENE
, O O
the O O
central B B_PERSON/B_GENE
immunoregulatory I I_PERSON/I_GENE
cytokine I I_PERSON/I_GENE
of O O
the O O
CD4 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
+ I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
) I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
T I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cell I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
arm I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O O
CMI O O
. O O

We O O
show O O
that O O
type B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
I I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
IFN I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O O
potent O O
inhibitors O O
of O O
IL-12 O O
production O O
by O O
human O O
monocytes/macrophages O O
. O O

The O O
underlying O O
mechanism O O
involves O O
transcriptional O O
inhibition O O
of O O
the O O
IL-12p40 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
marked O O
by O O
down-regulation O O
of O O
PU.1 O O
binding O O
activity O O
at O O
the O O
upstream B B_LOCATION/B_MEASURE
Ets I I_LOCATION/I_MEASURE
site I I_LOCATION/I_MEASURE
of O O
the O O
IL-12p40 B B_GENE
promoter I I_GENE
. O O

The O O
ability O O
of O O
IFN-alpha/beta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
suppress O O
IL-12 O O
production O O
while O O
up-regulating O O
IFN-gamma O O
production O O
suggests O O
a O O
possible O O
mechanistic O O
basis O O
for O O
the O O
difficulties O O
of O O
employing O O
these O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
diseases O O
involving O O
abnormalities O O
of O O
CMI O O
. O O

We O O
also O O
examined O O
the O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
troglitazone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
reactive O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxygen O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
species O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
generation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
p47 O B_GENE
( O O
phox O B_GENE
) O O
subunit O B_GENE
expression O I_GENE
, O O
9-hydroxyoctadecadienoic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
9-HODE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
, O O
13-HODE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
o-tyrosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
and O O
m-tyrosine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
obese O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
type O B_DISEASE
2 O I_DISEASE
diabetes O I_DISEASE
. O O

Seven O B_PERSON/B_BIO
obese O I_PERSON/I_BIO
patients O I_PERSON/I_BIO
with O O
type O B_DISEASE/B_LOCATION
2 O I_DISEASE/I_LOCATION
diabetes O I_DISEASE/I_LOCATION
were O O
treated O O
with O O
troglitazone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
400 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg/day O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
for O O
4 O B_DISEASE
weeks O I_DISEASE
. O O

Plasma B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocyte I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
chemoattractant I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
protein-1 I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
soluble B B_GENE
intracellular I I_GENE
adhesion I I_GENE
molecule-1 I I_GENE
concentrations O O
did O O
not O O
decrease O O
significantly O O
after O O
troglitazone O O
treatment O O
, O O
although O O
there O O
was O O
a O O
trend O O
toward O O
inhibition O O
. O O

Reactive O O
oxygen O O
species O O
generation O O
by O O
polymorphonuclear O O
cells O O
and O O
MNC O O
, O O
p47 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phox I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subunit I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
quantities O O
, O O
plasminogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activator I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibitor-1 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
C-reactive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O O
decreased O O
significantly O O
after O O
troglitazone O O
intake O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
HIV-1 O O
production O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
strongly O O
induced O O
. O O

Furthermore O O
, O O
enhanced O O
HIV-1 O O
transcription O O
in O O
gp34 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-stimulated O O
ACH-2/OX40 O O
cells O O
was O O
dependent O O
on O O
the O O
kappa B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
HIV-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
long I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repeat I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
the O O
OX40-gp34 O O
interaction O O
activated O O
NF-kappa B B_GENE
B I I_GENE
consisting O O
of O O
p50 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p65 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunits I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

When O O
primary O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
activated O O
CD4 O B_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
acutely O O
infected O O
with O O
HIV-1 O B_DISEASE/B_GENE
( O O
NL4-3 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
( O O
CXCR4-using O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
T-cell-line-tropic O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
) O O
were O O
cocultured O O
with O O
PFA-fixed O B_GENE
gp34 O I_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T-cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
leukemia O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
virus O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
type O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
1-bearing O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
MT-2 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
SV-T2/gp34 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
HIV-1 O O
production O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
also O O
markedly O O
enhanced O O
. O O

The O O
enhancement O O
was O O
again O O
significantly O O
inhibited O O
by O O
5A8 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Northern O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O O
that O O
osteopontin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
markedly O O
induced O O
in O O
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
PMA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Transient O O
transfection O O
assays O O
of O O
the O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
osteopontin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter/luciferase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
construct I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
which O O
contains O O
a O O
5'-flanking B B_LOCATION/B_MEASURE
region I I_LOCATION/I_MEASURE
between O O
-1500 O O
and O O
+87 O O
relative O O
to O O
the O O
transcription B B_GENE/B_MEASURE
start I I_GENE/I_MEASURE
site I I_GENE/I_MEASURE
demonstrate O O
that O O
either O O
treatment O O
with O O
troglitazone O O
or O O
cotransfection O O
of O O
PPARgamma B B_GENE
expression I I_GENE
vector I I_GENE
inhibits O O
osteopontin O O
promoter O O
activity O O
. O O

Recombinant B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
BTK I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
proteins I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
mutant O O
pleckstrin O O
homology O O
, O O
SH2 B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
or I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
SH3 I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
domains I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
were O O
capable O O
of O O
phosphorylating O O
STAT5A B B_GENE
, O O
whereas O O
recombinant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
BTK I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
proteins I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
with O O
SH1/kinase O O
domain O O
mutations O O
were O O
not O O
. O O

B O O
cell O O
antigen O O
receptor O O
ligation O O
resulted O O
in O O
enhanced O O
tyrosine O O
phosphorylation O O
of O O
STAT5 B B_GENE
in O O
BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-deficient O O
chicken O O
B O O
cells O O
reconstituted O O
with O O
wild B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
type I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
human I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
BTK I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
but O O
not O O
in O O
BTK B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-deficient O O
chicken O O
B O O
cells O O
reconstituted O O
with O O
kinase-inactive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
BTK I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

How O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
control O O
differentiation O O
of O O
helper O O
T O O
( O O
TH O O
) O O
cells O O
is O O
controversial O O
. O O

Furthermore O O
, O O
IL-4-driven O O
cell O O
expansion O O
was O O
also O O
normal O O
in O O
the O O
cells O O
infected O O
with O O
Y497F B B_DISEASE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
although O O
cells O O
infected O O
with O O
Y497F B B_DISEASE/B_VIRUS[BIO]
were O O
not O O
capable O O
of O O
phosphorylating O O
insulin B B_GENE
receptor I I_GENE
substrate I I_GENE
2 I I_GENE
. O O

Increase O O
secretion O O
of O O
IL-2 B B_GENE
, O O
the O O
major O O
T O O
cell O O
growth O O
and O O
differentiation O O
cytokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
may O O
play O O
a O O
decisive O O
role O O
in O O
sensitization O O
of O O
T O O
cells O O
for O O
activation O O
induced O O
apoptosis O O
and O O
indirect O O
death O O
of O O
activated O O
T O O
cells O O
through O O
augmented O O
virus O O
replication O O
. O O

We O O
investigated O O
the O O
cause O O
of O O
enhanced O O
IL-2 O O
secretion O O
and O O
found O O
that O O
the O O
HIV B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tat I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O O
this O O
effect O O
. O O

After O O
T O O
cell O O
activation O O
, O O
a O O
heterodimeric B B_LOCATION
activator I I_LOCATION
containing O O
p65 B B_GENE
and O O
c-Jun B B_GENE
binds O O
to O O
the O O
AP-1 B B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
IL-2/d I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
site I I_GENE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Our O O
data O O
provide O O
evidence O O
for O O
a O O
novel O O
mechanism O O
by O O
which O O
HIV B B_DISEASE
Tat I I_DISEASE
dysregulates O O
IL-2 O O
production O O
and O O
therefore O O
may O O
contribute O O
to O O
the O O
HIV-1 O O
infection O O
in O O
a O O
way O O
yet O O
to O O
be O O
clarified O O
. O O

This O O
final O O
maturation O O
step O O
is O O
crucial O O
for O O
the O O
B O O
cells O O
to O O
become O O
responsive O O
to O O
antigens B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
to O O
participate O O
in O O
the O O
immune O O
response O O
. O O

Therefore O O
, O O
upon O O
in O O
vivo O O
androgen O O
treatment O O
, O O
other O O
cells O O
containing O O
androgen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
than O O
thymocytes O O
are O O
probably O O
involved O O
in O O
inducing O O
the O O
increase O O
in O O
thymic O O
apoptosis O O
. O O

To O O
study O O
the O O
role O O
of O O
the O O
androgen B B_GENE
receptor I I_GENE
on O O
thymocyte O O
apoptosis O O
, O O
androgen B B_NUMBER[MEASURE]
receptor I I_NUMBER[MEASURE]
mutant O O
( O O
Tfm/Y O O
) O O
mice O O
were O O
treated O O
with O O
androgens O O
. O O

No O O
alterations O O
of O O
thymocyte O O
subpopulations O O
were O O
seen O O
, O O
suggesting O O
that O O
changes O O
in O O
the O O
percentage O O
of O O
CD4+ O O
CD8+ O O
thymocytes O O
after O O
administration O O
of O O
androgens O O
depend O O
on O O
the O O
presence O O
of O O
functional O O
androgen B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Inhibition O O
of O O
the O O
transcription B B_GENE/B_LOCATION
factors I I_GENE/I_LOCATION
AP-1 B I_GENE/I_LOCATION
and O O
NF-kappaB B B_GENE
in O O
CD4 O O
T O O
cells O O
by O O
peroxisome B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proliferator-activated I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ligands I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

PPARgamma B B_GENE
has O O
been O O
found O O
recently O O
to O O
regulate O O
macrophage O O
activation O O
in O O
response O O
to O O
mitogens B B_DISEASE
and O O
inflammation O O
. O O

PPARgamma B B_PERSON/B_DISEASE
ligands I I_PERSON/I_DISEASE
also O O
strongly O O
inhibited O O
SEA-induced O O
Vbeta3 O O
T O O
cell O O
activation O O
in O O
vivo O O
. O O

EMSAs O O
with O O
Abs B B_GENE
specific O O
for O O
various O O
protein B B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I I_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
AP-1 B B_GENE/B_LOCATION
family I I_GENE/I_LOCATION
revealed O O
that O O
multiple O O
members O O
of O O
the O O
Jun B B_PERSON/B_ORGANIZATION
family I I_PERSON/I_ORGANIZATION
are O O
involved O O
in O O
the O O
regulation O O
of O O
the O O
h2B4 B B_GENE
gene I I_GENE
. O O

Because O O
hematopoietic O O
cells O O
derived O O
from O O
Fanconi O O
anemia O O
( O O
FA O O
) O O
patients O O
of O O
the O O
C-complementation O O
group O O
( O O
FA-C O O
) O O
are O O
hypersensitive O O
to O O
the O O
inhibitory O O
effects O O
of O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IFNgamma B B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
the O O
products O O
of O O
certain O O
IFNgamma-inducible B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
known O O
to O O
influence O O
hematopoietic O O
cell O O
survival O O
were O O
quantified O O
. O O

High O O
constitutive O O
expression O O
of O O
the O O
IFNgamma-inducible B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
IFN-stimulated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
subunit I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ISGF3gamma B B_GENE/B_DISEASE
) O O
, O O
IFN B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulatory I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IRF-1 B B_GENE/B_DISEASE
) O O
, O O
and O O
the O O
cyclin-dependent B B_GENE/B_PERSON
kinase I I_GENE/I_PERSON
inhibitor I I_GENE/I_PERSON
p21 I I_GENE/I_PERSON
( O O
WAF1 B B_GENE/B_DISEASE
) O O
was O O
found O O
in O O
FANCC B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
mutant O O
B O O
lymphoblasts O O
, O O
low-density O O
bone O O
marrow O O
cells O O
, O O
and O O
murine O O
embryonic O O
fibroblasts O O
. O O

Paradoxically O O
, O O
these O O
cells O O
do O O
not O O
activate B B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
signal I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
transducer I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
activator I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
of I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
( I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
STAT I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
properly O O
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
D609 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
inhibited O O
the O O
formation O B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
alpha-phenyl-tert-butylnitrone-free O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
radical O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
spin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
adducts O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
lipid O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
peroxidation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
synaptosomal O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
membranes O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
the O O
Fenton O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
reagents O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

GILZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
also O O
potently O O
inhibited O O
AP-1-driven B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter-driven I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reporter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constructs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
recombinant O O
GILZ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
specifically O O
interacted O O
with O O
c-Fos B B_GENE
and O O
c-Jun B B_GENE/B_LOCATION
in O O
vitro O O
and O O
inhibited O O
the O O
binding O O
of O O
active B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
AP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
its O O
target O O
DNA O O
. O O

In O O
contrast O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O O
vaccination O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
a O O
peptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
encoding O O
an O O
adenovirus O B_VIRUS[BIO]/B_DISEASE
type O I_VIRUS[BIO]/I_DISEASE
5 O I_VIRUS[BIO]/I_DISEASE
( O O
Ad5 O B_PROTEIN[GENE]/B_SPECIES[BIO]
) O O
E1A O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CTL O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
epitope O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
CTL O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tolerance O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
enhanced O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
growth O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
an O O
Ad5 O B_DISEASE
E1A-expressing O I_DISEASE
tumor O I_DISEASE
. O O

To O O
determine O O
whether O O
a O O
difference O B_MEASURE
in O O
pharmacokinetics O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
can O O
explain O O
the O O
functional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contrasts O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
tritiated O O
Ad5 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
E1A O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
HPV16 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
E7 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
peptides O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
injected O O
into O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
data O O
suggest O O
that O O
ubiquitous O O
expression O O
of O O
the O O
tolerizing O O
Ad5 O O
E1A O O
peptide O O
within O O
a O O
short O O
period O O
of O O
time O O
causes O O
activation-induced O O
cell O O
death O O
of O O
Ad5 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
E1A I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
-specific O O
CTLs B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Transforming B B_GENE/B_DISEASE
growth I I_GENE/I_DISEASE
factor I I_GENE/I_DISEASE
( I I_GENE/I_DISEASE
TGF I I_GENE/I_DISEASE
) I I_GENE/I_DISEASE
-beta1 I I_GENE/I_DISEASE
is O O
well O O
established O O
as O O
a O O
critical O O
IgA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
isotype I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
switching I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Smad B B_GENE/B_MEASURE
molecules I I_GENE/I_MEASURE
have O O
been O O
reported O O
to O O
act O O
as O O
transducers B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
transcriptional B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
the O O
expression O O
of O O
TGF-beta1 B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
-targeted O O
genes B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

First O O
, O O
we O O
found O O
that O O
TGF-beta1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
significantly O O
increases O O
endogenous B B_DISEASE_ADJECTIVE[DISEASE]
germ-line I I_DISEASE_ADJECTIVE[DISEASE]
( I I_DISEASE_ADJECTIVE[DISEASE]
GL I I_DISEASE_ADJECTIVE[DISEASE]
) I I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DISEASE_ADJECTIVE[DISEASE]
transcripts I I_DISEASE_ADJECTIVE[DISEASE]
by O O
LPS-stimulated O O
CH12.LX.4933 O O
( O O
mu O O
( O O
+ O O
) O O
) O O
B O O
lymphoma O O
cells O O
. O O

To O O
elucidate O O
molecular O O
mechanism O O
of O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
-induced O O
cell O O
cycle O O
progression O O
, O O
we O O
systematically O O
examined O O
the O O
effects O O
of O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
biochemical O O
events O O
associated O O
with O O
cell O O
cycle O O
progression O O
. O O

Mutation O O
of O O
the O O
distal B B_LOCATION
( I I_LOCATION
-105/-97 I I_LOCATION
) I I_LOCATION
and O O
proximal B B_LOCATION/B_GENE
( I B_LOCATION/I_GENE
-76/-61 I B_LOCATION/I_GENE
) I B_LOCATION/I_GENE
NFAT B B_LOCATION/I_GENE
response I B_LOCATION/I_GENE
elements I B_LOCATION/I_GENE
in O O
the O O
COX-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
abolished O O
the O O
activation O O
induced O O
by O O
Cot B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

TCF-1 B B_MEASURE/B_PERSON
deficiency O O
resulted O O
in O O
the O O
altered O O
usage O O
of O O
additional O O
Ly-49 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Therefore O O
, O O
besides O O
TCF-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding O O
to O O
the O O
proximal B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
, O O
Ly-49 O O
acquisition O O
may O O
also O O
be O O
regulated O O
by O O
TCF-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding O O
to O O
more O O
distant O O
cis-acting B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
elements I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and/or O O
by O O
regulating O O
the O O
expression O O
of O O
additional O O
trans-acting B B_GENE/B_LOCATION
factors I I_GENE/I_LOCATION
. O O

Consistent O O
with O O
the O O
observed O O
differential O O
, O O
positive O O
or O O
negative O O
role O O
of O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
Ly-49 B B_GENE/B_DISEASE
receptor I I_GENE/I_DISEASE
acquisition O O
, O O
reporter O O
gene O O
assays O O
revealed O O
the O O
presence O O
of O O
an O O
inducing O O
as O O
well O O
as O O
a O O
repressing O O
TCF B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
certain O O
proximal O O
Ly-49 B B_GENE/B_LOCATION
promoters I I_GENE/I_LOCATION
. O O

Chemokines B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
adhesion B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecules I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
such O O
as O O
integrins B B_GENE/B_DISEASE
play O O
a O O
major O O
part O O
in O O
the O O
trafficking O O
, O O
extravasation O O
, O O
and O O
recruitment O O
of O O
leukocytes O O
to O O
inflammatory O O
sites O O
. O O

This O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
investigated O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O B_NUMBER[MEASURE]
) O O
integrin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
engagement O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
chemokine O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
production O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
by O O
freshly O O
isolated O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Because O O
the O O
promoters B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
these O O
chemokine B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contain O O
kappaB B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
assessed O O
the O O
possible O O
role O O
of O O
nuclear B B_GENE
factor-kappaB I I_GENE
( O O
NF-kappaB B B_GENE
) O O
in O O
controlling O O
induction O O
of O O
the O O
genes O O
through O O
beta O O
( O O
2 O O
) O O
integrin O O
engagement O O
. O O

Synergistic O O
transcriptional O O
activation O O
of O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Acyl-coenzyme I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
A I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cholesterol I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acyltransterase-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
interferon-gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
all-trans-retinoic O O
acid O O
THP-1 O O
cells O O
. O O

Acyl-coenzyme B B_GENE/B_ORGANIZATION
A I I_GENE/I_ORGANIZATION
: I I_GENE/I_ORGANIZATION
cholesterol I I_GENE/I_ORGANIZATION
acyltransferase I I_GENE/I_ORGANIZATION
( O O
ACAT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
is O O
an O O
intracellular B B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzyme I I_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involved O O
in O O
cellular O O
cholesterol O O
homeostasis O O
and O O
in O O
atherosclerotic O O
foam O O
cell O O
formation O O
. O O

Human B B_GENE/B_LOCATION
ACAT-1 I I_GENE/I_LOCATION
gene I I_GENE/I_LOCATION
contains O O
two O O
promoters B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
P1 B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
P7 B B_PROTEIN[GENE]
) O O
, O O
each O O
located O O
in O O
a O O
different O O
chromosome B B_LOCATION/B_PERSON
( I I_LOCATION/I_PERSON
1 I I_LOCATION/I_PERSON
and I I_LOCATION/I_PERSON
7 I I_LOCATION/I_PERSON
) I I_LOCATION/I_PERSON
( O O
Li O O
, O O
B. O O
L. O O
, O O
Li O O
, O O
X. O O
L. O O
, O O
Duan O O
, O O
Z. O O
J. O O
, O O
Lee O O
, O O
O. O O
, O O
Lin O O
, O O
S. O O
, O O
Ma O O
, O O
Z. O O
M. O O
, O O
Chang O O
, O O
C. O O
C. O O
, O O
Yang O O
, O O
X. O O
Y. O O
, O O
Park O O
, O O
J. O O
P. O O
, O O
Mohandas O O
, O O
T. O O
K. O O
, O O
Noll O O
, O O
W. O O
, O O
Chan O O
, O O
L. O O
, O O
and O O
Chang O O
, O O
T. O O
Y. O O
( O O
1999 O O
) O O
J. O O
Biol O O
Chem. O O
274 O O
, O O
11060-11071 O O
) O O
. O O

In O O
the O O
monocytic O O
cell O O
line O O
THP-1 O O
cell O O
, O O
the O O
combination O O
of O O
IFN-gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
all-trans-retinoic O O
acid O O
( O O
a O O
known O O
differentiation O O
agent O O
) O O
enhances O O
the O O
ACAT-1 B B_GENE
P1 I I_GENE
promoter I I_GENE
but O O
not O O
the O O
P7 B B_GENE
promoter I I_GENE
. O O

Additional O O
experiments O O
showed O O
that O O
all-trans-retinoic O O
acid O O
causes O O
large O O
induction O O
of O O
the O O
transcription B B_GENE
factor I I_GENE
STAT1 I I_GENE
, O O
while O O
IFN-gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
causes O O
activation O O
of O O
STAT1 B B_GENE
such O O
that O O
it O O
binds O O
to O O
the O O
GAS/Sp1 B B_GENE/B_MEASURE
site I I_GENE/I_MEASURE
in O O
the O O
ACAT-1 B B_GENE
P1 I I_GENE
promoter I I_GENE
. O O

Our O O
work O O
provides O O
a O O
molecular O O
mechanism O O
to O O
account O O
for O O
the O O
effect O O
of O O
IFN-gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
causing O O
transcriptional O O
activation O O
of O O
ACAT-1 B B_GENE
in O O
macrophage-like O O
cells O O
. O O

We O O
could O O
suppress O O
GATA-3 O O
expression O O
in O O
interleukin B B_GENE
( I I_GENE
IL I I_GENE
) I I_GENE
-4 I I_GENE
-producing O O
T O O
cells O O
in O O
vitro O O
and O O
in O O
vivo O O
by O O
an O O
antisense O O
phosphorothioate O O
oligonucleotide O O
overlapping O O
the O O
translation B B_LOCATION/B_ORGANIZATION
start I I_LOCATION/I_ORGANIZATION
site I I_LOCATION/I_ORGANIZATION
of O O
GATA-3 B B_GENE
, O O
whereas O O
nonsense O O
control O O
oligonucleotides O O
were O O
virtually O O
inactive O O
. O O

Such O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intrapulmonary O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
blockade O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
GATA-3 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
caused O O
an O O
abrogation O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
signs O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
lung O B_DISEASE/B_GENE
inflammation O I_DISEASE/I_GENE
including O O
infiltration O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
eosinophils O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
Th2 O B_DISEASE
cytokine O I_DISEASE
production O I_DISEASE
. O O

Furthermore O O
, O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
antisense O B_GENE
but O O
not O O
nonsense O B_GENE
oligonucleotides O I_GENE
induced O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
airway O B_DISEASE
hyperresponsiveness O I_DISEASE
in O O
OVA-sensitized O B_DISEASE/B_BIO
mice O I_DISEASE/I_BIO
to O O
levels O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparable O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
saline-treated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mice O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
as O O
assessed O O
by O O
both O O
enhanced O O
pause O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
PenH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
responses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
pulmonary O B_DISEASE_ADJECTIVE[DISEASE]
resistance O I_DISEASE_ADJECTIVE[DISEASE]
determined O O
by O O
body O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
plethysmography O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

T O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
helper-cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phenotype O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulates O O
atherosclerosis O B_DISEASE/B_GENE
in O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
under O O
conditions O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
mild O B_DISEASE
hypercholesterolemia O I_DISEASE
. O O

BACKGROUND O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O O
T O B_GENE
cells O I_GENE
are O O
implicated O O
in O O
atherosclerosis O B_DISEASE/B_LOCATION
, O O
but O O
little O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O O
known O O
about O O
the O O
genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
control O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathways O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
especially O O
under O O
conditions O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
mild O B_DISEASE
hypercholesterolemia O I_DISEASE
. O O

To O O
evaluate O O
T O B_DISEASE_ADJECTIVE[DISEASE]
helper-cell O I_DISEASE_ADJECTIVE[DISEASE]
phenotype O I_DISEASE_ADJECTIVE[DISEASE]
in O O
fatty O B_DISEASE
streak O I_DISEASE
formation O I_DISEASE
, O O
wild-type O O
C57Bl/6 O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
mice O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IA O B_PROTEIN[GENE]/B_DISEASE
( O O
b O O
) O O
+IE- O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
transgenic O B_BIO/B_GENE
mice O I_BIO/I_GENE
, O O
either O O
AB O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
o O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
IA O B_DISEASE/B_PROTEIN[GENE]
( O O
b O O
) O O
-IE- O O
; O O
ABEalpha O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IA-IE O B_LOCATION/B_PROTEIN[GENE]
( O O
k O B_MEASURE/B_PROTEIN[GENE]
) O O
+ O B_PROTEIN[GENE]/B_DISEASE
; O O
or O O
BL O B_LOCATION
: O O
TG O B_PROTEIN[GENE]/B_MEASURE
: O O
Ealpha O B_PROTEIN[GENE]/B_LOCATION
, O O
IA O B_PROTEIN[GENE]/B_DISEASE
( O O
b O O
) O O
+IE O B_LOCATION/B_PROTEIN[GENE]
( O O
k O B_MEASURE/B_PROTEIN[GENE]
) O O
+ O B_PROTEIN[GENE]/B_DISEASE
, O O
were O O
fed O O
a O O
high-cholesterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diet O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
16 O B_TIME[MEASURE]/B_ENT
weeks O I_TIME[MEASURE]/I_ENT
and O O
evaluated O O
histomorphometrically O O
for O O
aortic O B_DISEASE
lesions O I_DISEASE
. O O

Lesion O B_MEASURE/B_PERSON
size O B_MEASURE/I_PERSON
in O O
AB O B_LOCATION/B_PERSON
( O O
o O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
ABEalpha O B_LOCATION
, O O
and O O
BL O B_LOCATION
: O O
TG O B_LOCATION
: O O
Ealpha O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
strains O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
decreased O O
by O O
54 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
79 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
and O O
82 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
, O O
respectively O O
, O O
compared O O
with O O
wild-type O B_GENE
, O O
correlating O O
with O O
decreased O O
Th1 O B_GENE
and O O
increased O O
Th2 O O
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
suggesting O O
that O O
T O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
helper-cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phenotype O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
fatty O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lesion O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
development O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Decreasing O O
Th1 O O
cells O O
by O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
alpha-CD4 B B_GENE
) O O
or O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IL-4 B B_GENE
) O O
also O O
caused O O
> O O
/=80 O O
% O O
reductions O O
in O O
lesion O O
size O O
. O O

Confirming O O
these O O
findings O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mouse O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
strain O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
BALB/c O B_PERSON/B_GENE
Stat O I_PERSON/I_GENE
6 O I_PERSON/I_GENE
knockout O I_PERSON/I_GENE
mice O I_PERSON/I_GENE
( O O
Th2 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cell-deficient O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
developed O O
aortic O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lesions O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparable O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
C57Bl/6 O B_PERSON/B_BIO
mice O I_PERSON/I_BIO
on O O
the O O
same O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diet O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
NF-kappaB O O
response O O
was O O
blocked O O
with O O
a O O
synthetic O O
peptide O O
corresponding O O
to O O
the O O
putative B B_LOCATION
ligand-binding I I_LOCATION
domain I I_LOCATION
of O O
RAGE B B_GENE
, O O
with O O
anti- O O
RAGE B B_GENE
antiserum O O
, O O
and O O
by O O
coexpression O O
of O O
truncated B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
lacking O O
the O O
intracellular B B_LOCATION/B_PERSON
domain I B_LOCATION/I_PERSON
. O O

Activation O O
of O O
NF-kappaB B B_GENE
by O O
CML-modified B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
albumin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
increased O O
secretion O O
of O O
proinflammatory B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
interleukin-1beta B B_GENE
, O O
and O O
monocyte B B_GENE
chemoattractant I I_GENE
protein-1 I I_GENE
) O O
severalfold O O
, O O
and O O
inhibition O O
of O O
p38 B B_GENE
MAPK I I_GENE
blocked O O
these O O
increases O O
. O O

Tetramer-guided O O
epitope O O
mapping O O
: O O
rapid O O
identification O O
and O O
characterization O O
of O O
immunodominant O O
CD4+ O O
T O O
cell O O
epitopes O O
from O O
complex O O
antigens B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

T O O
cell O O
responses O O
to O O
Ags B B_DISEASE/B_VIRUS[BIO]
involve O O
recognition O O
of O O
selected O O
peptide B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
epitopes I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
contained O O
within O O
the O O
antigenic B B_PROTEIN[GENE]
protein I I_PROTEIN[GENE]
. O O

In O O
this O O
report O O
, O O
we O O
describe O O
a O O
new O O
approach O O
for O O
direct O O
identification O O
of O O
CD4+ O O
T O O
cell O O
epitopes O O
of O O
complex O O
Ags B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O O
uses O O
human B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
class I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
II I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
tetramers I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
identify O O
reactive O O
cells O O
. O O

With O O
a O O
panel O O
of O O
60 O O
overlapping O O
peptides O O
covering O O
the O O
entire O O
sequence O O
of O O
the O O
VP16 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
major O O
Ag B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
HSV-2 O O
, O O
we O O
generated O O
a O O
panel O O
of O O
class B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MHC I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tetramers I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loaded O O
with O O
peptide O O
pools O O
that O O
were O O
used O O
to O O
stain O O
peripheral O O
lymphocytes O O
of O O
an O O
HSV-2 O O
infected O O
individual O O
. O O

With O O
this O O
approach O O
, O O
we O O
identified O O
four O O
new O O
DRA1*0101/DRB1*0401- O O
and O O
two O O
DRA1*0101/DRB1*0404-restricted O O
, O O
VP16-specific B B_LOCATION/B_PERSON
epitopes I I_LOCATION/I_PERSON
. O O

By O O
using O O
tetramers B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
sort O O
individual O O
cells O O
, O O
we O O
easily O O
obtained O O
a O O
large O O
number O O
of O O
clones O O
specific O O
to O O
these O O
epitopes B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
rapid O O
approach O O
to O O
detecting O O
CD4+ O O
T O O
cell O O
epitopes O O
from O O
complex O O
Ags B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O O
be O O
applied O O
to O O
any O O
known O O
Ag B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
gives O O
a O O
T O O
cell O O
response O O
. O O

The O O
role O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
transcription O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
other O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
models O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
pancreatitis O B_DISEASE
has O O
not O O
been O O
established O O
. O O

The O O
objective O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
to O O
test O O
whether O O
CD45 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
influence O O
signaling O O
processes O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
activated O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoblasts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
this O O
end O O
, O O
we O O
generated O O
lymphoblasts O O
which O O
proliferate O O
in O O
response O O
to O O
common O O
gamma-chain B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytokines I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
readily O O
undergo O O
apoptosis O O
after O O
cytokine O O
withdrawal O O
. O O

Addition O O
of O O
CD3 B B_GENE
mAb I I_GENE
OKT-3 I I_GENE
had O O
no O O
influence O O
on O O
IL-2-mediated O O
proliferation O O
( O O
with O O
or O O
without O O
UCHL-1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
. O O

We O O
did O O
not O O
find O O
induction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
apoptosis O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
following O O
CD45R0 O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
signaling O B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
we O O
illustrate O O
that O O
CD45R0 O B_GENE
signals O I_GENE
control O O
early O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokine O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor-associated O O
signaling O O
processes O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O O
mRNA O B_GENE
and O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
synthesis O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
activated O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoblasts O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Pax5 B B_GENE
thus O O
functions O O
both O O
as O O
a O O
transcriptional O O
repressor O O
and O O
activator O O
, O O
depending O O
on O O
its O O
interactions O O
with O O
corepressors B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
the O O
Groucho B B_GENE/B_LOCATION
protein I I_GENE/I_LOCATION
family I I_GENE/I_LOCATION
or O O
with O O
positive O O
regulators O O
such O O
as O O
the O O
TATA-binding B B_GENE
protein I I_GENE
. O O

Concomitant O O
induction O O
of O O
NFAT B B_GENE
and O O
AP-1 B B_GENE
requires O O
concerted O O
activation O O
of O O
two O O
different O O
signaling O O
pathways O O
: O O
calcium/calcineurin O O
, O O
which O O
promotes O O
NFAT O O
dephosphorylation O O
, O O
nuclear O O
translocation O O
and O O
activation O O
; O O
and O O
protein B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
C I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
PKC I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
/Ras I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
promotes O O
the O O
synthesis O O
, O O
phosphorylation O O
and O O
activation O O
of O O
members O O
of O O
the O O
Fos B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
and I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Jun I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
families I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O O
transcription B B_GENE/B_DISEASE
factors I I_GENE/I_DISEASE
. O O

Pharmacological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
interference O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
theNFAT O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
AP-1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
interaction O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
useful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
selective O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
manipulation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
immune O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
response O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Cytokine O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
production O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
Vgamma O B_GENE
( O O
+ O B_PROTEIN[GENE]/B_DISEASE
) O O
-T-cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
subsets O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
is O O
an O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factor O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
determining O O
CD4 O B_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
-Th-cell O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
phenotype O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
and O O
susceptibility O B_DISEASE
of O O
BALB/c O B_SPECIES[BIO]/B_PERSON
mice O I_SPECIES[BIO]/I_PERSON
to O O
coxsackievirus O O
B3-induced O B_DISEASE_ADJECTIVE[DISEASE]
myocarditis O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Depleting O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Vgamma4 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
+ O B_GENE/B_DISEASE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
suppressed O O
myocarditis O B_DISEASE/B_GENE
and O O
reduced O O
CD4 O B_GENE
( O O
+ O B_GENE/B_DISEASE
) O O
IFN-gamma O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
+ O B_DISEASE/B_GENE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
but O O
increased O O
CD4 O B_GENE
( O O
+ O B_GENE/B_DISEASE
) O O
IL-4 O B_GENE
( O O
+ O B_OTHER/B_DISEASE
) O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

Stat4ko O B_GENE/B_MEASURE
Vgamma1 O I_GENE/I_MEASURE
( O O
+ O B_DISEASE/B_GENE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O O
IL-4 O B_GENE
( O O
+ O B_GENE/B_DISEASE
) O O
) O O
suppress O O
myocarditis O B_DISEASE/B_GENE
. O O

Stat6ko O B_GENE
Vgamma1 O I_GENE
( O O
+ O B_GENE/B_DISEASE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O O
IFN-gamma O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
+ O B_DISEASE/B_PROTEIN[GENE]
) O O
) O O
were O O
not O O
inhibitory O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O O

Stat6ko O B_GENE/B_MEASURE
Vgamma4 O I_GENE/I_MEASURE
( O O
+ O B_GENE/B_DISEASE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
IFN-gamma O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
+ O B_DISEASE/B_GENE
) O O
) O O
significantly O O
enhanced O O
myocarditis O B_DISEASE
. O O

Stat4ko O B_GENE
Vgamma4 O I_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
IL-4 O B_GENE
( O O
+ O B_GENE/B_DISEASE
) O O
) O O
neither O O
inhibited O O
nor O O
enhanced O B_DISEASE_ADJECTIVE[DISEASE]
disease O I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O O
that O O
distinct O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
gammadelta-T-cell O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
subsets O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
control O O
myocarditis O B_DISEASE
susceptibility O I_DISEASE
and O O
bias O O
the O O
CD4 O B_GENE
( O O
+ O B_GENE/B_DISEASE
) O O
-Th-cell O B_MEASURE/B_LOCATION
response O I_MEASURE/I_LOCATION
. O O

The O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
produced O O
by O O
the O O
Vgamma O O
subpopulation O O
have O O
a O O
significant O O
influence O O
on O O
the O O
CD4 B B_GENE
( O O
+ O O
) O O
-Th-cell O O
phenotype O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
indicated O O
plasmin B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
activation O O
of O O
NF-kappaB B B_GENE
; O O
DNA-binding B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
complexes I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
composed O O
of O O
p50 B B_GENE
, O O
p65 B B_GENE
, O O
and O O
c-Rel B B_GENE
, O O
as O O
shown O O
by O O
supershift O O
experiments O O
. O O

Bruton B B_GENE
's I I_GENE
tyrosine I I_GENE
kinase I I_GENE
( O O
Btk B B_LOCATION/B_ORGANIZATION
) O O
, O O
a O O
member O O
of O O
the O O
Tec B B_GENE/B_LOCATION
family I I_GENE/I_LOCATION
of I I_GENE/I_LOCATION
cytosolic I I_GENE/I_LOCATION
kinases I I_GENE/I_LOCATION
, O O
is O O
essential O O
for O O
B O O
cell O O
development O O
and O O
function O O
. O O

Residues O O
Tyr357 O O
and O O
Tyr462 O O
are O O
contained O O
within O O
the O O
loop B B_LOCATION/B_ORGANIZATION
regions I I_LOCATION/I_ORGANIZATION
of O O
adjacent O O
helix-loop-helix-like B B_LOCATION/B_BIO
repeats I B_LOCATION/I_BIO
within O O
BAP/TFII-I B B_GENE
. O O

However O O
, O O
most O O
effector O O
CD8+ O O
T O O
cells O O
recovered O O
after O O
exposure O O
to O O
Ag B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
do O O
not O O
produce O O
sufficient O O
IL-2 B B_GENE
to O O
sustain O O
growth O O
, O O
and O O
depend O O
on O O
CD4+ O O
T O O
helper O O
cells O O
for O O
this O O
obligate O O
growth O O
factor O O
. O O

IL-2 O O
expression O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
CD4+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
primarily O O
controlled O O
at O O
the O O
level O B_MEASURE/B_LOCATION
of O O
transcription O B_GENE
, O O
but O O
mechanisms O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
restricting O O
IL-2 O O
production O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
CD8+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
have O O
not O O
been O O
elucidated O O
. O O

A O O
m O O
ultipotent O O
immature O O
myeloid O O
cell O O
population O O
was O O
produced O O
from O O
a O O
basic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fibroblast I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
bFGF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
-dependent O O
hematopoietic O O
stem O O
cell O O
line O O
, O O
A-6 O O
, O O
when O O
cultured O O
with O O
stem B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
SCF B B_GENE/B_LOCATION
) O O
replacing O O
bFGF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Among O O
various O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
interleukin-3 B B_GENE
( O O
IL-3 B B_GENE
) O O
induced O O
erythroid O O
precursor O O
cells O O
that O O
expressed O O
the O O
erythroid-specific B B_GENE
GATA-1 I I_GENE
and O O
beta-major B B_GENE
globin I I_GENE
. O O

Their O O
descendants O O
, O O
double-positive O O
( O O
DP O O
; O O
CD4 O O
( O O
+ O O
) O O
/CD8 O O
( O O
+ O O
) O O
) O O
cortical O O
thymocytes O O
, O O
expressed O O
EZH2 B B_GENE
without O O
BMI-1 B B_TIME[MEASURE]
. O O

Most O B_GENE
EZH2 O I_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
DN O B_PROTEIN[GENE]/B_DISEASE
and O O
DP O B_LOCATION
thymocytes O I_LOCATION
were O O
dividing O O
, O O
while O O
DN O B_GENE/B_LOCATION
BMI-1 O I_GENE/I_LOCATION
( O O
+ O B_DISEASE/B_GENE
) O O
/EZH2 O B_GENE
( O O
- O O
) O O
thymocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O O
resting O O
and O O
proliferation O B_TIME[MEASURE]/B_DISEASE
was O O
occasionally O O
noted O O
in O O
DN O B_GENE
BMI-1 O I_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
/EZH2 O B_GENE
( O O
+ O B_DISEASE/B_PROTEIN[GENE]
) O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
multilineage O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
progenitor O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
MLP O B_LOCATION/B_ORGANIZATION
) O O
assay O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
enabled O O
us O O
to O O
discriminate O O
among O O
seven O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
types O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
hematopoietic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
are O O
multipotent O B_DISEASE_ADJECTIVE[DISEASE]
progenitor O I_DISEASE_ADJECTIVE[DISEASE]
p-MTB O I_DISEASE_ADJECTIVE[DISEASE]
( O O
capable O B_PERSON/B_LOCATION
of O O
generating O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
myeloid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
bipotent O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p-MT O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
p-MB O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
p-TB O B_DISEASE/B_PROTEIN[GENE]
, O O
and O O
unipotent O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
p-M O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
p-T O O
and O O
p-B O O
. O O

EBV O O
binds O O
to O O
CR2 B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O O
its O O
major B B_GENE/B_BIO
envelope I I_GENE/I_BIO
glycoprotein-350 I I_GENE/I_BIO
( O O
gp350 B B_GENE
) O O
and O O
is O O
also O O
a O O
remarkable O O
immunomodulating O O
agent O O
. O O

In O O
a O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
we O O
found O O
that O O
treating O O
transgenic O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Big O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Blue O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
hepatocarcinogen O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N-hydroxy-2-acetylaminofluorene O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
N-OH-AAF O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
produced O O
the O O
same O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
major O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adduct O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
target O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
liver O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
the O O
nontarget O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
spleen O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
bone O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
marrow O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
induced O O
lacI O B_DISEASE
mutants O I_DISEASE
in O O
the O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
and O O
induced O O
much O O
lower O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
frequencies O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
l O B_GENE/B_DISEASE
acI O I_GENE/I_DISEASE
and O O
hprt O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutants O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
spleen O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

Although O O
there O O
were O O
similarities O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
among O O
the O O
mutational O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
patterns O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
derived O O
from O O
N-OH-AAF-treated O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
rats O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
e.g. O B_DISEASE/B_PROTEIN[GENE]
, O O
G O O
: O B_OTHER/B_LOCATION
C O O
-- O B_MEASURE/B_GENE
> O O
T O B_MEASURE/B_LOCATION
: O I_MEASURE/I_LOCATION
A O O
transversion O O
was O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
the O O
most O O
common O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]
in O I_DISEASE_ADJECTIVE[DISEASE]
all O O
mutation O O
sets O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
) O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
there O O
were O O
significant O O
differences O B_MEASURE
in O I_MEASURE
the O O
patterns O O
of O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
basepair O O
substitution O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
frameshift O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O O
liver O O
and O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
spleen O O
lymphocyte O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
lacI O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
mutants O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
P O O
= O B_PROTEIN[GENE]/B_LOCATION
0.02 O O
) O B_MEASURE
and O O
between O O
the O O
spleen O O
lymphocyte O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
lacI O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
and O B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
hprt O O
mutants O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
( O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
P O O
= O B_PROTEIN[GENE]/B_LOCATION
0.04 O O
) O B_MEASURE
. O O

Gads B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
is O O
distinguished O O
from O O
Grb2 B B_GENE/B_BIO
and O O
the O O
closely O O
related O O
Grap B B_GENE/B_BIO
protein I I_GENE/I_BIO
by O O
the O O
presence O O
of O O
a O O
120 B B_LOCATION/B_MEASURE
amino I I_LOCATION/I_MEASURE
acid I I_LOCATION/I_MEASURE
unique I I_LOCATION/I_MEASURE
region I I_LOCATION/I_MEASURE
between O O
the O O
SH2 B B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain I I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
carboxy B B_ENZYME[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
terminal I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SH3 I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain I I_ENZYME[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Targeting O O
of O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
interleukin-2 B B_GENE
promoter I I_GENE
via O O
CREB-Rel O O
cross-talk O O
during O O
mitogen B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
oncogenic O O
molecular O O
signaling O O
in O O
activated O O
T-cells O O
. O O

Recruitment O O
of O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
cAMP-responsive B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
element-binding I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
protein-Rel I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
cross-talk O O
at O O
the O O
composite B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CD28 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
response I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
element I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CD28RE B B_GENE/B_LOCATION
) O O
- O O
TRE B B_MEASURE/B_LOCATION
element I B_MEASURE/I_LOCATION
of O O
the O O
IL-2 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
is O O
essential O O
for O O
promoter O O
inducibility O O
during O O
T-cell O O
activation O O
, O O
and O O
CD28RE-TRE B B_GENE/B_LOCATION
is O O
the O O
exclusive O O
target O O
of O O
the O O
human O O
T-cell O O
lymphotropic O O
virus O O
type O O
I O O
oncoprotein B B_GENE/B_DISEASE
Tax I I_GENE/I_DISEASE
. O O

The O O
intrinsic O O
histone O O
acetyltransferase O O
activity O O
of O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
dispensable O O
for O O
activation O O
of O O
the O O
IL-2 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
, O O
and O O
the O O
N-terminal B B_LOCATION/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
743 I B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
residues I B_LOCATION/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contain O O
the O O
minimal O O
structural O O
requirements O O
for O O
synergistic O O
transactivation O O
of O O
the O O
CD28RE-TRE B B_GENE/B_LOCATION
, O O
the O O
IL-2 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
, O O
and O O
endogenous O O
IL-2 B B_GENE
gene I I_GENE
expression O O
. O O

These O O
findings O O
provide O O
evidence O O
that O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assembles O O
at O O
the O O
IL-2 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
to O O
form O O
an O O
enhanceosome-like O O
signal O O
transduction O O
target O O
that O O
is O O
centrally O O
integrated O O
at O O
the O O
CD28RE-TRE B B_LOCATION
element I I_LOCATION
of O O
the O O
IL-2 B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION
through O O
specific O O
protein O O
module-targeted O O
associations O O
in O O
activated O O
T-cells O O
. O O

As O O
inflammatory O B_DISEASE/B_LOCATION
gene O B_DISEASE/I_LOCATION
expression O B_DISEASE/I_LOCATION
contributes O O
to O O
the O O
pathogenesis O B_DISEASE_ADJECTIVE[DISEASE]
of O O
demyelinating O O
diseases O B_DISEASE/B_LOCATION
, O O
we O O
tested O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
SR O B_GENE/B_DISEASE
on O O
the O O
progression O B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
demyelinating O O
disease O B_DISEASE
experimental O I_DISEASE
autoimmune O I_DISEASE
encephalomyelitis O I_DISEASE
( O O
EAE O B_DISEASE/B_LOCATION
) O O
. O O

T-cell O O
activation O O
, O O
assessed O O
by O O
the O O
production O O
of O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IFNgamma B B_PROTEIN[GENE]/B_LOCATION
) O O
in O O
response O O
to O O
MOG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
35-55 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
was O O
also O O
decreased O O
by O O
the O O
HSR O O
. O O

The O O
HSR O O
reduced O O
inflammatory O O
gene O O
expression O O
in O O
the O O
brain O O
that O O
normally O O
occurs O O
during O O
EAE O O
, O O
including O O
the O O
early O O
increase O O
in O O
RANTES B B_GENE
( O O
regulated B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
on I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
activation I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
normal I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
T-cell I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
expressed I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
secreted I I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
expression O O
, O O
and O O
the O O
later O O
expression O O
of O O
the O O
inducible O O
form O O
of O O
nitric B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
oxide I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intracellular O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathways O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
developing O O
thymocytes O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O O

To O O
this O O
end O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
we O O
have O O
developed O O
a O O
novel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
system O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O O
facilitates O O
the O O
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
signal O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transduction O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathways O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O O
T-lymphocyte O B_DISEASE/B_ORGANISM_FUNCTION
development O I_DISEASE/I_ORGANISM_FUNCTION
. O O

Importantly O O
, O O
this O O
powerful O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
technique O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
preserves O O
the O O
structural O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
integrity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
the O O
thymus O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
, O O
and O O
will O O
provide O O
an O O
invaluable O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
tool O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O O
study O O
how O O
thymocytes O O
respond O O
to O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
environmental O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimuli O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
encountered O O
during O O
differentiation O B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
within O O
the O O
thymic O B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
milieu O I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O O

Sequences O O
responsible O O
for O O
the O O
inability O O
of O O
CBFbeta B B_PROTEIN[GENE]/B_DISEASE
-SMMHC O O
to O O
rescue O O
definitive O O
hematopoiesis O O
reside O O
in O O
the O O
SMMHC B B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
portion I I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
fusion B B_GENE/B_LOCATION
protein I I_GENE/I_LOCATION
. O O

The O O
nasal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
type O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
extranodal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
natural O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
killer O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
T O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
NK/T O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
-cell O B_DISEASE
lymphoma O I_DISEASE
is O O
usually O O
associated O O
with O O
latent O B_DISEASE/B_VIRUS[BIO]
Epstein-Barr O B_DISEASE/I_VIRUS[BIO]
virus O B_DISEASE/I_VIRUS[BIO]
( O O
EBV O B_VIRUS[BIO]/B_DISEASE
) O O
infection O B_DISEASE
. O O

The O O
implication O O
of O O
EBV O O
in O O
the O O
skin O O
lesions O O
was O O
determined O O
by O O
the O O
presence O O
of O O
EBV-DNA B B_VIRUS[BIO]/B_GENE
, O O
EBV-encoded B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
nuclear I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
RNA I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
EBER B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
a O O
clonality O O
of O O
EBV-DNA B B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
fragments I I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
containing O O
the O O
terminal B B_GENE/B_DISEASE
repeats I I_GENE/I_DISEASE
. O O

Transcripts O O
of O O
EBV-encoded B B_DISEASE/B_BIO
genes I I_DISEASE/I_BIO
were O O
screened O O
by O O
reverse O O
transcription- O O
polymerase O O
chain O O
reaction O O
( O O
RT-PCR O O
) O O
, O O
and O O
confirmed O O
by O O
Southern O O
blot O O
hybridization O O
. O O

Immunostaining O O
showed O O
no O O
LMP-1 B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
EBNA-2 I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ZEBRA I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antigens I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
paraffin-embedded O O
tissue O O
sections O O
, O O
although O O
they O O
were O O
positive O O
in O O
the O O
cell O O
line O O
cells O O
. O O

A O O
patient O B_PERSON/B_BIO
with O O
NK-cell O B_DISEASE
lymphoma O I_DISEASE
expressing O O
both O O
transcripts O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
died O O
of O O
rapid O B_DISEASE_ADJECTIVE[DISEASE]
progression O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
illness O B_DISEASE
. O O

Synthetic O B_NUMBER[MEASURE]/B_GENE
high O I_NUMBER[MEASURE]/I_GENE
affinity O I_NUMBER[MEASURE]/I_GENE
peroxisome O I_NUMBER[MEASURE]/I_GENE
proliferator-activated O O
receptor O B_GENE
( O O
PPAR O B_LOCATION/B_ORGANIZATION
) O O
agonists O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
known O O
, O O
but O O
biologic O B_NUMBER[MEASURE]/B_ORGANIZATION
ligands O I_NUMBER[MEASURE]/I_ORGANIZATION
are O O
of O O
low O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
affinity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

[ O O
( O O
3 O O
) O O
H O O
] O O
azPC O O
bound O O
recombinant B B_GENE
PPARgamma I I_GENE
with O O
an O O
affinity O O
( O O
K O O
( O O
d O O
) O O
( O O
( O O
app O O
) O O
) O O
approximately O O
40 O O
nm O O
) O O
that O O
was O O
equivalent O O
to O O
rosiglitazone O O
( O O
BRL49653 O O
) O O
, O O
and O O
competition O O
with O O
rosiglitazone O O
showed O O
that O O
binding O O
occurred O O
in O O
the O O
ligand-binding B B_LOCATION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pocket I B_LOCATION/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Results O O
with O O
a O O
small O O
molecule O O
phospholipid B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flippase I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mimetic I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
azPC O O
acts O O
intracellularly O O
and O O
that O O
cellular O O
azPC O O
accumulation O O
was O O
efficient O O
. O O

Methionine B B_GENE
adenosyltransferase I I_GENE
( O O
MAT B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
catalyzes O O
the O O
biosynthesis O O
of O O
S-adenosylmethionine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
AdoMet B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
) O O
, O O
a O O
key O O
molecule O O
in O O
transmethylation O O
reactions O O
and O O
polyamine O O
biosynthesis O O
. O O

Transcription O O
of O O
the O O
MAT2B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
initiates O O
at O O
position O O
-203 O O
relative O O
to O O
the O O
translation B B_PERSON/B_ORGANIZATION
start I I_PERSON/I_ORGANIZATION
site I I_PERSON/I_ORGANIZATION
. O O

Promoter B B_PERSON
deletion I I_PERSON
analysis I I_PERSON
defined O O
a O O
minimal B B_GENE/B_LOCATION
promoter I B_GENE/I_LOCATION
between O O
positions B B_NUMBER[MEASURE]/B_LOCATION
+52 I I_NUMBER[MEASURE]/I_LOCATION
and I I_NUMBER[MEASURE]/I_LOCATION
+93 I I_NUMBER[MEASURE]/I_LOCATION
base O O
pairs O O
, O O
a O O
GC-rich B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
region I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Inclusion O O
of O O
the O O
sequences O O
between O O
-4 O O
and O O
+52 O O
enhanced O O
promoter O O
activity O O
; O O
this O O
was O O
primarily O O
because O O
of O O
an O O
Sp1 B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
recognition I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
site I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O O
+9/+15 O O
. O O

Supershift O O
assays O O
showed O O
no O O
effect O O
of O O
the O O
anti-Sp1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
complex O O
formation O O
, O O
whereas O O
the O O
anti-Sp3 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
a O O
strong O O
effect O O
on O O
protein.DNA O O
complex O O
formation O O
, O O
suggesting O O
that O O
Sp3 B B_GENE
is O O
one O O
of O O
the O O
main O O
factors O O
binding O O
to O O
this O O
Sp1 B B_GENE/B_LOCATION
site I I_GENE/I_LOCATION
. O O

Influenza O B_DISEASE/B_MEASURE
A O O
virus O B_VIRUS[BIO]/B_DISEASE
, O O
which O O
replicates O O
in O O
epithelial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
leukocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
regulates O O
host O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcriptional O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
translational O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
activates O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
as O O
well O O
as O O
downregulates O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
apoptotic O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
pathways O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Influenza O O
A O O
virus O O
infection O O
results O O
in O O
the O O
production O O
of O O
chemotactic O O
( O O
RANTES B B_GENE/B_LOCATION
, O O
MIP-1 B B_LOCATION/B_ORGANIZATION
alpha I I_LOCATION/I_ORGANIZATION
, O O
MCP-1 B B_GENE/B_LOCATION
, O O
MCP-3 B B_GENE
, O O
and O O
IP-10 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
pro-inflammatory O O
( O O
IL-1 B B_GENE
beta I I_GENE
, O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
IL-18 B B_GENE
, O O
and O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
and O O
antiviral B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
IFN-alpha/beta I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cytokines I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Influenza O O
A O O
virus-induced O O
IFN-alpha/beta B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
essential O O
in O O
host O O
's O O
antiviral O O
defence O O
by O O
activating O O
the O O
expression O O
of O O
antiviral B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Mx I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
PKR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
oligoadenylate I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
synthetase I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hprt O B_GENE
and O O
lacI O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutant O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
frequency O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
adduct O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
formation O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
N-hydroxy-2-acetylaminofluorene-treated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
Big O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
Blue O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
rats O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
taken O O
after O O
four O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
doses O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
adduct O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O O
103 O B_MEASURE
, O O
28 O B_MEASURE
, O O
and O O
7 O B_MEASURE
fmol/microg O I_MEASURE
of O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
liver O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
spleen O B_BODY_PART_OR_ORGAN_COMPONENT
lymphocytes O I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
bone O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
marrow O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
respectively O O
. O O

To O O
investigate O O
more O O
closely O O
any O O
effects O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
Mad1 O B_GENE
expression O I_GENE
on O O
thymocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O O
we O O
examined O O
thymic O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
selection O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
MHC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
class O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I-restricted O O
H-Y-TCR O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transgenic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mice O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Mad1 O B_GENE
expression O I_GENE
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
reduces O O
the O O
efficiency O B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
positive O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
selection O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

The O O
growth O O
inhibition O O
caused O O
by O O
Mad1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
is O O
overcome O O
by O O
expression O O
of O O
active B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
c-Myc I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
better O O
understand O O
the O O
mechanisms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
their O O
proinflammatory O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
studied O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
several O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
components O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
extracted O O
from O O
DEPs O B_DISEASE/B_BIO
on O O
interleukin O B_GENE
( O O
IL O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
-8 O O
expression O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
bronchial O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
epithelial O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cell O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
line O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
BEAS-2B O I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
normal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_NUMBER[MEASURE]
human O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_NUMBER[MEASURE]
airway O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_NUMBER[MEASURE]
epithelial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_NUMBER[MEASURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_NUMBER[MEASURE]
obtained O O
from O O
very O O
peripheral O B_PERSON/B_TIME[MEASURE]
airways O B_PERSON/I_TIME[MEASURE]
by O O
an O O
ultrathin O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bronchoscope O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Simultaneous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O O
PPAR-gamma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ligands O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
e.g. O B_MEASURE/B_DISEASE
15-deoxy-Delta O O
( O B_GENE/B_MEASURE
12 O O
, O B_MEASURE
14 O O
) O B_MEASURE
-prostaglandin O O
J O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
2 O O
) O B_NUMBER[MEASURE]
, O O
troglitazone O O
) O B_MEASURE
showed O O
drastic O O
inhibition O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proliferation O O
and O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
significant O O
decreases O B_DISEASE_ADJECTIVE[DISEASE]
in O I_DISEASE_ADJECTIVE[DISEASE]
cell O O
viability O B_DISEASE_ADJECTIVE[DISEASE]
. O I_DISEASE_ADJECTIVE[DISEASE]

These O O
observations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
PPAR-gamma O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
agonists O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
play O O
an O O
important O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
regulating O O
T O B_OTHER/B_GENE
cell-mediated O O
immune O B_DISEASE_ADJECTIVE[DISEASE]
responses O I_DISEASE_ADJECTIVE[DISEASE]
by O O
inducing O O
apoptosis O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

T O B_DISEASE/B_GENE
cell O B_DISEASE/I_GENE
death O B_DISEASE/I_GENE
via O O
PPAR-gamma O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ligation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O O
act O O
as O O
a O O
potent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anti-inflammatory O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
signal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
immune O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
ligands O B_PERSON/B_LOCATION
could O O
possibly O O
be O O
used O O
to O O
control O O
disorders O B_DISEASE/B_LOCATION
in O O
which O O
excessive O B_DISEASE
inflammation O I_DISEASE
occurs O O
. O O

We O O
hypothesized O O
that O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
proteasome O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
CI-1 O O
would O O
block O O
NF-kappaB O B_DISEASE
activation O I_DISEASE
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
after O O
intraperitoneal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
i.p. O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
treatment O O
with O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
bacterial O O
lipopolysaccharide O B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O B_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LPS O O
) O B_LOCATION/B_ORGANIZATION
, O O
and O O
that O O
NF-kappaB O O
inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
would O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
be O O
associated O O
with O O
suppression O O
of O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chemokine O O
gene O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attenuation O O
of O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
neutrophilic O O
alveolitis O B_DISEASE
. O I_DISEASE

Notch O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regulates O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
fate O I_DISEASE_ADJECTIVE[DISEASE]
decisions O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
in O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
lineages O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
. O O

We O O
recently O O
reported O O
the O O
SART3 B B_BIO/B_DISEASE
tumour-rejection I I_BIO/I_DISEASE
antigen I I_BIO/I_DISEASE
as O O
possessing O O
tumour O O
epitopes O O
capable O O
of O O
inducing O O
HLA-class O O
I-restricted O O
cytotoxic O O
T O O
lymphocytes O O
( O O
CTLs O O
) O O
. O O

As O O
an O O
essential O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
step O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
in O O
the O O
lytic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cascade O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
Rta O B_BIO/B_GENE
homologues O I_BIO/I_GENE
of O O
gammaherpesviruses O B_BACTERIUM[BIO]/B_GENE
all O O
activate O O
their O O
own O B_GENE
expression O I_GENE
. O O

We O O
analyzed O O
the O O
activity O O
of O O
RpCAT B B_GENE/B_BACTERIUM[BIO]
in O O
response O O
to O O
Rta B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O O
deletional O O
and O O
site-directed O O
mutagenesis O O
. O O

Two O O
cognate B B_LOCATION/B_BIO
Sp1 I I_LOCATION/I_BIO
binding I I_LOCATION/I_BIO
sites I I_LOCATION/I_BIO
located O O
at O O
-279 O O
and O O
-45 O O
relative O O
to O O
the O O
transcriptional B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
start I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
site I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
proved O O
crucial O O
for O O
Rta-mediated O O
activation O O
. O O

During O O
the O O
lytic O O
cycle O O
, O O
ZEBRA B B_PERSON/B_GENE
bound O O
Rp B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
near O O
the O O
Sp1/Sp3 B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
site I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Solid O B_DISEASE/B_PERSON
tumors O I_DISEASE/I_PERSON
meet O O
their O O
demands O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
nascent O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vessels O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
increased O O
glycolysis O B_ORGAN_OR_TISSUE_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE
, O O
to O O
combat O O
hypoxia O B_DISEASE
, O O
by O O
activating O O
multiple O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
genes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
involved O O
in O O
angiogenesis O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
glucose O B_DISEASE
metabolism O I_DISEASE
. O O

It O O
activates O O
the O O
transcription O B_GENE
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
important O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
maintaining O O
oxygen O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
homeostasis O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

We O O
have O O
recently O O
shown O O
that O O
over-expression O O
of O O
the O O
full-length O O
, O O
most O O
highly O O
expressed O O
Runx2 B B_GENE
isoform O O
in O O
the O O
thymus O O
perturbs O O
T-cell O O
development O O
, O O
leads O O
to O O
development O O
of O O
spontaneous O O
lymphomas O O
at O O
low O O
frequency O O
and O O
is O O
strongly O O
synergistic O O
with O O
Myc B B_DISEASE/B_SPECIES[BIO]
. O O

Here O O
, O O
we O O
report O O
that O O
both O O
human O B_GENE
CD34 O I_GENE
( O O
+ O B_OTHER/B_DISEASE
) O O
stem O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
-derived O O
DCs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O O
CD34DCs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
) O O
and O O
human O B_GENE
CD14 O I_GENE
( O O
+ O B_GENE/B_DISEASE
) O O
monocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
-derived O O
DCs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O O
MoDCs O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
express O O
TRAIL O B_GENE
and O O
exhibit O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cytotoxicity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
some O O
types O B_MEASURE/B_DISEASE
of O O
tumor O B_DISEASE
cells O I_DISEASE
partially O O
through O O
TRAIL O B_GENE
. O O

Moderate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
TRAIL O B_GENE
appeared O O
on O O
CD34DCs O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
the O O
8th O B_TIME[MEASURE]/B_LOCATION
day O B_TIME[MEASURE]/I_LOCATION
of O O
culture O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
and O O
was O O
also O O
seen O O
on O O
freshly O O
isolated O O
monocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

The O O
level O B_MEASURE
of O O
TRAIL O B_GENE
expression O I_GENE
remained O O
constant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
until O O
DC O B_TIME[MEASURE]/B_LOCATION
maturation O I_TIME[MEASURE]/I_LOCATION
. O O

Thus O O
, O O
an O O
innate O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanism O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
DC-mediated O B_DISEASE
antitumor O I_DISEASE
immunity O I_DISEASE
might O O
exist O O
in O O
vivo O B_PERSON/B_DISEASE
in O O
which O O
DCs O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
act O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O O
effectors O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O O
directly O O
kill O O
tumor O B_DISEASE
cells O I_DISEASE
partially O O
via O O
TRAIL O B_GENE
. O O

Tumor O B_PERSON/B_DISEASE
cells O I_PERSON/I_DISEASE
regulate O O
the O O
lytic O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
tumor-specific O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cytotoxic O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
t O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
by O O
modulating O O
the O O
inhibitory O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
natural O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
killer O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
p58+ O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
were O O
found O O
to O O
express O O
a O O
memory O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
phenotype O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
corresponded O O
to O O
clonal O O
TCRBV3 O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
T-cell O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
expansion O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

However O O
, O O
this O O
lytic O O
activity O O
was O O
significantly O O
increased O O
after O O
blockade O O
of O O
p58 B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O O
specific O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Culture O O
with O O
the O O
murine O O
fetal O O
liver O O
cell O O
line O O
AFT024 O O
and O O
defined O O
cytokines B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
was O O
capable O O
of O O
inducing O O
TCF-1 B B_GENE/B_DISEASE
mRNA I I_GENE/I_DISEASE
. O O

These O O
results O O
suggest O O
that O O
TCF-1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
does O O
not O O
target O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
killer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
immunoglobulin I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
TCF-1 B B_LOCATION
is O O
uniquely O O
expressed O O
in O O
circulating O O
CD56 O O
( O O
+bright O O
) O O
NK O O
cells O O
, O O
and O O
specific O O
TCF-1 B B_GENE/B_BIO
isoforms I I_GENE/I_BIO
may O O
play O O
an O O
important O O
role O O
in O O
regulating O O
NK O O
differentiation O O
from O O
a O O
common O O
NK/T-cell O O
progenitor O O
. O O

contextual O O
requirements O O
for O O
the O O
function O O
of O O
bright B B_PERSON/B_ORGANIZATION
. O O

We O O
show O O
here O O
that O O
Bright B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
has O O
multiple O O
contextual O O
requirements O O
to O O
function O O
as O O
a O O
transcriptional B B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activator I I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Bright B B_PERSON/B_GENE
can O O
not O O
transactivate O O
via O O
out O O
of O O
context O O
, O O
concatenated B B_LOCATION
binding I I_LOCATION
sites I I_LOCATION
. O O

The O O
Bright B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
DNA I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
binding I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
domain I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
defined O O
a O O
new O O
family O O
, O O
which O O
includes O O
SWI1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
component O O
of O O
the O O
SWI.SNF B B_LOCATION/B_BIO
complex I I_LOCATION/I_BIO
shown O O
to O O
have O O
high O O
mobility O O
group-like O O
DNA O O
binding O O
characteristics O O
. O O

BCL-6 B B_GENE
is O O
essential O O
for O O
germinal O O
center O O
formation O O
and O O
thus O O
for O O
affinity O O
maturation O O
of O O
immunoglobulin B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
Ig I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
somatic O O
mutations O O
. O O

Classic O B_DISEASE/B_GENE
Hodgkin O B_DISEASE/I_GENE
disease O B_DISEASE/I_GENE
( O O
cHD O B_LOCATION/B_ORGANIZATION
) O O
is O O
also O O
derived O O
from O O
B O B_DISEASE/B_BIO
cells O I_DISEASE/I_BIO
with O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loads O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
somatic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
thus O O
a O O
further O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
candidate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
BCL-6 O B_DISEASE
mutations O I_DISEASE
. O O

While O O
in O O
most O O
tissues O O
all O O
Gadd45 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
family I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
members I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
are O O
expressed O O
, O O
Gadd45gamma B B_GENE
is O O
the O O
only O O
member O O
that O O
is O O
induced O O
by O O
IL-2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

These O O
data O O
demonstrate O O
that O O
Gadd45gamma B B_GENE
is O O
not O O
essential O O
for O O
normal O O
mouse O O
development O O
and O O
hematopoiesis O O
, O O
possibly O O
due O O
to O O
functional O O
redundancy O O
among O O
the O O
Gadd45 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
family I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
members I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O O

The O O
levels O O
of O O
molecules O O
whose O O
expressions O O
are O O
associated O O
with O O
myc B B_DISEASE/B_SPECIES[BIO]
, O O
such O O
as O O
STAM B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
prothymosin-alpha B B_GENE/B_LOCATION
, O O
and O O
NFkappaB B B_GENE

Skin O O
lesions O O
of O O
dermatophytosis O O
are O O
thought O O
to O O
be O O
a O O
result O O
of O O
a O O
T O O
cell O O
-dependent O O
inflammatory O O
response O O
that O O
is O O
mediated O O
by O O
various O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
examined O O
whether O O
IFN-gamma-positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
as O O
expression O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
Th1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
response O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O O
were O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
skin O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lesions O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
dermatophytosis O B_DISEASE/B_LOCATION
in O O
situ O B_PERSON/B_SPECIES[BIO]
by O O
immunohistochemical O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
techniques O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Mixtures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
CD4-positive O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
T O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
CD8-positive O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
found O O
to O O
be O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
dermal O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infiltrates O B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
lesions O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
pattern O O
of O O
IFN-gamma B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
staining O O
appeared O O
to O O
be O O
intracellular O O
in O O
mononuclear O O
lymphoid O O
cells O O
. O O

Over O O
the O O
last O B_TIME[MEASURE]/B_LOCATION
decade O I_TIME[MEASURE]/I_LOCATION
the O O
concept O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
T O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
co-stimulation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
has O O
emerged O O
to O O
take O O
a O O
central O B_LOCATION/B_PERSON
role O I_LOCATION/I_PERSON
in O O
the O O
process O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O O
T O B_DISEASE
cell O I_DISEASE
activation O I_DISEASE
. O O

Regulation O O
of O O
activator B B_GENE
protein-1 I I_GENE
and O O
NF-kappa B B_GENE
B I I_GENE
in O O
CD8+ O O
T O O
cells O O
exposed O O
to O O
peripheral B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
self-antigens I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
transcriptional O O
events O O
that O O
control O O
T O O
cell O O
tolerance O O
to O O
peripheral B B_DISEASE
self I I_DISEASE
Ags I I_DISEASE
are O O
still O O
unknown O O
. O O

We O O
found O O
that O O
the O O
self-reactive O B_GENE
CD8 O I_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
Des O B_GENE/B_DISEASE
( O O
+ O B_GENE/B_DISEASE
) O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
were O O
transiently O O
activated O O
, O O
then O O
became O O
unresponsive O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
and O O
were O O
further O O
deleted O O
. O O

Indeed O O
, O O
in O O
vivo O O
primed O O
T O O
cells O O
predominantly O O
express O O
p50/p50 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
p65/p50 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
dimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
whereas O O
these O O
p50-containing B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complexes I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
are O O
barely O O
detectable O O
in O O
tolerant O O
T O O
cells O O
that O O
express O O
p65- B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-Rel-containing I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Transcriptional O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
regulation O B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O

Lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
have O O
been O O
used O O
to O O
investigate O O
many O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cellular O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
processes O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
including O O
lineage O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
commitment O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
, O O
differentiation O B_PROTEIN[GENE]/B_ORGANISM_FUNCTION
, O O
proliferation O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
and O O
apoptosis O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

Its O O
agonistic O O
action O O
on O O
RXR/RAR B B_GENE/B_LOCATION
heterodimer I I_GENE/I_LOCATION
, O O
on O O
the O O
other O O
hand O O
, O O
was O O
neutralized O O
by O O
the O O
RAR B B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist O O
. O O

During O O
HL60 O O
cell O O
differentiation O O
, O O
atRA O O
induced O O
RARbeta B B_GENE/B_DISEASE
mRNA I I_GENE/I_DISEASE
, O O
while O O
the O O
RXR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
had O O
no O O
effect O O
. O O

Similar O O
to O O
transmembrane B B_GENE
PTP I I_GENE
, O O
CD45 B B_GENE/B_TIME[MEASURE]
, O O
the O O
membrane-associated O O
populations O O
of O O
SHP-1 B B_GENE
and O O
SHP-2 B B_GENE
are O O
essentially O O
excluded O O
from O O
lipid O O
rafts O O
, O O
where O O
other O O
signaling B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
molecules I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such O O
as O O
Lck B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
linker I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
for I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
CD3 B B_GENE
zeta I I_GENE
are O O
enriched O O
. O O

It O O
suggests O O
that O O
a O O
restricted O O
partition O O
of O O
PTPs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
among O O
membrane O O
subdomains O O
may O O
regulate O O
protein O O
tyrosine O O
phosphorylation O O
in O O
T O O
cell O O
membrane O O
. O O

Although O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
-12 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
IL-4 B B_MEASURE/B_GENE
polarize O O
naive O O
CD4 O O
( O O
+ O O
) O O
T O O
cells O O
toward O O
T O O
helper O O
cell O O
type O O
1 O O
( O O
Th1 O O
) O O
or O O
Th2 O O
phenotypes O O
, O O
it O O
is O O
not O O
known O O
whether O O
cytokines B B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
instruct O O
the O O
developmental O O
fate O O
in O O
uncommitted O O
progenitors O O
or O O
select O O
for O O
outgrowth O O
of O O
cells O O
that O O
have O O
stochastically O O
committed O O
to O O
a O O
particular O O
fate O O
. O O

To O O
distinguish O O
these O O
instructive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
selective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
models O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
we O O
used O O
surface O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
affinity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
matrix O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
technology O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
isolate O O
committed O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
progenitors O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
based O O
on O O
cytokine O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
secretion O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenotype O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
developed O O
retroviral-based O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tagging O O
approaches O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
to O O
directly O O
monitor O O
individual O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
progenitor O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fate O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
decisions O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O O
the O O
clonal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O O
population O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
would O O
seem O O
to O O
exclude O O
selection O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O O
an O O
exclusive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanism O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
Th1 O B_LOCATION/B_PERSON
/ O O
Th2 O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
support O O
an O O
instructive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
cytokine-driven O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transcriptional O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
programming O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
fate O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
decisions O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

In O O
this O O
study O O
, O O
T O O
cell O O
nuclear O O
extracts O O
from O O
female O O
lupus O O
patients O O
and O O
normal O O
donors O O
were O O
tested O O
for O O
biologically O O
active O O
ER B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
capable O O
of O O
binding O O
to O O
the O O
human B B_GENE
estrogen I I_GENE
response I I_GENE
element I I_GENE
( O O
hERE B B_GENE/B_BIO
) O O
by O O
electrophoretic O O
mobility O O
shift O O
assays O O
. O O

When O O
peripheral O O
blood O O
T O O
cells O O
were O O
stimulated O O
with O O
17beta-estradiol O O
( O O
E2 O O
) O O
, O O
PMA O O
and O O
ionomycin O O
, O O
two O O
major O O
retarded O O
bands O O
in O O
T O O
cell O O
nuclear O O
extracts O O
exhibited O O
a O O
migration O O
pattern O O
similar O O
to O O
slow O O
migrating O O
protein-ERE B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
complexes I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
human O O
breast O O
cancer O O
cell O O
extracts O O
. O O

There O O
was O O
no O O
notable O O
difference O O
in O O
the O O
migration O O
pattern O O
of O O
ERE-binding B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
between O O
the O O
SLE O O
and O O
normal O O
T O O
cell O O
extracts O O
. O O

Mechanism O O
of O O
the O O
inhibitory O O
effect O O
of O O
protease O O
inhibitor O O
on O O
tumor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
production O O
of O O
monocytes O O
. O O

Monocytes O O
are O O
extremely O O
important O O
cells O O
for O O
regulating O O
the O O
cytokine O O
network O O
and O O
tumor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
necrosis I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
TNFalpha B B_GENE/B_LOCATION
) O O
and O O
interleukin- B B_GENE
( I I_GENE
IL I I_GENE
) I I_GENE
10 I I_GENE
, O O
which O O
are O O
mainly O O
synthesized O O
by O O
monocytes O O
, O O
are O O
representative O O
cytokines B B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
play O O
a O O
central O O
role O O
in O O
the O O
cytokine O O
network O O
. O O

Protease O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
inhibitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
such O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
as O O
gabexate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mesilate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GM O B_ORGANIZATION/B_LOCATION
) O O
and O O
ulinastatin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
UTI O B_ORGANIZATION/B_LOCATION
) O O
have O O
been O O
shown O O
to O O
have O O
various O B_DISEASE_ADJECTIVE[DISEASE]
beneficial O I_DISEASE_ADJECTIVE[DISEASE]
effects O I_DISEASE_ADJECTIVE[DISEASE]
by O O
inhibiting O O
the O O
activation O B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O O
leukocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
but O O
the O O
mechanism O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O O
this O O
has O O
yet O O
to O O
be O O
fully O O
elucidated O O
. O O

SDF1 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
treatment O O
of O O
Jurkat O O
T O O
cells O O
increased O O
the O O
activity O O
of O O
NO B B_GENE
synthase I I_GENE
, O O
which O O
catalyzes O O
the O O
generation O O
of O O
NO O O
. O O

These O O
studies O O
suggest O O
that O O
NO-related O O
signaling O O
pathways O O
may O O
mediate O O
SDF1 B B_GENE
alpha I I_GENE
-induced O O
chemotaxis O O
, O O
but O O
not O O
mitogen-activated B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
kinase I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
activation O O
. O O

The O O
lack O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
NF-kappa O B_GENE
B O I_GENE
transactivation O I_GENE
and O O
PKC O B_GENE
epsilon O I_GENE
expression O I_GENE
in O O
CD4 O B_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
CD8 O B_GENE
( O O
+ O B_DISEASE/B_PROTEIN[GENE]
) O O
thymocytes O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
correlates O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O O
negative O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
selection O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Deletion O O
of O O
autoreactive O O
thymocytes O O
at O O
the O O
DP O O
stage O O
is O O
the O O
basis O O
for O O
tolerance O O
to O O
thymus-expressed B B_DISEASE
self I I_DISEASE
antigens I I_DISEASE
. O O

In O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
we O O
investigated O O
whether O O
distinct O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signalling O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathways O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
induced O O
in O O
DP O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
thymocytes O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
as O O
compared O O
to O O
mature O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
upon O O
stimulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
antigen O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Lack O O
of O O
NF-kappa B B_GENE/B_DISEASE
B I I_GENE/I_DISEASE
induction O O
correlated O O
with O O
increased O O
death O O
in O O
response O O
to O O
antigen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

The O O
PML B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
induced O O
by O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
involved O O
in O O
major B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
histocompatibility I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
complex I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
class I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
I I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
presentation O O
, O O
and O O
necessary O O
for O O
certain O O
types O O
of O O
apoptosis O O
. O O

To O O
examine O O
whether O O
Epstein-Barr O O
virus O O
( O O
EBV O O
) O O
lytic O O
replication O O
interferes O O
with O O
PML O O
bodies O O
, O O
we O O
expressed O O
the O O
EBV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immediate-early I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
BZLF1 B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Z I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
BRLF1 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
R I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
EBV-positive O O
cell O O
lines O O
and O O
examined O O
PML B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
localization O O
. O O

Both O O
Z O O
and O O
R O O
expression O O
resulted O O
in O O
PML B B_DISEASE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
dispersion O O
in O O
EBV-positive O O
cells O O
. O O

Z O B_OTHER/B_LOCATION
but O O
not O O
R O B_PROTEIN[GENE]/B_LOCATION
expression O I_PROTEIN[GENE]/I_LOCATION
is O O
sufficient O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
disrupt O O
PML O B_DISEASE/B_GENE
bodies O I_DISEASE/I_GENE
in O O
EBV-negative O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lines O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

We O O
show O O
that O O
dispersion O O
of O O
PML O O
bodies O O
by O O
Z B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requires O O
a O O
portion O O
of O O
the O O
transcriptional B B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation I B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
domain I B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
Z B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
not O O
the O O
DNA-binding O O
function O O
. O O

As O O
was O O
previously O O
reported O O
for O O
the O O
HSV-1 B B_DISEASE/B_BIO
ICP0 I I_DISEASE/I_BIO
and I I_DISEASE/I_BIO
CMV I I_DISEASE/I_BIO
IE1 I I_DISEASE/I_BIO
proteins I I_DISEASE/I_BIO
, O O
Z B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduces O O
the O O
amount O O
of O O
SUMO-1-modified B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
PML I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
disruption O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
PML O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bodies O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
important O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
efficient O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
lytic O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
replication O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
EBV O B_VIRUS[BIO]/B_DISEASE
. O O

Plasma B B_MEASURE/B_LOCATION
tumor I I_MEASURE/I_LOCATION
necrosis I I_MEASURE/I_LOCATION
factor I I_MEASURE/I_LOCATION
( I I_MEASURE/I_LOCATION
TNF I I_MEASURE/I_LOCATION
) I I_MEASURE/I_LOCATION
-alpha I I_MEASURE/I_LOCATION
, O O
soluble B B_GENE
intercellular I I_GENE
adhesion I I_GENE
molecule-1 I I_GENE
( O O
sICAM-1 B B_GENE/B_LOCATION
) O O
, O O
monocyte B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chemoattractant I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
MCP-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
plasminogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activator I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
inhibitor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
type I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
1 I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
PAI-1 B B_GENE/B_LOCATION
) O O
, O O
C-reactive B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
CRP I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
interleukin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
IL I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
-10 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
antiinflammatory B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cytokine I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O O
concentrations O O
were O O
also O O
measured O O
as O O
mediators O O
of O O
inflammatory O O
activity O O
that O O
are O O
regulated O O
by O O
the O O
proinflammatory B B_GENE
transcription I I_GENE
factor I I_GENE
NFkappaB I I_GENE
. O O

Plasma O B_GENE
insulin O I_GENE
concentrations O I_GENE
fell O O
significantly O O
at O O
week O B_TIME[MEASURE]
1 O I_TIME[MEASURE]
, O O
from O O
31.2 O B_MEASURE
+/- O O
29.1 O B_MEASURE
to O O
14.2 O B_MEASURE
+/- O O
11.4 O B_MEASURE
mU/L O I_MEASURE
( O O
P O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
0.01 O I_MEASURE/I_LOCATION
) O O
and O O
remained O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
throughout O O
4 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O O

Requirement O O
for O O
p56 B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
LCK I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
ZAP-70 I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
tyrosine I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
kinases I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Nevertheless O O
, O O
innate O O
immunity O O
is O O
preserved O O
in O O
XHM-ED O O
patients O O
because O O
APCs O O
retain O O
the O O
capacity O O
to O O
respond O O
to O O
stimulation O O
by O O
lipopolysaccharide O O
or O O
Staphylococcus B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
aureus I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
Cowan I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
's I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
antigen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
( O O
SAC B B_MEASURE/B_DISEASE
) O O
. O O

However O O
, O O
ATRA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
metabolism O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
appears O O
to O O
be O O
involved O O
in O O
the O O
growth O B_DISEASE/B_ORGANISM_FUNCTION
inhibition O I_DISEASE/I_ORGANISM_FUNCTION
of O O
several O B_DISEASE
cancer O I_DISEASE
cell O I_DISEASE
lines O I_DISEASE
in O O
vitro O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O O
that O O
the O O
principal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ATRA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Phase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolites O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
elicit O O
leukemia O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
differentiation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
through O O
the O O
RAR O B_GENE
alpha O I_GENE
signaling O O
pathway O B_LOCATION/B_ORGANIZATION
, O O
and O O
they O O
suggest O O
that O O
these O O
metabolites O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O O
play O O
a O O
role O B_TIME[MEASURE]/B_PERSON
in O O
ATRA O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antileukemic O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

METHODS O O
: O O
Expression O O
of O O
oestrogen B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
ER B B_LOCATION/B_ORGANIZATION
) O O
and O O
progesterone B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PR B B_LOCATION/B_ORGANIZATION
) O O
was O O
examined O O
using O O
immunohistochemistry O O
in O O
formalin O O
fixed O O
nasal O O
polyp O O
tissues O O
from O O
47 O O
subjects O O
. O O

The O O
cells O O
positive O O
for O O
ER B B_LOCATION
or O O
PR B B_LOCATION
were O O
confirmed O O
by O O
spatial O O
location O O
, O O
dual O O
immunolabelling O O
, O O
and O O
histochemical O O
staining O O
. O O

RESULTS O O
: O O
Consistent O O
with O O
the O O
known O O
features O O
of O O
nasal O O
polyps O O
, O O
CD4+ O O
( O O
T O O
helper/inducer O O
) O O
, O O
CD8+ O O
( O O
cytotoxic/suppressor O O
) O O
, O O
CD68+ O O
( O O
macrophages O O
) O O
, O O
mast O O
cells O O
, O O
eosinophils O O
and O O
neutrophils O O
were O O
all O O
clearly O O
detected O O
by O O
their O O
relevant O O
monoclonal B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
appropriate O O
histochemical O O
staining O O
, O O
but O O
only O O
mast O O
cells O O
tested O O
positive O O
for O O
ER B B_LOCATION
/PR O O
labelling O O
with O O
their O O
polyclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
monoclonal I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
antibodies I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
frequencies O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
expression O B_DISEASE/B_GENE
were O O
61.7 O B_MEASURE
% O I_MEASURE
for O O
ER O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
positive O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
59.6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
for O O
PR O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
positive O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cells O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

The O O
expression O O
of O O
ER B B_PROTEIN[GENE]/B_LOCATION
/ O O
PR B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
independent O O
of O O
patient O O
sex O O
and O O
age O O
but O O
was O O
highly O O
correlated O O
with O O
the O O
numbers O O
of O O
mast O O
cells O O
( O O
r O O
= O O
0.973 O O
, O O
p O O
< O O
0.001 O O
for O O
ER B B_PROTEIN[GENE]/B_LOCATION
; O O
r O O
= O O
0.955 O O
, O O
p O O
< O O
0.001 O O
for O O
PR B B_LOCATION
) O O
. O O

Fewer O O
than O O
5 O O
% O O
of O O
mast O O
cells O O
were O O
found O O
to O O
be O O
negative O O
for O O
ER B B_LOCATION
/ O O
PR B B_LOCATION
expression O O
. O O

CONCLUSIONS O O
: O O
Mast O O
cells O O
alone O O
, O O
but O O
not O O
lymphocytes O O
, O O
macrophages O O
, O O
or O O
other O O
immune O O
cells O O
, O O
express O O
ER B B_LOCATION
/ O O
PR B B_LOCATION
in O O
human O O
upper O O
airways O O
. O O

NF O B_GENE
kappa O I_GENE
b O O
signaling O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
posthypoxic O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
endothelial O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
: O O
relevance O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
E-selectin O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
neutrophil O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
adhesion O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

In O O
the O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
we O O
found O O
that O O
DMA-2 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
4-D O B_NUMBER[MEASURE]/B_LOCATION
is O O
able O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
cause O O
apoptosis O B_DISEASE
in O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
healthy O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
individuals O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O O
Jurkat O B_PERSON/B_DISEASE
T O I_PERSON/I_DISEASE
cells O I_PERSON/I_DISEASE
. O O

Our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
DMA-2 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
4-D O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kills O O
human O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocytes O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
initiating O O
apoptosis O B_DISEASE
via O O
a O O
direct O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effect O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O O
mitochondria O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

Inhibition O O
of O O
Th1 O O
differentiation O O
by O O
IL-6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
mediated O O
by O O
SOCS1 B B_GENE
. O O

While O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
-directed O O
CD4 B B_GENE/B_DISEASE
+ O O
Th2 O O
differentiation O O
is O O
mediated O O
by O O
IL-4 B B_GENE
, O O
inhibition O O
of O O
Th1 O O
differentiation O O
by O O
IL-6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
independent O O
of O O
IL-4 B B_GENE
. O O

IL-6 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
upregulates O O
suppressor B B_GENE
of I I_GENE
cytokine I I_GENE
signaling I I_GENE
1 I I_GENE
( O O
SOCS1 B B_GENE/B_LOCATION
) O O
expression O O
in O O
activated O O
CD4+ O O
T O O
cells O O
, O O
thereby O O
interfering O O
with O O
signal B B_GENE
transducer I I_GENE
and I I_GENE
activator I I_GENE
of I I_GENE
transcription I I_GENE
1 I I_GENE
( O O
STAT1 B B_GENE
) O O
phosphorylation O O
induced O O
by O O
interferon B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gamma I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
IFNgamma B B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

Inhibition O O
of O O
IFNgamma B B_GENE/B_LOCATION
receptor-mediated O O
signals O O
by O O
IL-6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prevents O O
autoregulation O O
of O O
IFNgamma B B_GENE
gene I I_GENE
expression O O
by O O
IFNgamma B B_GENE
during O O
CD4+ O O
T O O
cell O O
activation O O
, O O
thereby O O
preventing O O
Th1 O O
differentiation O O
. O O

Electrophoretic O O
mobility O O
shift O O
analyses O O
indicated O O
that O O
selected O O
ATF/CREB B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
site I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
variants I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
assisted O O
in O O
the O O
recruitment O O
of O O
C/EBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
an O O
adjacent O O
, O O
naturally O O
occurring O O
, O O
low-affinity O O
C/EBP B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Most O O
importantly O O
, O O
sequence O O
variation O O
at O O
the O O
ATF/CREB B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
affected O O
basal O O
LTR B B_GENE/B_DISEASE
activity O O
as O O
well O O
as O O
LTR B B_GENE/B_DISEASE
function O O
following O O
interleukin-6 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stimulation O O
, O O
a O O
treatment O O
that O O
leads O O
to O O
increases O O
in O O
C/EBP O O
activation O O
. O O

Selective O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
inhibition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
interleukin-4 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
aspirin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicated O O
that O O
aspirin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
acetylsalicylic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
acid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
ASA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
] O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O O
can O O
have O O
profound O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
immunomodulatory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
by O O
regulating O O
cytokine O B_GENE
gene O I_GENE
expression O I_GENE
in O O
several O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
types O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
cells O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

OBJECTIVE O O
: O O
To O O
examine O O
the O O
molecular O O
and O O
cellular O O
mechanisms O O
in O O
a O O
model O O
of O O
acute O O
inflammatory O O
monarticular O O
arthritis O O
induced O O
by O O
methylated B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bovine I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
serum I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
albumin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
mBSA B B_LOCATION/B_ORGANIZATION
) O O
and O O
interleukin-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
IL-1 B B_GENE
) O O
. O O

METHODS O O
: O O
Mice O O
were O O
injected O O
intraarticularly O O
with O O
mBSA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
day O O
0 O O
and O O
subcutaneously O O
with O O
recombinant B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
human I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
IL-1beta I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
days O O
0-2 O O
. O O

RESULTS O O
: O O
C57BL/6 O O
( O O
B6 O O
) O O
, O O
129/Sv O O
, O O
and O O
( O O
B6 O O
x O O
129/ O O
Sv O O
) O O
F1 O O
hybrid O O
mice O O
, O O
all O O
H-2b O O
strains O O
, O O
were O O
susceptible O O
to O O
mBSA B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/IL-1-induced O O
arthritis O O
, O O
whereas O O
C3H/HeJ O O
( O O
H-2k O O
) O O
mice O O
were O O
not O O
. O O

B6 O O
mice O O
lacking O O
T O O
and O O
B O O
cells O O
( O O
RAG1-/- O O
) O O
or O O
major B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
histocompatibility I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
complex I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
MHC I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
class I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
II I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
antigens I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
MHCII-/- O O
) O O
, O O
and O O
B6 O O
mice O O
treated O O
with O O
a O O
CD4+ B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
T I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
cell-depleting I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
monoclonal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
were O O
resistant O O
to O O
disease O O
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
B O B_GENE/B_PERSON
cell-deficient O I_GENE/I_PERSON
( O O
muMT/ O B_PROTEIN[GENE]/B_LOCATION
muMT O I_PROTEIN[GENE]/I_LOCATION
) O O
mice O B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developed O O
arthritis O B_DISEASE
at O O
an O O
incidence O B_MEASURE/B_LOCATION
and O O
severity O B_MEASURE/B_PERSON
similar O I_MEASURE/I_PERSON
to O O
that O O
of O O
controls O B_DISEASE/B_PERSON
. O O

RelB-deficient O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
RelB-/- O O
) O O
bone O B_SPECIES[BIO]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
marrow O I_SPECIES[BIO]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chimeric O I_SPECIES[BIO]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mice O I_SPECIES[BIO]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
had O O
arthritis O B_DISEASE
that O O
was O O
significantly O O
reduced O O
in O O
incidence O B_MEASURE
and O O
severity O B_MEASURE
. O O

CONCLUSION O O
: O O
Arthritis O O
induced O O
by O O
mBSA B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
IL-1 B B_LOCATION/B_PERSON
is O O
strain O O
specific O O
and O O
dependent O O
on O O
CD4+ O O
T O O
lymphocytes O O
and O O
at O O
least O O
partially O O
on O O
RelB B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
on O O
B O O
lymphocytes O O
or O O
antibody B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
human O O
T O O
cells O O
CBFalpha2 B B_GENE
is O O
usually O O
transcribed O O
from O O
a O O
different B B_MEASURE/B_BIO
promoter I I_MEASURE/I_BIO
( O O
distal B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
promoter I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
than O O
in O O
myeloid O O
cells O O
( O O
proximal B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
promoter I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
, O O
but O O
the O O
developmental O O
and O O
functional O O
significance O O
of O O
this O O
promoter O O
switch O O
has O O
not O O
been O O
known O O
. O O

Here O O
, O O
we O O
report O O
that O O
both O O
coding B B_LOCATION/B_PERSON
and I I_LOCATION/I_PERSON
noncoding I I_LOCATION/I_PERSON
sequences I I_LOCATION/I_PERSON
of O O
the O O
distal B B_GENE
5 I I_GENE
' I I_GENE
end I I_GENE
are O O
highly O O
conserved O O
between O O
the O O
human B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
murine I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genes I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
distal B B_GENE
promoter I I_GENE
is O O
responsible O O
for O O
the O O
overwhelming O O
majority O O
of O O
CBFalpha2 O O
expression O O
in O O
murine O O
hematopoietic O O
stem O O
cells O O
as O O
well O O
as O O
in O O
T O O
cells O O
. O O

Distal O B_GENE
promoter O I_GENE
activity O I_GENE
is O O
maintained O O
throughout O O
T O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
development O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
and O O
at O O
lower O B_MEASURE/B_LOCATION
levels O I_MEASURE/I_LOCATION
in O O
B O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
development O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
but O O
downregulated O O
in O O
natural O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
killer O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
development O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Constitutive O B_GENE
PI3-K O I_GENE
activity O I_GENE
is O O
essential O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
proliferation O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
but O O
not O O
survival O B_DISEASE_ADJECTIVE[DISEASE]
, O O
of O O
Theileria O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
parva-transformed O O
B O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Here O O
, O O
we O O
show O O
that O O
infected O O
B O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
display O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constitutive O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
phosphoinositide O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3-kinase O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PI3-K O B_GENE
) O O
activity O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
, O O
which O O
appears O O
to O O
be O O
necessary O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
proliferation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
but O O
not O O
survival O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Importantly O O
, O O
we O O
demonstrate O O
that O O
one O O
mechanism O O
by O O
which O O
PI3-K B B_GENE/B_VIRUS[BIO]
mediates O O
the O O
proliferation O O
of O O
infected O O
B O O
lymphocytes O O
is O O
through O O
the O O
induction O O
of O O
a O O
granulocyte-monocyte B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
colony-stimulating I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
GM-CSF B B_LOCATION/B_PERSON
) O O
-dependent O O
autocrine O O
loop O O
. O O

PI3-K B B_PERSON
induction O O
of O O
GM-CSF B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
appears O O
to O O
be O O
at O O
the O O
transcriptional O O
level O O
and O O
, O O
consistently O O
, O O
we O O
demonstrate O O
that O O
PI3-K B B_GENE
is O O
also O O
involved O O
in O O
the O O
constitutive O O
induction O O
of O O
AP-1 B B_GENE
and O O
NF-kappaB B B_GENE
, O O
which O O
characterizes O O
Theileria-infected O O
leucocytes O O
. O O

sIg B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-induced O O
STAT3 O O
activation O O
was O O
completely O O
inhibited O O
by O O
combining O O
IL-6- B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
IL-10-specific I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
neutralizing I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
or O O
by O O
adding O O
individual O O
neutralizing B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
B O O
cells O O
obtained O O
from O O
lymphokine-deficient O O
animals O O
. O O

Transcription B B_GENE
factor I I_GENE
AP-4 I I_GENE
is O O
a O O
ligand B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
immunoglobulin-kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E-box I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Immunoglobulin B B_GENE/B_BIO
( I I_GENE/I_BIO
Ig I I_GENE/I_BIO
) I I_GENE/I_BIO
-kappa I I_GENE/I_BIO
promoters I I_GENE/I_BIO
from O O
humans O O
and O O
mice O O
share O O
conserved B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequences I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
octamer B B_LOCATION/B_MEASURE
element I I_LOCATION/I_MEASURE
is O O
common O O
to O O
all O O
Ig B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoters I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
pivotal O O
for O O
their O O
function O O
. O O

These O O
conserved O O
motifs O O
do O O
not O O
stimulate O O
transcription O O
in O O
the O O
absence O O
of O O
an O O
octamer B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

Based O O
on O O
these O O
data O O
, O O
and O O
the O O
conservation O O
of O O
the O O
5'-CAGCTG-3 B B_GENE/B_MEASURE
' I I_GENE/I_MEASURE
motif I I_GENE/I_MEASURE
among O O
human B B_GENE/B_PERSON
and I I_GENE/I_PERSON
murine I I_GENE/I_PERSON
kappa I I_GENE/I_PERSON
promoters I I_GENE/I_PERSON
, O O
we O O
propose O O
that O O
AP-4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
major B B_PERSON/B_LOCATION
ligand I I_PERSON/I_LOCATION
for O O
Ig-kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
E-boxes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
16-mer O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
RQIKIWFQNRRMKWKK O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
from O O
antennapedia O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
preferentially O O
targets O O
the O O
Class O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
I O O
pathway O O
. O O

Translocation O O
of O O
antigenic O O
peptides O O
into O O
the O O
cytosol O O
of O O
antigen O O
presenting O O
cells O O
facilitates O O
proteosomal O O
processing O O
and O O
loading O O
into O O
Class B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
I I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
MHC O O
presentation O O
on O O
the O O
cell O O
surface O O
. O O

We O O
now O O
demonstrate O O
that O O
a O O
16 O B_PROTEIN[GENE]
amino O I_PROTEIN[GENE]
acid O I_PROTEIN[GENE]
peptide O I_PROTEIN[GENE]
from O O
antennapedia O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
can O O
facilitate O O
the O O
cytoplasmic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
uptake O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O O
CTL O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
epitope O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
9-mer O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
peptides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
ability O O
of O O
the O O
hybrid O O
peptide O O
to O O
be O O
processed O O
and O O
presented O O
by O O
APCs O O
was O O
similar O O
, O O
whether O O
the O O
SIINFEKL O O
sequence O O
was O O
appended O O
at O O
the O O
C-terminus B B_LOCATION/B_MEASURE
or O O
N-terminus B B_LOCATION
of O O
the O O
Antennapedia O O
peptide O O
. O O

The O O
production O B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
synthetic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O O
other O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
CTL O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
peptide O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
epitopes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
useful O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
priming O O
CTLs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
vitro O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]

Inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
was O O
even O O
observed O O
by O O
preparing O O
EBV-CTL O B_DISEASE/B_MEASURE
generating O O
cultures O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
trans-wells O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O O
separated O O
the O O
autologous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
BMC O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
the O O
PBL O B_GENE
+ O O
EBV-B O B_DISEASE/B_LOCATION
. O O

These O O
results O O
show O O
that O O
the O O
BMC O O
inhibition O O
is O O
mediated O O
by O O
soluble B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
cytokines B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
that O O
cell-cell O O
contact O O
in O O
this O O
autologous O O
system O O
is O O
not O O
required O O
, O O
so O O
that O O
BMC O O
( O O
at O O
least O O
partially O O
, O O
via O O
cytokine O O
production O O
) O O
promote O O
TH2 O O
polarization O O
in O O
culture O O
. O O

Moreover O O
, O O
TH2 O O
cells O O
induced O O
by O O
culturing O O
with O O
autologous O O
BMC O O
directly O O
inhibit O O
EBV-CTL O O
generation O O
, O O
and O O
TH2 B B_LOCATION/B_PERSON
associated O O
PKA B B_GENE
, O O
CCR3 B B_GENE/B_LOCATION
, O O
and O O
STAT-6 B B_GENE
phosphorylation O O
are O O
enhanced O O
by O O
BMC O O
. O O

In O O
contrast O O
, O O
a O O
significant O O
reduction O O
in O O
the O O
DNA O O
binding O O
activity O O
of O O
Pax-5a B B_GENE
but O O
not O O
Pax-5d B B_GENE
protein O O
was O O
observed O O
in O O
aged O O
B O O
cells O O
in O O
vitro O O
, O O
while O O
Western O O
blot O O
analyses O O
showed O O
that O O
similar O O
levels O O
of O O
Pax-5a B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5d I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins O O
were O O
present O O
in O O
both O O
age O O
groups O O
. O O

NF-kappa B B_PERSON/B_LOCATION
B/Rel I I_PERSON/I_LOCATION
participation O O
in O O
the O O
lymphokine-dependent O O
proliferation O O
of O O
T O O
lymphoid O O
cells O O
. O O

Proliferative O O
responses O O
of O O
lymphoid O O
cells O O
to O O
IL-2 B B_GENE
and O O
IL-4 B B_GENE
depend O O
on O O
activation O O
of O O
the O O
cells O O
, O O
but O O
the O O
mechanism O O
( O O
s O O
) O O
by O O
which O O
activation O O
enhances O O
cellular O O
competence O O
to O O
respond O O
to O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
not O O
fully O O
understood O O
. O O

These O O
results O O
indicate O O
that O O
the O O
NF-kappaB/Rel/IkappaBalpha O O
system O O
can O O
regulate O O
cytokine B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
receptor I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
capacitation O O
through O O
effects O O
on O O
the O O
induction O O
of O O
downstream O O
signaling O O
by O O
the O O
Stat B B_GENE
transcription I I_GENE
factor I I_GENE
family I I_GENE
. O O

Here O O
we O O
find O O
that O O
Egr2 B B_GENE
and O O
Egr3 B B_GENE
are O O
NFAT B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
target I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
genes I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Specific O O
nongenomic O O
effects O O
occur O O
within O O
a O O
few O O
minutes O O
and O O
are O O
mediated O O
by O O
steroid-selective B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
membrane I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Up-regulation O O
of O O
ICAM-1 B B_GENE
protein O O
and O O
mRNA O O
was O O
also O O
found O O
in O O
IL-1-beta B B_DISEASE_ADJECTIVE[DISEASE]
and O O
TNF-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
-stimulated O O
mesangial O O
cells O O
. O O

Functional O O
blocking O O
of O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
on O O
mesangial O O
cells O O
with O O
rat B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
intercellular I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
adhesion I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
molecule-1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
monoclonal I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
calphostin O O
C O O
, O O
staurosporine O O
, O O
or O O
N-tosyl-L-phenylalanine O O
chloromethyl O O
ketone O O
significantly O O
inhibited O O
high O O
glucose- O O
or O O
high O O
mannitol-induced O O
increase O O
in O O
leukocyte O O
adhesion O O
( O O
p O O
< O O
< O O
0.05 O O
) O O
. O O

Combined O O
corticosteroid/ O O
granulocyte B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
colony-stimulating I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
factor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
G-CSF B B_LOCATION/B_GENE
) O O
therapy O O
in O O
the O O
treatment O O
of O O
severe O O
congenital O O
neutropenia O O
unresponsive O O
to O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
Activated O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synergize O O
with O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
signals O O
. O O

More O O
than O O
90 O O
% O O
of O O
patients O O
with O O
severe O O
congenital O O
neutropenia O O
( O O
SCN O O
) O O
respond O O
to O O
granulocyte B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
G-CSF B B_LOCATION/B_ORGANIZATION
) O O
therapy O O
. O O

To O O
address O O
this O O
issue O O
, O O
we O O
studied O O
a O O
child O O
with O O
SCN O O
who O O
was O O
totally O O
unresponsive O O
to O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
had O O
a O O
novel O O
point O O
mutation O O
in O O
the O O
extracellular B B_GENE
domain I I_GENE
of O O
the O O
G-CSF B B_GENE
receptor I I_GENE
( O O
GCSF-R B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Marrow O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
stromal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
support O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
granulopoiesis O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
evaluated O O
by O O
plating O O
CD34 O B_GENE
( O O
+ O B_OTHER/B_DISEASE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
on O O
preformed O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stromal O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
layers O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Patient O B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
's O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stroma O I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supported O O
granulopoiesis O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
derived O O
from O O
control O B_GENE
marrow O I_GENE
CD34 O I_GENE
( O O
+ O B_OTHER/B_DISEASE
) O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
a O O
normal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
manner O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O O

Normal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
stroma O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
however O O
, O O
failed O O
to O O
induce O O
granulopoiesis O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
patient O B_GENE
's O I_GENE
CD34 O I_GENE
( O O
+ O B_OTHER/B_DISEASE
) O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Clonogenic O O
assays O O
of O O
the O O
patient O O
's O O
marrow O O
mononuclear O O
cells O O
incorporating O O
either O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
hydrocortisone O O
produced O O
little O O
neutrophil O O
growth O O
. O O

In O O
contrast O O
, O O
inclusion O O
of O O
both O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
hydrocortisone O O
in O O
the O O
cytokine B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
`` I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocktail I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
'' I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markedly O O
increased O O
the O O
neutrophil O O
numbers O O
. O O

Proliferation O O
of O O
32D O O
cells O O
expressing O O
the O O
mutated B B_GENE
receptor I I_GENE
and O O
STAT5 O O
activation O O
were O O
improved O O
by O O
a O O
combination O O
of O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dexamethasone O O
. O O

When O O
small O O
daily O O
doses O O
of O O
oral O O
prednisone O O
were O O
then O O
administered O O
to O O
the O O
patient O O
with O O
conventional O O
doses O O
of O O
subcutaneous B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G-CSF I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
patient O O
responded O O
with O O
increased O O
neutrophil O O
numbers O O
and O O
with O O
a O O
complete O O
reversal O O
of O O
the O O
infectious O O
problems O O
. O O

These O O
data O O
provide O O
insight O O
into O O
SCN O O
unresponsive O O
to O O
standard O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O O
and O O
to O O
the O O
potential O O
corrective O O
action O O
of O O
combined O O
treatment O O
with O O
G-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
corticosteroids O O
through O O
synergistic O O
activation O O
of O O
STAT5 B B_GENE
. O O

We O O
have O O
studied O O
in O O
cultured O O
human O O
mesangial O O
cells O O
( O O
CHMC O O
) O O
several O O
effects O O
of O O
9-cis O O
retinoic O O
acid O O
( O O
9-cRA O O
) O O
, O O
an O O
activator O O
of O O
both O O
retinoic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
RARs B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
retinoid B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
RXRs B B_LOCATION/B_ORGANIZATION
) O O
. O O

It O O
also O O
prevented O O
CHMC O B_DISEASE/B_GENE
death O I_DISEASE/I_GENE
induced O O
by O O
the O O
inflammatory O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
mediator O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
H O I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
( O O
2 O B_NUMBER[MEASURE]/B_LOCATION
) O O
O O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O B_NUMBER[MEASURE]/B_LOCATION
) O O
. O O

This O O
preventive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
not O O
due O O
to O O
any O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
H O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
2 O B_MEASURE/B_LOCATION
) O O
O O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O B_NUMBER[MEASURE]/B_LOCATION
) O O
catabolism O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
it O O
persisted O O
even O O
when O O
both O O
catalase O B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
glutathione O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
synthesis O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
inhibited O O
. O O

Finally O O
, O O
9-cRA O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diminished O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monocyte O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adhesion O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
FCS-stimulated O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
CHMC O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Modulation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
oxidant/antioxidant O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
balance O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
failed O O
to O O
inhibit O O
apoptosis O B_DISEASE
. O O

We O O
conclude O O
that O O
mesangial O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
might O O
be O O
a O O
target O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
for O O
the O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
inflammatory O B_DISEASE
glomerulopathies O I_DISEASE
with O O
9-cRA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

In O O
mammals O O
, O O
defensins B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
are O O
among O O
the O O
most O O
abundant O O
of O O
these O O
broad-spectrum O O
antibiotics O O
, O O
and O O
are O O
expressed O O
in O O
epithelial O O
and O O
hematopoietic O O
cells O O
. O O

The O O
defensin O B_GENE/B_BIO
peptides O I_GENE/I_BIO
are O O
especially O O
abundant O B_DISEASE_ADJECTIVE[DISEASE]
in O O
neutrophils O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
; O O
however O O
, O O
gene O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
limited O O
to O O
the O O
promyelocyte O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
stage O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
had O O
previously O O
shown O O
that O O
activation O O
of O O
the O O
arylhydrocarbon B B_GENE/B_PERSON
receptor I I_GENE/I_PERSON
( O O
AHR B B_LOCATION/B_ORGANIZATION
) O O
, O O
a O O
member O O
of O O
the O O
bHLH-PAS B B_GENE/B_MEASURE
family I I_GENE/I_MEASURE
of I I_GENE/I_MEASURE
transcription I I_GENE/I_MEASURE
factors I I_GENE/I_MEASURE
, O O
leads O O
to O O
increased O O
mRNA O O
expression O O
of O O
IL-2 B B_GENE
in O O
murine O O
fetal O O
thymocytes O O
. O O

Binding O O
motifs O O
for O O
the O O
liganded B B_GENE/B_BACTERIUM[BIO]
AHR I I_GENE/I_BACTERIUM[BIO]
can O O
be O O
identified O O
in O O
the O O
distal B B_LOCATION/B_BIO
region I I_LOCATION/I_BIO
-1300 I I_LOCATION/I_BIO
to I I_LOCATION/I_BIO
-800 I I_LOCATION/I_BIO
of O O
the O O
mouse B B_GENE/B_LOCATION
IL-2 I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
. O O

Thus O O
, O O
the O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
contains O O
novel O O
distal B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
regulatory I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
elements I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
that O O
can O O
be O O
addressed O O
by O O
the O O
AHR B B_DISEASE/B_GENE
to O O
induce O O
IL-2 B B_GENE/B_DISEASE
and O O
can O O
cooperate O O
with O O
the O O
proximal B B_GENE/B_LOCATION
promoter I I_GENE/I_LOCATION

Visualization O O
of O O
Syk-antigen B B_GENE/B_BIO
receptor I I_GENE/I_BIO
interactions O O
using O O
green B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fluorescent I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
differential O O
roles O O
for O O
Syk B B_GENE/B_PERSON
and O O
Lyn B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
regulation O O
of O O
receptor O O
capping O O
and O O
internalization O O
. O O

The O O
cross-linking O O
of O O
the O O
B B B_GENE
cell I I_GENE
Ag I I_GENE
receptor I I_GENE
( O O
BCR B B_LOCATION/B_ORGANIZATION
) O O
is O O
coupled O O
to O O
the O O
stimulation O O
of O O
multiple O O
intracellular O O
signal O O
transduction O O
cascades O O
via O O
receptor-associated O O
, O O
protein B B_GENE/B_BIO
tyrosine I I_GENE/I_BIO
kinases I I_GENE/I_BIO
of O O
both O O
the O O
Src B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
Syk I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
families I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

Treatment O O
of O O
these O O
cells O O
with O O
anti-IgM B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Abs I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
leads O O
to O O
the O O
recruitment O O
of O O
the O O
kinase B B_GENE
from O O
cytoplasmic O O
and O O
nuclear O O
compartments O O
to O O
the O O
site O O
of O O
the O O
cross-linked B B_GENE
receptor I I_GENE
at O O
the O O
plasma O O
membrane O O
. O O

The O O
Syk-receptor B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
aggregate O O
into O O
membrane O O
patches O O
that O O
redistribute O O
to O O
form O O
a O O
cap O O
at O O
one O O
pole O O
of O O
the O O
cell O O
. O O

Catalytically O O
active O O
Syk B B_GENE/B_BACTERIUM[BIO]
promotes O O
and O O
stabilizes O O
the O O
formation O O
of O O
tightly B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
capped I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
BCR I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
at O O
the O O
plasma O O
membrane O O
. O O

In O O
the O O
absence O O
of O O
Lyn B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
receptor-Syk B B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
complexes I B_GENE/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
at O O
the O O
plasma O O
membrane O O
are O O
long O O
lived O O
, O O
and O O
the O O
receptor-mediated O O
activation O O
of O O
the O O
NF-AT B B_GENE
transcription I I_GENE
factor I I_GENE
is O O
enhanced O O
. O O

HLA-DQ B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
tetramers I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
identify O O
epitope-specific O O
T O O
cells O O
in O O
peripheral O O
blood O O
of O O
herpes O O
simplex O O
virus O O
type O O
2-infected O O
individuals O O
: O O
direct O O
detection O O
of O O
immunodominant O O
antigen-responsive O O
cells O O
. O O

MHC B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tetramers I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
which O O
constitute O O
a O O
labeled B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
MHC-peptide I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
ligand I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
suitable O O
for O O
binding O O
to O O
the O O
Ag-specific B B_GENE
receptor I I_GENE
on O O
T O O
cells O O
, O O
provide O O
a O O
novel O O
approach O O
for O O
the O O
detection O O
and O O
characterization O O
of O O
such O O
rare O O
cells O O
. O O

Peptides O O
representing O O
potential O O
epitope B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regions I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
VP16 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
from O O
HSV-2 O O
were O O
loaded O O
onto O O
recombinant B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DQ0602 I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecules I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
generate O O
a O O
panel O O
of O O
Ag-specific B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DQ0602 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tetramers I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

VP16 B B_VIRUS[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
Ag I I_VIRUS[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
-specific O O
DQ-restricted O O
T O O
cells O O
were O O
identified O O
and O O
expanded O O
from O O
the O O
peripheral O O
blood O O
of O O
HSV-2-infected O O
individuals O O
, O O
representing O O
two O O
predominant O O
epitope O O
specificities O O
. O O

Immunoglobulin O B_GENE/B_DISEASE
expression O B_GENE/I_DISEASE
was O O
lacking O O
in O O
cHD O B_DISEASE
but O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
LPHD O B_DISEASE
. O O

Paraffin-embedded O O
tissues O O
from O O
23 O O
cutaneous O O
lesions O O
and O O
a O O
single O O
lymph O O
node O O
biopsy O O
from O O
patients O O
diagnosed O O
with O O
MF O O
were O O
evaluated O O
for O O
p65 O O
( O O
Rel O O
A O O
) O O
expression O O
by O O
using O O
a O O
monoclonal B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mouse I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antibody I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
detects O O
the O O
activated O O
form O O
of O O
p65 B B_GENE
( I I_GENE
Rel I I_GENE
A I I_GENE
) I I_GENE
. O O

Apoptosis O B_DISEASE/B_GENE
after O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
the O O
NF-kappa O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
B O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gliotoxin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
MG132 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
BAY O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
11-7082 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
and O O
BAY O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
11-7085 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O O
quantitatively O O
measured O O
in O O
the O O
CTCL O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lines O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
HuT-78 O O
and O O
HH O B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
by O O
propidium O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
iodide O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PI O B_PROTEIN[GENE]
) O O
/cell O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycle O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O O
a O O
hypodiploid O B_DISEASE_ADJECTIVE[DISEASE]
( O O
sub-G O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
0 O B_MEASURE/B_LOCATION
) O O
) O O
population O B_PERSON/B_LOCATION
and O O
by O O
determination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
increased O O
Annexin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
V/7-amino-actinomycin O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
7-AAD O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
expression O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Nuclear O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
extracts O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
CTCL O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
before O O
and O O
after O O
chemical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
inhibition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
were O O
analyzed O O
for O O
NF-kappa O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
DNA-binding O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
by O O
electrophoretic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mobility O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
shift O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EMSA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
with O O
quantitative O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
densitometry O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Compared O O
with O O
untreated O B_PERSON/B_BIO
control O I_PERSON/I_BIO
cells O I_PERSON/I_BIO
, O O
a O O
marked O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
apoptosis O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
NF-kappa O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
B O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
DNA-binding O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activity O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
and O O
a O O
marked O O
decrease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
nuclear O B_GENE
p65 O I_GENE
( O O
Rel O B_GENE/B_DISEASE
A O I_GENE/I_DISEASE
) O O
expression O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
seen O O
in O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
from O O
both O O
CTCL O B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
lines O I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
after O O
chemical O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
NF-kappa O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
B O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
inhibition O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Two O O
Tax B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differentially O O
activated O O
expression O O
of O O
these O O
two O O
elements O O
. O O

Tax703 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preferentially O O
activated O O
the O O
kappaB B B_GENE/B_LOCATION
element I I_GENE/I_LOCATION
but O O
not O O
the O O
CRE-like O O
one O O
, O O
whereas O O
TaxM22 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O O
the O O
reverse O O
. O O

Unlike O O
the O O
wild-type B B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Tax I I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Tax703 B B_GENE/B_ORGANIZATION
and O O
TaxM22 B B_GENE/B_MEASURE
only O O
weakly O O
activated O O
the O O
AP-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
T-cell O O
line O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
showed O O
that O O
Tax B B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
strong O O
binding O O
activity O O
to O O
an O O
AP-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
CTLL-2 O O
, O O
whereas O O
Tax703 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
, O O
indicating O O
that O O
the O O
induction O O
of O O
binding O O
activity O O
to O O
the O O
AP-1 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
site I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O O
essential O O
for O O
the O O
transcriptional O O
activation O O
by O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Other O O
AP-1 B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
undetectable O O
. O O

Strict O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
human O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
immunodeficiency O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
virus O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
type O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
replication O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
by O O
a O O
genetic O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
switch O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
: O O
Tet O B_GENE/B_BACTERIUM[BIO]
for O O
Tat O B_GENE
. O O

We O O
therefore O O
designed O O
HIV-1 B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
genomes I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
that O O
replicate O O
exclusively O O
upon O O
addition O O
of O O
the O O
nontoxic O O
effector O O
doxycycline O O
( O O
dox O O
) O O
. O O

Furthermore O O
, O O
such O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
viruses O I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
represent O O
improved O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
vaccine O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
candidates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
because O O
their O O
replication O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
can O O
be O O
turned O O
on O O
and O O
off O O
at O O
will O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Incubation O O
of O O
SF O O
with O O
neutralizing B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antibodies I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
against O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor-alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
TNF-alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
against O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-6 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
significantly O O
reduced O O
the O O
induction O O
of O O
p65/p50 O O
binding O O
activity O O
in O O
SF O O
from O O
subjects O O
with O O
RA O O
and O O
OA O O
. O O

The O O
induction O O
of O O
this O O
complex O O
by O O
SF O O
was O O
not O O
affected O O
by O O
neutralization O O
of O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
SF O O
, O O
and O O
the O O
complex O O
was O O
not O O
inducible O O
by O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
IL-1beta O O
, O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
IL-1beta B B_GENE
, O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
platelet B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
derived I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
growth I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
lipopolysaccharide O O
, O O
or O O
tetradecanoyl O O
phorbol O O
acetate O O
. O O

The O O
slowly O O
migrating B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
complex I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
could O O
not O O
be O O
supershifted O O
with O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
against O O
NF-kappaB B B_GENE
, O O
Jun B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
or O O
the O O
transcriptional O O
coactivators O O
p300 B B_GENE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
CBP B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

A O O
property O O
of O O
SF O O
that O O
is O O
independent O O
of O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
other O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O O
responsible O O
for O O
the O O
induction O O
of O O
a O O
novel O O
slowly O O
migrating O O
NF-kappaB-binding B B_DISEASE/B_GENE
complex I I_DISEASE/I_GENE
. O O

The O O
mechanism O B_LOCATION
by O O
which O O
PPAR-gamma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agonists O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
induce O O
cytotoxicity O B_DISEASE/B_GENE
is O O
via O O
apoptosis O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
shown O O
by O O
annexin O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
V O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
staining O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
as O O
confirmed O O
by O O
DNA O B_DISEASE_ADJECTIVE[DISEASE]
fragmentation O I_DISEASE_ADJECTIVE[DISEASE]
detected O O
using O O
the O O
TUNEL O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
assay O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Interestingly O O
, O O
addition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
PGF O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2alpha O B_PROTEIN[GENE]/B_MEASURE
) O O
, O O
which O O
was O O
not O O
known O O
to O O
affect O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
, O O
dramatically O O
attenuated O O
the O O
deleterious O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
PPAR-gamma O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agonists O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
B O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphomas O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Surprisingly O O
, O O
15d-PGJ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
2 O B_NUMBER[MEASURE]
) O O
induced O O
a O O
massive O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
nuclear O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mitogen-activated O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
protein O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
kinase O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
activation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
and O O
pretreatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
with O O
PGF O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2alpha O B_PROTEIN[GENE]/B_MEASURE
) O O
blunted O O
the O O
mitogen-activated O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
is O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
evaluating O O
PPAR-gamma O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
significance O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
B O B_DISEASE/B_LOCATION
lymphocytes O I_DISEASE/I_LOCATION
. O O

Inhibition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
STAT3 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
signaling O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leads O O
to O O
apoptosis O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
leukemic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
large O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
granular O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
decreased O O
Mcl-1 O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
expression O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
. O O

Large O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
granular O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lymphocyte O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
LGL O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
leukemia O B_DISEASE
is O O
characterized O O
by O O
the O O
expansion O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
antigen-activated O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cytotoxic O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Moreover O O
, O O
using O O
an O O
antisense O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
oligonucleotide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
approach O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
diminish O O
STAT3 O B_GENE/B_DISEASE
expression O I_GENE/I_DISEASE
, O O
we O O
found O O
that O O
Fas O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sensitivity O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
restored O O
in O O
leukemic O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
LGL O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

AG-490-induced O B_DISEASE/B_GENE
apoptosis O I_DISEASE/I_GENE
in O O
leukemic O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
LGL O B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
independent O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
Bcl-xL O B_GENE
or O O
Bcl-2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
we O O
found O O
that O O
the O O
Bcl-2-family B B_DISEASE_ADJECTIVE[DISEASE]
protein I I_DISEASE_ADJECTIVE[DISEASE]
Mcl-1 I I_DISEASE_ADJECTIVE[DISEASE]
was O O
significantly O O
reduced O O
by O O
AG-490 O O
treatment O O
. O O

To O O
better O O
define O O
the O O
role O O
of O O
ATF-2 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
inflammation O O
, O O
adult O O
mice O O
expressing O O
small O O
amounts O O
of O O
a O O
mutant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
ATF-2 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
challenged O O
with O O
lipopolysaccharide O O
( O O
LPS O O
) O O
, O O
anti-CD3 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_VIRUS[BIO]
antibody I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_VIRUS[BIO]
or O O
virus O O
. O O

Blockade O O
of O O
LIGHT B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
its O O
soluble B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
lymphotoxin B B_GENE/B_LOCATION
beta I I_GENE/I_LOCATION
receptor-Ig I I_GENE/I_LOCATION
or O O
HVEM-Ig B B_GENE
, O O
inhibits O O
the O O
induction O O
of O O
DC O O
-mediated O O
primary O O
allogeneic O O
T O O
cell O O
response O O
. O O

Suppression O O
of O O
HIV O O
type O O
1 O O
replication O O
by O O
a O O
dominant-negative B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Ets-1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mutant I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

BACKGROUND O O
: O O
Eosinophils O O
are O O
now O O
known O O
to O O
produce O O
a O O
variety O O
of O O
proinflammatory B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytokines I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
although O O
the O O
molecular O O
factors O O
that O O
regulate O O
their O O
production O O
are O O
poorly O O
understood O O
. O O

Unlike O O
activated O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
which O O
express O O
multiple O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
NFATc O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
isoforms O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
eosinophils O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
preferentially O O
express O O
the O O
approximately O O
85-kd O B_PROTEIN[GENE]/B_MEASURE
isoform O I_PROTEIN[GENE]/I_MEASURE
. O O

B B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
lymphocyte I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
stimulator I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
BLyS B B_LOCATION/B_DISEASE
) O O
is O O
a O O
novel O O
member O O
of O O
the O O
TNF B B_GENE/B_LOCATION
family I I_GENE/I_LOCATION
of I I_GENE/I_LOCATION
proteins I I_GENE/I_LOCATION
expressed O O
by O O
myeloid O O
cells O O
as O O
membrane-bound O O
and O O
soluble O O
forms O O
. O O

The O O
present O O
study O O
was O O
undertaken O O
to O O
characterize O O
binding O O
of O O
radiolabeled B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
BLyS I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O O
its O O
cognate B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
human O O
B O O
lymphocytes O O
and O O
examine O O
intracellular O O
events O O
initiated O O
by O O
BLyS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
binding O O
. O O

Similar O O
to O O
other O O
TNF B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
family I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
members I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O O
BLyS B B_GENE/B_DISEASE
is O O
present O O
in O O
solution O O
as O O
a O O
homotrimer B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O O
determined O O
by O O
gel O O
filtration O O
chromatography O O
and O O
light O O
scattering O O
analysis O O
. O O

BLyS B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
binding O O
to O O
B O O
cells O O
is O O
specific O O
as O O
other O O
TNF B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
family I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
members I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tested O O
did O O
not O O
compete O O
for O O
( O O
125 O O
) O O
I- O O
BLyS B B_GENE/B_DISEASE
binding O O
. O O

Scatchard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
binding O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
revealed O O
a O O
single O B_MEASURE/B_LOCATION
class O I_MEASURE/I_LOCATION
of O O
high-affinity O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
binding O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
on O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
B O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O O
approximately O O
2600 O B_NUMBER[MEASURE]
binding O O
sites O B_LOCATION/B_ENT
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
and O O
an O O
apparent O B_MEASURE/B_LOCATION
dissociation O I_MEASURE/I_LOCATION
constant O I_MEASURE/I_LOCATION
( O O
K O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
D O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
) O O
of O O
about O O
0.1 O B_MEASURE
nM O I_MEASURE
. O O

This O O
has O O
been O O
attributed O O
to O O
effects O O
of O O
Nef B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
on O O
cell O O
proliferation O O
and O O
apoptosis O O
. O O

Using O O
this O O
inducible O O
Nef B B_BACTERIUM[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
we O O
also O O
compared O O
the O O
specific O O
requirements O O
for O O
CD4 B B_GENE
and O O
HLA-A2 B B_GENE
downmodulation O O
in O O
a O O
SupT1 O O
T-cell O O
line O O
. O O

In O O
contrast O O
, O O
50 O O
% O O
downmodulation O O
of O O
HLA-A2 B B_GENE
by O O
Nef B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
required O O
16 O O
to O O
24 O O
h O O
and O O
about O O
50- O O
to O O
100-fold-greater O O
concentrations O O
of O O
4-HT O O
. O O

These O O
data O O
suggest O O
that O O
HLA-A2 B B_GENE
downmodulation O O
may O O
require O O
certain O O
threshold O O
levels O O
of O O
active O O
Nef B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O O

Regulation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
chemokine O B_GENE
mRNA O I_GENE
expression O I_GENE
in O O
a O O
rat O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
vanadium-induced O B_DISEASE
pulmonary O I_DISEASE
inflammation O I_DISEASE
. O O

Significant O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
polymorphonuclear O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
leukocyte O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PMN O B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O O
influx O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
P O B_PROTEIN[GENE]/B_LOCATION
< O O
0.01 O B_MEASURE
) O O
into O O
the O O
lung O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
was O O
noted O O
4 O B_MEASURE/B_LOCATION
h O O
after O O
NaVO3 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
instillation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O O
whereas O O
alveolar O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AMs O B_LOCATION/B_ORGANIZATION
) O O
in O O
bronchoalveolar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
lavage O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
BAL O B_LOCATION
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
appeared O O
to O O
decrease O O
significantly O O
. O O

The O O
facts O O
that O O
PMN O O
influx O O
was O O
preceded O O
by O O
increased O O
MIP-2 O O
mRNA O O
expression O O
, O O
suggesting O O
that O O
MIP-2 B B_LOCATION/B_ORGANIZATION
is O O
involved O O
in O O
the O O
development O O
of O O
NaVO3-induced O O
pulmonary O O
inflammation O O
, O O
whereas O O
increased O O
MIP-1alpha B B_GENE/B_LOCATION
mRNA I I_GENE/I_LOCATION
expression O O
was O O
followed O O
by O O
decreased O O
AMs O O
in O O
BAL O O
cells O O
, O O
suggesting O O
AMs O O
might O O
be O O
activated O O
by O O
MIP-1alpha B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
adherent O O
to O O
the O O
lining O O
surface O O
of O O
the O O
airways O O
and O O
then O O
resistant O O
to O O
be O O
washed O O
out O O
. O O

Activation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
signal O B_GENE
transduction O I_GENE
and O O
apoptosis O B_DISEASE/B_GENE
in O O
healthy O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lymphomonocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
exposed O O
to O O
bystander O O
HIV-1-infected O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cells O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Apoptosis O O
induction O O
could O O
be O O
abrogated O O
mainly O O
by O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
tumour B B_GENE
necrosis I I_GENE
factor-alpha I I_GENE
( O O
TNF-alpha B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
and O O
, O O
to O O
a O O
lesser O O
extent O O
, O O
by O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
against O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Among O O
six O O
or O O
so O O
PKC B B_GENE
isoforms I I_GENE
expressed O O
in O O
T O O
cells O O
, O O
only O O
PKCtheta B B_NUMBER[MEASURE]/B_ORGANIZATION
participates O O
in O O
the O O
assembly O O
of O O
the O O
supramolecular O O
activation O O
clusters O O
at O O
the O O
contact O O
site O O
of O O
the O O
TCR B B_GENE
with O O
Ag B B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

IKKs B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
recruited O O
to O O
these O O
lipid O O
rafts O O
were O O
capable O O
of O O
phosphorylating O O
a O O
recombinant O O
IkappaBalpha O O
sustrate O O
. O O

This O O
inhibition O O
of O O
osteoclastogenesis O O
is O O
rescued O O
by O O
overexpressing O O
TRAF6 B B_GENE
in O O
precursor O O
cells O O
, O O
which O O
indicates O O
that O O
TRAF6 B B_GENE
is O O
the O O
target O O
critical O O
for O O
the O O
IFN-gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
action O O
. O O

Our O O
study O O
shows O O
that O O
there O O
is O O
cross-talk O O
between O O
the O O
tumour B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
IFN B B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
families I I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
of O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
through O O
which O O
IFN-gamma B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O O
a O O
negative O O
link O O
between O O
T-cell O O
activation O O
and O O
bone O O
resorption O O
. O O

We O O
propose O O
that O O
alpha3beta1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha6beta4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
heterodimers I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
induced O O
to O O
cluster O O
at O O
the O O
TEC O O
surface O O
recognizing O O
yet O O
unknown O O
cellular B B_BIO/B_LOCATION
ligands I I_BIO/I_LOCATION
differentially O O
expressed O O
during O O
T O O
cell O O
development O O
. O O

This O O
result O O
was O O
confirmed O O
using O O
clones O O
of O O
EL4 O O
cells O O
stably O O
expressing O O
an O O
inducible O O
form O O
of O O
SKAT-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
thus O O
SKAT-2 B B_LOCATION/B_PERSON
is O O
a O O
novel O O
Th2-specific B B_GENE/B_PERSON
gene I I_GENE/I_PERSON
that O O
may O O
play O O
a O O
role O O
in O O
selective O O
regulation O O
of O O
cytokine B B_GENE/B_DISEASE
genes I I_GENE/I_DISEASE
in O O
T O O
cells O O
. O O

Reticulocyte O O
lysate O O
contains O O
a O O
chaperone O O
system O O
that O O
assembles O O
glucocorticoid B B_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DISEASE_ADJECTIVE[DISEASE]
( I I_DISEASE_ADJECTIVE[DISEASE]
GR I I_DISEASE_ADJECTIVE[DISEASE]
) I I_DISEASE_ADJECTIVE[DISEASE]
.hsp90 I I_DISEASE_ADJECTIVE[DISEASE]
heterocomplexes I I_DISEASE_ADJECTIVE[DISEASE]
. O O

Using O O
purified B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
proteins I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
we O O
have O O
prepared O O
a O O
five-protein O O
heterocomplex O O
assembly O O
system O O
consisting O O
of O O
two O O
proteins O O
essential O O
for O O
heterocomplex O O
assembly- O O
hsp90 B B_GENE
and O O
hsp70 B B_GENE
-and O O
three O O
proteins O O
that O O
act O O
as O O
co-chaperones O O
to O O
enhance O O
assembly- O O
Hop B B_DISEASE/B_GENE
, O O
hsp40 B B_GENE
, O O
p23 B B_GENE
[ O O
Morishima O O
, O O
Y. O O
, O O
Kanelakis O O
, O O
K. O O
C. O O
, O O
Silverstein O O
, O O
A. O O
M. O O
, O O
Dittmar O O
, O O
K. O O
D. O O
, O O
Estrada O O
, O O
L. O O
, O O
and O O
Pratt O O
, O O
W. O O
B. O O
( O O
2000 O O
) O O
J. O O
Biol. O O
Chem. O O
275 O O
, O O
6894-6900 O O
] O O
. O O

The O O
hsp70 B B_GENE
co-chaperone I I_GENE
Hip I I_GENE
has O O
been O O
recovered O O
in O O
receptor.hsp90 B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
heterocomplexes I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
at O O
an O O
intermediate O O
stage O O
of O O
assembly O O
in O O
reticulocyte O O
lysate O O
, O O
and O O
Hip B B_DISEASE/B_GENE
is O O
also O O
thought O O
to O O
be O O
an O O
intrinsic O O
component O O
of O O
the O O
assembly O O
machinery O O
. O O

Here O O
we O O
show O O
that O O
immunodepletion O O
of O O
Hip B B_GENE/B_DISEASE
from O O
reticulocyte O O
lysate O O
or O O
addition O O
of O O
high O O
levels O O
of O O
Hip B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
the O O
purified O O
five-protein O O
system O O
does O O
not O O
affect O O
GR.hsp90 O O
heterocomplex O O
assembly O O
or O O
the O O
activation O O
of O O
steroid O O
binding O O
activity O O
that O O
occurs O O
with O O
assembly O O
. O O

Despite O O
the O O
fact O O
that O O
Hip B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
does O O
not O O
affect O O
assembly O O
, O O
it O O
is O O
recovered O O
in O O
GR.hsp90 B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
heterocomplexes I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
assembled O O
by O O
both O O
systems O O
. O O

Tumor O B_PERSON/B_ORGANIZATION
immunologists O I_PERSON/I_ORGANIZATION
have O O
hypothesized O O
that O O
Th1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
critical O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
in O O
tumor O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
immunity O I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O O
they O O
facilitate O O
differentiation O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
CD8 O B_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
which O O
are O O
potent O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti-tumor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effectors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
have O O
used O O
STAT4 O B_GENE
( O O
-/- O O
) O O
and O O
STAT6 O B_GENE
( O O
-/- O O
) O O
mice O B_BIO/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
test O O
this O O
hypothesis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BALB/c O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
knockout O B_SPECIES[BIO]/B_GENE
mice O I_SPECIES[BIO]/I_GENE
were O O
challenged O O
in O O
the O O
mammary O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
gland O I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
with O O
the O O
highly O O
malignant O B_DISEASE_ADJECTIVE[DISEASE]
and O O
spontaneously O O
metastatic O B_DISEASE_ADJECTIVE[DISEASE]
BALB/c-derived O I_DISEASE_ADJECTIVE[DISEASE]
4T1 O I_DISEASE_ADJECTIVE[DISEASE]
mammary O I_DISEASE_ADJECTIVE[DISEASE]
carcinoma O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Primary O B_DISEASE_ADJECTIVE[DISEASE]
tumor O I_DISEASE_ADJECTIVE[DISEASE]
growth O I_DISEASE_ADJECTIVE[DISEASE]
and O O
metastatic O B_DISEASE
disease O I_DISEASE
are O O
reduced O O
in O O
STAT6 O B_GENE
( O O
-/- O B_PERSON/B_PROTEIN[GENE]
) O O
mice O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
relative O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O O
BALB/c O B_GENE/B_PERSON
and O O
STAT4 O B_GENE
( O O
-/- O O
) O O
mice O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Ab O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
depletions O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
demonstrate O O
that O O
the O O
effect O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O O
mediated O O
by O O
CD8 O B_GENE
( O O
+ O B_DISEASE/B_GENE
) O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
and O O
immunized O O
STAT6 O B_GENE
( O O
-/- O O
) O O
mice O B_BIO/B_PERSON
have O O
higher O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
levels O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
4T1-specific O B_DISEASE/B_GENE
CTL O I_DISEASE/I_GENE
than O O
BALB/c O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
STAT4 O B_GENE
( O O
-/- O O
) O O
mice O B_BIO/B_PERSON
. O O

Surprisingly O O
, O O
Th1 O B_GENE/B_LOCATION
or O O
Th2 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O O
not O O
involved O O
, O O
because O O
CD4 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
depletion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
does O O
not O O
diminish O O
the O O
anti-tumor O B_DISEASE
effect O I_DISEASE
. O O

A O O
transient O O
transfection O O
study O O
showed O O
that O O
Tax B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O O
activate O O
transcription O O
through O O
the O O
AP-1-binding B B_GENE/B_LOCATION
site I I_GENE/I_LOCATION
in O O
a O O
human O O
T O O
cell O O
line O O
, O O
whereas O O
any O O
combination O O
of O O
AP-1 B B_GENE/B_BIO
proteins I I_GENE/I_BIO
did O O
so O O
much O O
less O O
than O O
Tax B B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
indicating O O
that O O
the O O
activation O O
of O O
the O O
AP-1 B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
Tax B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O O
require O O
a O O
mechanism O O
other O O
than O O
the O O
induction O O
of O O
AP-1 B B_GENE
mRNA I I_GENE
. O O

In O O
contrast O O
when O O
the O O
Raf-responsive O O
cells O O
were O O
induced O O
to O O
differentiate O O
with O O
PMA O O
and O O
GM-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
in O O
the O O
absence O O
of O O
deltaRaf B B_GENE
: I I_GENE
ER I I_GENE
activation O O
, O O
increased O O
levels O O
of O O
the O O
CD11b B B_GENE/B_MEASURE
and I I_GENE/I_MEASURE
CD18 I I_GENE/I_MEASURE
molecules I I_GENE/I_MEASURE
were O O
detected O O
. O O

Thus O O
deregulated O O
Raf O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
can O O
alter O O
cytokine O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
dependency O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
integrin O B_GENE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
expression O B_GENE/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O O
the O O
stage O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
differentiation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

These O O
Raf-responsive O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
lines O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
will O O
be O O
useful O B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
elucidating O O
the O O
roles O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
MAP O B_GENE
kinase O I_GENE
cascade O I_GENE
on O O
hematopoietic O B_DISEASE/B_ORGANISM_FUNCTION
cell O I_DISEASE/I_ORGANISM_FUNCTION
differentiation O I_DISEASE/I_ORGANISM_FUNCTION
and O O
malignant O B_DISEASE/B_ORGANISM_FUNCTION
transformation O I_DISEASE/I_ORGANISM_FUNCTION

cAMP O B_GENE
is O O
an O O
important O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
second O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
messenger O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O O
immunomodulatory O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
properties O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Elevation O O
of O O
intracellular O O
cAMP O O
in O O
T O O
cells O O
, O O
induced O O
by O O
agents O O
such O O
as O O
IL-1alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O O
PGs B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
inhibits O O
T O O
cell O O
activation O O
. O O

IL-4 B B_GENE
and O O
IL-13 B B_GENE/B_MEASURE
are O O
pleiotropic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
whose O O
biological O O
activities O O
overlap O O
with O O
each O O
other O O
. O O

IL-13 B B_GENE
receptor I I_GENE
alpha I I_GENE
chain I I_GENE
1 I I_GENE
( O O
IL-13R B B_PROTEIN[GENE]
alpha I I_PROTEIN[GENE]
1 I I_PROTEIN[GENE]
) O O
is O O
necessary O O
for O O
binding O O
to O O
IL-13 B B_GENE
, O O
and O O
the O O
heterodimer O O
composed O O
of O O
IL-13R B B_GENE
alpha I I_GENE
1 I I_GENE
and O O
IL-4R B B_PROTEIN[GENE]/B_MEASURE
alpha I I_PROTEIN[GENE]/I_MEASURE
chain I I_PROTEIN[GENE]/I_MEASURE
transduces O O
IL-13 B B_GENE
and O O
IL-4 B B_GENE
signals O O
; O O
however O O
, O O
the O O
functional O O
mapping O O
of O O
the O O
intracellular B B_LOCATION
domain I I_LOCATION
of O O
IL-13R B B_GENE
alpha I I_GENE
1 I I_GENE
is O O
not O O
fully O O
understood O O
. O O

Furthermore O O
, O O
we O O
found O O
that O O
the O O
Box1 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
region I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
and O O
the O O
C-terminal B B_GENE/B_LOCATION
tail I I_GENE/I_LOCATION
of O O
IL-13R B B_GENE
alpha I I_GENE
1 I I_GENE
were O O
critical O O
for O O
binding O O
to O O
Tyk2 B B_GENE
, O O
and O O
activation O O
of O O
Jak1 B B_GENE
, O O
Tyk2 B B_GENE
, O O
the O O
insulin B B_GENE
receptor I I_GENE
substrate-1 I I_GENE
and O O
STAT6 B B_GENE
respectively O O
. O O

Functional O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
uncoupling O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
Janus O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinase O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
3-Stat5 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
malignant O B_DISEASE/B_ORGANISM_FUNCTION
growth O I_DISEASE/I_ORGANISM_FUNCTION
of O O
human O B_DISEASE/B_LOCATION
T O I_DISEASE/I_LOCATION
cell O I_DISEASE/I_LOCATION
leukemia O I_DISEASE/I_LOCATION
virus O I_DISEASE/I_LOCATION
type O I_DISEASE/I_LOCATION
1-transformed O I_DISEASE/I_LOCATION
human O I_DISEASE/I_LOCATION
T O I_DISEASE/I_LOCATION
cells O I_DISEASE/I_LOCATION
. O O

Here O O
we O O
demonstrate O O
that O O
disruption O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Jak3/Stat5a/b O B_GENE
signaling O O
with O O
AG-490 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
50 O B_TIME[MEASURE]/B_LOCATION
& O O
mgr O B_MEASURE/B_PERSON
; O O
M O B_MEASURE
) O O
blocked O O
the O O
proliferation O B_DISEASE/B_ORGANISM_FUNCTION
of O O
primary O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
human O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O O
but O O
paradoxically O O
failed O O
to O O
inhibit O O
the O O
proliferation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
HTLV-1-transformed O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
human O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cell O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lines O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
HuT-102 O O
and O O
MT-2 O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Structural O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
homologues O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
AG-490 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O O
inhibited O O
the O O
proliferation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
primary O B_DISEASE_ADJECTIVE[DISEASE]
human O I_DISEASE_ADJECTIVE[DISEASE]
T O I_DISEASE_ADJECTIVE[DISEASE]
cells O I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
HTLV-1-infected O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

In O O
contrast O O
, O O
AG-490 O O
had O O
no O O
effect O O
on O O
DNA O O
binding O O
by O O
p50/p65 B B_GENE/B_MEASURE
components I I_GENE/I_MEASURE
of O O
NF-kappaB B B_GENE
, O O
a O O
transcription B B_GENE/B_LOCATION
factor I I_GENE/I_LOCATION
activated O O
by O O
the O O
HTLV-1-encoded B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
phosphoprotein I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Tax I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Collectively O O
, O O
these O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
the O O
Jak3-Stat5 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
HTLV-1-transformed O B_DISEASE
T O I_DISEASE
cells O I_DISEASE
has O O
become O O
functionally O O
redundant O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
proliferation O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Bandshift O O
studies O O
indicate O O
that O O
this O O
region O O
contains O O
three O O
factor O O
binding O O
sites O O
, O O
termed O O
sites B B_GENE/B_DISEASE
B I I_GENE/I_DISEASE
, I I_GENE/I_DISEASE
C I I_GENE/I_DISEASE
, I I_GENE/I_DISEASE
and I I_GENE/I_DISEASE
D I I_GENE/I_DISEASE
, O O
in O O
addition O O
to O O
a O O
previously O O
characterized O O
CREB B B_LOCATION/B_NUMBER[MEASURE]
site I I_LOCATION/I_NUMBER[MEASURE]
. O O

Here O O
we O O
show O O
that O O
site B B_PROTEIN[GENE]
C I I_PROTEIN[GENE]
binds O O
members O O
of O O
the O O
ubiquitously O O
expressed O O
RFX B B_GENE/B_BIO
family I I_GENE/I_BIO
of I I_GENE/I_BIO
proteins I I_GENE/I_BIO
, O O
notably O O
RFX1 B B_GENE/B_DISEASE
, O O
RFX3 B B_GENE/B_DISEASE
, O O
and O O
the O O
associated O O
factor O O
MIBP1 B B_GENE
, O O
whereas O O
sites B B_LOCATION/B_PERSON
B I B_LOCATION/I_PERSON
and I B_LOCATION/I_PERSON
D I B_LOCATION/I_PERSON
both O O
bind O O
the O O
B-cell-specific B B_GENE/B_BIO
activator I I_GENE/I_BIO
protein I I_GENE/I_BIO
BSAP/Pax5 I I_GENE/I_BIO
. O O

In O O
reporter O O
assays O O
with O O
mutant B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Wp I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constructs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
loss O O
of O O
factor O O
binding O O
to O O
any O O
one O O
of O O
these O O
sites O O
severely O O
impaired O O
promoter O O
activity O O
in O O
B O O
cells O O
, O O
while O O
the O O
wild-type B B_SEQUENCE[MEASURE]/B_PERSON
promoter I I_SEQUENCE[MEASURE]/I_PERSON
could O O
be O O
activated O O
in O O
non-B O O
cells O O
by O O
ectopic O O
BSAP O O
expression O O
. O O

A O O
proline-rich B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
region I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
residues O O
132-141 O O
, O O
binds O O
to O O
the O O
SH3 B B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
domain I I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
Lck B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
show O O
here O O
that O O
the O O
other O O
Lck-binding B B_LOCATION/B_PROTEIN[GENE]
domain I B_LOCATION/I_PROTEIN[GENE]
, O O
residues O O
104-113 O O
, O O
binds O O
to O O
the O O
carboxyl-terminal B B_LOCATION/B_MEASURE
half I I_LOCATION/I_MEASURE
of O O
Lck B B_GENE/B_BACTERIUM[BIO]
and O O
that O O
this O O
binding O O
does O O
not O O
require O O
the O O
Lck B B_GENE
SH3 I I_GENE
domain I I_GENE
. O O

Mutated O O
Tip B B_PROTEIN[GENE]
containing O O
only O O
one O O
functional O O
Lck-binding B B_LOCATION/B_MEASURE
domain I I_LOCATION/I_MEASURE
can O O
bind O O
stably O O
to O O
Lck B B_GENE/B_BACTERIUM[BIO]
, O O
although O O
not O O
as O O
strongly O O
as O O
wild-type B B_GENE
Tip I I_GENE
. O O

Interaction O O
of O O
Tip B B_GENE
with O O
Lck B B_GENE/B_BACTERIUM[BIO]
through O O
either O O
Lck-binding B B_LOCATION
domain I I_LOCATION
increases O O
the O O
activity O O
of O O
Lck B B_GENE/B_BACTERIUM[BIO]
in O O
vivo O O
. O O

Full O O
biological O O
activity O O
of O O
Tip B B_GENE
, O O
therefore O O
, O O
appears O O
to O O
require O O
both O O
Lck-binding B B_LOCATION
domains I I_LOCATION
. O O

Proteasome O O
function O O
was O O
also O O
necessary O O
for O O
the O O
lysosomal O O
degradation O O
of O O
IL-2 B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
internalized O O
by O O
IL-2R B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O O
were O O
comprised O O
of O O
cytoplasmic B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tailless I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
beta- B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gamma I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
c-subunits I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
suggesting O O
that O O
the O O
target O O
protein O O
for O O
the O O
proteasome B B_ENZYME[GENE]
is O O
independent O O
of O O
either O O
the O O
cytoplasmic B B_MEASURE/B_LOCATION
tail I B_MEASURE/I_LOCATION
of O O
the O O
IL-2R B B_GENE
beta- B I_GENE
or I I_GENE
gamma I I_GENE
c-subunits I I_GENE
and O O
their O O
associated O O
signaling O O
components O O
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
Human B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
p45 I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
mRNAs I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
have O O
two O O
alternative O O
isoforms O O
, O O
aNF-E2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
fNF-E2 B B_GENE
, O O
and O O
these O O
isoforms O O
are O O
transcribed O O
from O O
the O O
alternative B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
promoters I B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

We O O
investigated O O
lineage-specific O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
both O O
isomers O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
erythroid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
megakaryocytic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
reverse O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
transcriptase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
polymerase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
or O O
Northern O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O O
When O O
CD34 O B_GENE
( O O
+ O B_OTHER/B_DISEASE
) O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
isolated O O
from O O
human O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cord O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
blood O I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
induced O O
to O O
unilineage O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
erythroid O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
megakaryocytic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
differentiation O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
liquid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
suspension O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
culture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O O
both O O
transcripts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
although O O
barely O O
detected O O
at O O
day O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
were O O
induced O O
in O O
both O O
erythroid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
and O O
megakaryocytic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cultures O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
heme B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxygenase-1 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O O
no O O
permissive O O
effect O O
on O O
sinusoidal O O
perfusion O O
and O O
does O O
not O O
affect O O
liver O O
injury O O
in O O
this O O
model O O
. O O

Thus O O
, O O
we O O
set O O
out O O
to O O
find O O
differences O O
in O O
the O O
modes O O
of O O
proliferative O O
and O O
apoptotic O O
responses O O
to O O
TNF- B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
We O O
screened O O
a O O
panel O O
of O O
acute O O
myeloid O O
leukemia-derived O O
cell O O
lines O O
for O O
TNF- B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
-responsiveness O O
. O O

In O O
two O O
lines O O
( O O
OCI-AML-1 O O
, O O
OCI-AML-11 O O
) O O
, O O
TNF- B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acted O O
as O O
an O O
apoptotic O O
agent O O
; O O
in O O
others O O
( O O
HU-3 O O
, O O
M-07e O O
, O O
TF-1 O O
) O O
, O O
it O O
had O O
the O O
opposite O O
effect O O
, O O
preventing O O
apoptosis O O
and O O
inducing O O
proliferation O O
. O O

RESULTS O O
: O O
All O O
cell O O
lines O O
tested O O
expressed O O
TNF- B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
responded O O
to O O
TNF- B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
upregulation O O
of O O
intercellular B B_GENE
adhesion I I_GENE
molecule-1 I I_GENE
. O O

In O O
contrast O O
to O O
granulocyte-macrophage B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colony-stimulating I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GM-CSF B B_ORGANIZATION/B_LOCATION
) O O
, O O
TNF- B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
did O O
not O O
activate O O
the O O
MAP B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
p70S6 O O
kinase O O
pathways O O
. O O

Supporting O O
this O O
notion O O
, O O
TNF-alpha B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
-induced O O
upregulation O O
of O O
GM-CSF B B_GENE
mRNA I I_GENE
levels O O
and O O
protein O O
secretion O O
in O O
the O O
TNF-alpha B B_DISEASE/B_GENE
-proliferative O O
, O O
but O O
not O O
in O O
the O O
TNF-alpha-apoptotic O O
cell O O
lines O O
. O O

CONCLUSION O O
: O O
These O O
data O O
identify O O
GM-CSF B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synthesis O O
as O O
an O O
early O O
and O O
essential O O
step O O
in O O
TNF- O O
alpha-induced O O
proliferation O O
. O O

Glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
measured O O
in O O
T O O
lymphocytes O O
that O O
were O O
isolated O O
from O O
peripheral O O
blood O O
by O O
either O O
nylon O O
wool O O
filtration O O
or O O
E-rosette O O
sedimentation O O
. O O

This O O
difference O B_MEASURE
in O O
the O O
amount O B_MEASURE/B_LOCATION
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
bound O O
by O O
the O O
two O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
preparations O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
p O B_MEASURE
less O I_MEASURE
than O O
.001 O B_NUMBER[MEASURE]/B_LOCATION
) O O
and O O
was O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immediately O O
after O O
cell O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
isolation O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
and O O
glucocorticoid O O
sensitivity O O
of O O
human O O
leukemic O O
cells O O
. O O

We O O
have O O
established O O
optimal O O
conditions O O
for O O
the O O
measurement O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
GR B B_LOCATION/B_ORGANIZATION
) O O
in O O
human O O
white O O
cells O O
using O O
a O O
whole-cell O O
binding O O
assay O O
with O O
[ O O
3H O O
] O O
dexamethasone O O
as O O
the O O
ligand O O
, O O
and O O
the O O
subsequent O O
determination O O
of O O
the O O
GR B B_PROTEIN[GENE]/B_DISEASE
content O O
in O O
normal O O
human O O
lymphocytes O O
and O O
in O O
leukemic O O
cells O O
of O O
patients O O
with O O
various O O
forms O O
of O O
acute O O
and O O
chronic O O
leukemia O O
. O O

Steroidal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
compounds O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O O
a O O
known O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
potency O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
effectively O O
competed O O
for O O
the O O
binding O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
whereas O O
steroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
devoid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
glucocorticoid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O O
e.g. O B_DISEASE/B_PROTEIN[GENE]
estradiol-17 O O
beta O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testosterone O O
) O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
ineffective O O
. O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]

There O O
was O O
no O O
apparent O O
correlation O O
between O O
the O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentration O O
and O O
the O O
sensitivity O O
of O O
the O O
cells O O
in O O
vitro O O
to O O
glucocorticoids O O
as O O
judged O O
by O O
[ O O
3H O O
] O O
thymidine O O
incorporation O O
studies O O
. O O

Distribution O O
of O O
the O O
surface O O
markers O O
in O O
the O O
leukemic O O
cell O O
lines O O
did O O
not O O
relate O O
to O O
the O O
GR B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentration O O
. O O

One O O
mechanism O O
by O O
which O O
glucocorticoids O O
could O O
exert O O
their O O
anti-inflammatory O O
action O O
is O O
via O O
rapidly O O
saturable O O
, O O
stereo-specific B B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
cytoplasmic I B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
protein I B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
receptors I B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O O

Synovium O O
, O O
obtained O O
from O O
knee O O
joints O O
of O O
rheumatoid O O
patients O O
undergoing O O
surgery O O
, O O
was O O
incubated O O
with O O
clostridiopeptidase B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
trypsin-EDTA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
to O O
obtain O O
cell O O
suspensions O O
. O O

Glucorticoid B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
studied O O
in O O
various O O
populations O O
of O O
normal O O
human O O
peripheral O O
blood O O
lymphocytes O O
and O O
leukemic O O
lymphoblasts O O
. O O

Phytohemagglutinin B B_BIO/B_TIME[MEASURE]
treatment O O
increases O O
levels O O
about O O
3-fold O O
. O O

Presence O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
receptor O B_GENE/B_DISEASE
is O O
correlated O O
with O O
in O O
vitro O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivitiy O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
in O O
vivo O B_DISEASE_ADJECTIVE[DISEASE]
response O I_DISEASE_ADJECTIVE[DISEASE]
to O O
therapy O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Quantity O B_TIME[MEASURE]/B_PERSON
of O O
receptor O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
also O O
correlated O O
with O O
complete O B_DISEASE
remission O I_DISEASE
duration O I_DISEASE
independently O O
of O O
leukemic O B_TIME[MEASURE]/B_DISEASE
cell O I_TIME[MEASURE]/I_DISEASE
type O I_TIME[MEASURE]/I_DISEASE
( O O
T O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
or O O
null O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
, O O
initial O B_MEASURE
WBC O I_MEASURE
, O O
or O O
age O B_MEASURE
of O O
patient O B_PERSON/B_DISEASE
. O O

SRE B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O O
also O O
stimulated O O
by O O
both O O
normal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
active I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Lck I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Furthermore O O
, O O
normal B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
active I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fyn I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulated O O
transcription O O
from O O
the O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
when O O
transfected O O
cells O O
were O O
stimulated O O
by O O
concanavalin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
plus O O
12-O-tetradecanoylphorbol-13-acetate O O
. O O

The O O
predominant O O
inducible O O
form O O
of O O
the O O
NF-kappa B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
a O O
heteromeric B B_LOCATION
complex I I_LOCATION
containing O O
two O O
Rel-related B B_GENE/B_LOCATION
DNA-binding I I_GENE/I_LOCATION
subunits I I_GENE/I_LOCATION
, O O
termed B B_GENE
p65 I I_GENE
and O O
p50 B B_GENE
. O O

Prior O O
transfection O O
studies O O
have O O
shown O O
that O O
when O O
these O O
p65 B B_GENE
and I I_GENE
p50 I I_GENE
subunits I I_GENE
are O O
expressed O O
independently O O
as O O
stable B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homodimers I I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
p65 B B_GENE
stimulates O O
kappa O O
B-directed O O
transcription O O
, O O
whereas O O
p50 B B_MEASURE/B_GENE
functions O O
as O O
a O O
kappa O O
B-specific O O
repressor O O
. O O

While O O
authentic O O
p50 B B_GENE
homodimers I I_GENE
( O O
previously O O
termed O O
KBF1 B B_GENE
) O O
have O O
been O O
detected O O
in O O
nuclear O O
extracts O O
from O O
nontransfected O O
cells O O
, O O
experimental O O
evidence O O
supporting O O
the O O
existence O O
of O O
p65 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
homodimers I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O O
vivo O O
was O O
lacking O O
. O O

As O O
with O O
the O O
prototypical O O
NF-kappa B B_GENE/B_MEASURE
B I I_GENE/I_MEASURE
p50-p65 I I_GENE/I_MEASURE
heterodimer I I_GENE/I_MEASURE
, O O
this O O
novel O O
p65 B B_MEASURE/B_LOCATION
homodimeric I I_MEASURE/I_LOCATION
form I I_MEASURE/I_LOCATION
of O O
NF-kappa B B_GENE/B_LOCATION
B I I_GENE/I_LOCATION
is O O
functionally O O
sequestered O O
in O O
the O O
cytoplasm O O
but O O
rapidly O O
appears O O
in O O
the O O
nuclear O O
compartment O O
following O O
cellular O O
stimulation O O
. O O

These O O
later O O
findings O O
indicate O O
that O O
neither O O
homo- O O
nor O O
heterodimer O O
formation O O
is O O
an O O
absolute O O
prerequisite O O
for O O
I B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
kappa I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
B I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
recognition O O
of O O
p65 B B_GENE
. O O

Carrier O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
determination O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
X-linked O B_DISEASE/B_GENE
agammaglobulinemia O B_DISEASE/I_GENE
using O O
X O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inactivation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
purified O O
B O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

While O O
mitogenic O O
doses O O
of O O
Fab'2 B B_GENE
anti-Ig I I_GENE
induce O O
large O O
and O O
rapid O O
increases O O
in O O
Egr-1 O O
expression O O
, O O
IgG B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti-Ig I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
results O O
in O O
smaller O O
increases O O
in O O
Egr-1 B B_GENE
mRNA I I_GENE
, O O
comparable O O
to O O
that O O
seen O O
with O O
submitogenic O O
concentrations O O
of O O
Fab'2 B B_GENE
anti-Ig I I_GENE
. O O

However O O
, O O
the O O
correlation O O
between O O
Egr-1 O O
expression O O
and O O
B O O
cell O O
proliferation O O
breaks O O
down O O
when O O
IL-4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
added O O
as O O
a O O
co-mitogen O O
to O O
induce O O
B O O
cell O O
proliferation O O
with O O
IgG B B_DISEASE_ADJECTIVE[DISEASE]
anti-Ig I I_DISEASE_ADJECTIVE[DISEASE]
or O O
submitogenic O O
concentrations O O
of O O
Fab'2 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
anti-Ig I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Therefore O O
, O O
IL-4 B B_LOCATION/B_PERSON
overcomes O O
Fc O O
receptor-mediated O O
inhibition O O
of O O
B O O
cell O O
proliferation O O
without O O
affecting O O
inhibition O O
of O O
Egr-1 B B_GENE
mRNA I I_GENE
induction O O
, O O
as O O
demonstrated O O
earlier O O
for O O
c-myc B B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mRNA I B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
this O O
system O O
. O O

When O O
HL-60 O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
treated O O
with O O
sodium O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
butyrate O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
induced O O
monocytic O B_DISEASE
differentiation O I_DISEASE
, O O
a O O
remarkable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
AP-1 O O
binding O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
detected O O
. O O

Glucocorticoid B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
receptors I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
sensitivity O O
in O O
leukemias O O
. O O

In O O
an O O
attempt O O
to O O
investigate O O
the O O
utility O O
of O O
glucocorticoid B B_GENE/B_MEASURE
receptor I I_GENE/I_MEASURE
determination O O
to O O
predict O O
clinical O O
responsiveness O O
in O O
human O O
leukemias O O
we O O
have O O
studied O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
leukemic O O
cells O O
from O O
46 O O
patients O O
and O O
in O O
the O O
lymphocytes O O
from O O
18 O O
normal O O
donors O O
. O O

'Activation-labile B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
' I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
glucocorticoid-receptor I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
complexes I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
a O O
steroid-resistant O O
variant O O
of O O
CEM-C7 O O
human O O
lymphoid O O
cells O O
. O O

Activation O O
can O O
be O O
achieved O O
in O O
vitro O O
by O O
increased O O
ionic O O
strength O O
, O O
dilution O O
or O O
gel O O
filtration O O
and O O
is O O
manifested O O
by O O
an O O
increased O O
affinity O O
of O O
steroid-receptor B B_GENE
complex I I_GENE
for O O
DNA B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
an O O
altered O O
elution O O
profile O O
from O O
ion-exchange O O
resins O O
. O O

Munck O O
and O O
Foley O O
have O O
shown O O
that O O
activated B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isolated O O
from O O
thymocytes O O
elute O O
from O O
DEAE-cellulose O O
in O O
a O O
manner O O
identical O O
to O O
complexes O O
activated O O
in O O
vitro O O
. O O

We O O
report O O
here O O
that O O
DEAE-cellulose O O
chromatography O O
of O O
steroid-receptor B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
complexes I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
from O O
CEM-C7 O O
, O O
a O O
cloned O O
human O O
leukaemic O O
T-cell O O
line O O
sensitive O O
to O O
the O O
cytolytic O O
action O O
of O O
glucocorticoids O O
, O O
and O O
its O O
steroid-resistant O O
subclone O O
4R4 O O
demonstrated O O
that O O
steroid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O O
clone O O
4R4 O O
can O O
not O O
form O O
stable O O
activated O O
complexes O O
. O O

This O O
defines O O
a O O
new O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
defect O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
receptor O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action O I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
activation O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
lability O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
r+act1 O B_LOCATION/B_ORGANIZATION
) O O
, O O
which O O
is O O
unlike O O
either O O
the O O
r- O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
r+nt- O O
, O O
or O O
r+nti O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
phenotypes O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
previously O O
described O O
for O O
mouse O B_DISEASE/B_BIO
lymphoid O I_DISEASE/I_BIO
variants O I_DISEASE/I_BIO
. O O

We O O
suggest O O
that O O
this O O
correlates O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
the O O
suggestion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
the O O
granulocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
constitute O O
a O O
receptor O B_GENE/B_LOCATION
system O B_GENE/I_LOCATION
for O O
oestrogens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Glucocorticoid O B_GENE
binding O I_GENE
was O O
measured O O
in O O
resident O B_PERSON/B_BIO
and O O
thioglycollate-elicited O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mouse O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
peritoneal O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
macrophages O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
rabbit O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
alveolar O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
macrophages O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
monocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
mononuclear O O
phagocytes O O
contained O O
approximately O O
equal O O
to O O
4 O O
-- O O
10 O O
X O O
10 O O
( O O
3 O O
) O O
high B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
affinity I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
per O O
cell O O
, O O
with O O
dissociation O O
constants O O
of O O
approximately O O
equal O O
to O O
2 O O
-- O O
8 O O
nM O O
dexamethasone O O
. O O

The O O
binding O O
to O O
the O O
saturable B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
specific O O
for O O
steroids O O
with O O
glucocorticoid O O
or O O
antiglucocorticoid O O
activity O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O O
that O O
corticosteroids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
interact O O
with O O
macrophages O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
physiological O B_MEASURE/B_LOCATION
concentrations O B_MEASURE/I_LOCATION
. O O

One O O
of O O
the O O
binding B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
possessed O O
biochemical O O
and O O
immunological O O
features O O
identical O O
to O O
those O O
of O O
the O O
transcription B B_GENE/B_BIO
factor I I_GENE/I_BIO
AP1 I I_GENE/I_BIO
. O O

The O O
presence O O
of O O
CLE0-like B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
elements I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
promoters B B_LOCATION/B_ORGANIZATION
of O O
interleukin-3 B B_GENE/B_BIO
( I I_GENE/I_BIO
IL-3 I I_GENE/I_BIO
) I I_GENE/I_BIO
, I I_GENE/I_BIO
IL-4 I I_GENE/I_BIO
, I I_GENE/I_BIO
IL-5 I I_GENE/I_BIO
, I I_GENE/I_BIO
GM-CSF I I_GENE/I_BIO
, I I_GENE/I_BIO
and I I_GENE/I_BIO
NFAT I I_GENE/I_BIO
sites I I_GENE/I_BIO
in O O
the O O
IL-2 B B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
promoter I I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
suggests O O
that O O
the O O
factors O O
we O O
detected O O
, O O
or O O
related O O
factors O O
that O O
recognize O O
these O O
sites O O
, O O
may O O
account O O
for O O
the O O
coordinate O O
induction O O
of O O
these O O
genes O O
during O O
T-cell O O
activation O O
. O O

As O O
an O O
initial O O
step O O
towards O O
understanding O O
the O O
molecular O O
basis O O
for O O
tissue-specific O O
expression O O
of O O
this O O
gene O O
, O O
we O O
surveyed O O
the O O
surrounding O O
chromatin O O
structure O O
for O O
potential O O
cis-acting B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulatory I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regions I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
DNase B B_GENE
I I I_GENE
hypersensitivity O O
mapping O O
and O O
found O O
four O O
hypersensitive O O
sites O O
, O O
three O O
of O O
which O O
were O O
T O O
cell O O
restricted O O
. O O

Deletion O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O O
that O O
the O O
minimal O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancer O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
adjacent O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
to O O
a O O
negative O B_GENE/B_LOCATION
regulatory O I_GENE/I_LOCATION
element O I_GENE/I_LOCATION
. O O

In O O
addition O O
, O O
the O O
5 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
' I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
end I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
enhancer B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
composed O O
of O O
an O O
Alu O O
repeat O O
which O O
contained O O
the O O
GATA-3 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bHLH I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
LyF-1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Deletion O O
analysis O O
revealed O O
that O O
T O O
cell O O
specificity O O
was O O
conferred O O
by O O
a O O
49-bp B B_GENE/B_LOCATION
fragment I I_GENE/I_LOCATION
( O O
bp B B_PROTEIN[GENE]/B_MEASURE
-319 I I_PROTEIN[GENE]/I_MEASURE
to I I_PROTEIN[GENE]/I_MEASURE
-270 I I_PROTEIN[GENE]/I_MEASURE
) O O
that O O
included O O
a O O
potential B B_GENE/B_LOCATION
binding I B_GENE/I_LOCATION
site I B_GENE/I_LOCATION
for O O
AP-1 B B_GENE
transcription I I_GENE
factors I I_GENE
6 O O
bp O O
upstream O O
of O O
a O O
binding B B_GENE/B_LOCATION
site I I_GENE/I_LOCATION
for I I_GENE/I_LOCATION
Elf-1 I I_GENE/I_LOCATION
, O O
a O O
member O O
of O O
the O O
Ets B B_PERSON/B_LOCATION
family I B_PERSON/I_LOCATION
of O O
transcription B B_GENE
factors I I_GENE
. O O

In O O
vitro-transcribed O O
and O O
-translated O O
Elf-1 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
bound O O
specifically O O
to O O
the O O
Elf-1 B B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
Elf-1 O O
antisera O O
competed O O
and O O
super O O
shifted O O
nuclear O O
protein O O
complexes O O
present O O
in O O
MLA-144 O O
nuclear O O
extracts O O
. O O

Moreover O O
, O O
addition O O
of O O
anti-Jun O O
family O O
antiserum O O
in O O
electrophoretic O O
mobility O O
shift O O
assay O O
reactions O O
completely O O
blocked O O
formation O O
of O O
the O O
AP-1-related B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
mechanisms O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
contributing O O
to O O
persistent O B_DISEASE_ADJECTIVE[DISEASE]
T O I_DISEASE_ADJECTIVE[DISEASE]
cell O I_DISEASE_ADJECTIVE[DISEASE]
activation O I_DISEASE_ADJECTIVE[DISEASE]
and O O
poor O B_DISEASE
response O I_DISEASE
to O O
glucocorticoids O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
inflammatory O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
illnesses O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
such O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
as O O
steroid O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
resistant O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
SR O B_PROTEIN[GENE]/B_DISEASE
) O O
asthma O B_DISEASE/B_LOCATION
are O O
poorly O O
defined O O
. O O

A O O
[ O O
3H O O
] O O
dexamethasone O O
radioligand-binding O O
assay O O
was O O
used O O
to O O
measure O O
the O O
number O O
of O O
glucocorticoid B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
GR B B_LOCATION/B_ORGANIZATION
) O O
and O O
dissociation O O
constant O O
( O O
Kd O O
) O O
in O O
PBMC O O
from O O
normal O O
donors O O
and O O
patients O O
with O O
SR O O
asthma O O
, O O
cultured O O
in O O
the O O
absence O O
and O O
presence O O
of O O
these O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Furthermore O O
, O O
when O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O O
non-T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
individually O O
stimulated O O
with O O
combination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
IL-2 O O
+ O O
IL-4 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reduction O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
GR-binding O B_DISEASE/B_GENE
affinity O I_DISEASE/I_GENE
was O O
observed O O
only O O
in O O
the O O
T O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cell O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
population O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
p O B_OTHER/B_PROTEIN[GENE]
= O O
0.0001 O B_MEASURE
) O O
. O O

The O O
IL-2 O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
+ O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
IL-4-induced O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
alteration O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
PBMC O B_PROTEIN[GENE]/B_LOCATION
GR O I_PROTEIN[GENE]/I_LOCATION
Kd O I_PROTEIN[GENE]/I_LOCATION
was O O
associated O O
with O O
an O O
increase O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
GR O B_MEASURE/B_DISEASE
number O I_MEASURE/I_DISEASE
( O O
8348 O B_MEASURE
+/- O I_MEASURE
964 O I_MEASURE
vs O I_MEASURE
1710 O I_MEASURE
+/- O I_MEASURE
228 O I_MEASURE
sites/cell O I_MEASURE
; O O
p O O
= O O
0.0003 O B_MEASURE
) O O
. O O

These O O
effects O O
of O O
IL-2 B B_GENE
+ O O
IL-4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
PBMC O O
GR B B_GENE/B_DISEASE
affinity O O
and O O
response O O
to O O
MPN O O
were O O
blocked O O
by O O
co-incubation O O
with O O
IFN-gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Freshly O O
isolated O O
PBMC O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
from O O
four O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
with O O
SR O B_DISEASE/B_LOCATION
asthma O I_DISEASE/I_LOCATION
had O O
a O O
significantly O O
reduced O O
GR-binding O B_GENE/B_MEASURE
affinity O B_GENE/I_MEASURE
( O O
Kd O B_PROTEIN[GENE]/B_MEASURE
= O O
40.0 O B_MEASURE
+/- O I_MEASURE
2.68 O I_MEASURE
nM O I_MEASURE
; O O
p O B_OTHER/B_PROTEIN[GENE]
= O O
0.0001 O B_MEASURE
) O O
when O O
compared O O
with O O
seven O B_PERSON/B_MEASURE
normal O I_PERSON/I_MEASURE
subjects O I_PERSON/I_MEASURE
( O O
7.15 O B_MEASURE/B_PROTEIN[GENE]
+/- O I_MEASURE/I_PROTEIN[GENE]
0.41 O I_MEASURE/I_PROTEIN[GENE]
nM O I_MEASURE/I_PROTEIN[GENE]
) O O
. O O

The O O
altered O O
PBMC O O
GR O O
binding O O
from O O
patients O O
with O O
SR O O
asthma O O
reversed O O
to O O
normal O O
when O O
incubated O O
with O O
medium O O
alone O O
, O O
but O O
was O O
sustained O O
with O O
IL-2 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O O
IL-4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Furthermore O O
, O O
the O O
effects O O
of O O
IL-2 B B_GENE
and O O
IL-4 B B_GENE
were O O
blocked O O
by O O
IFN-gamma B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Characterization O O
of O O
the O O
human B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CD4 I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
gene I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
promoter I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O O
transcription O O
from O O
the O O
CD4 B B_GENE/B_LOCATION
gene I I_GENE/I_LOCATION
core I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
is O O
tissue-specific O O
and O O
is O O
activated O O
by O O
Ets B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
proteins I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
located O O
the O O
transcription B B_GENE/B_LOCATION
initiation I I_GENE/I_LOCATION
site I I_GENE/I_LOCATION
and O O
showed O O
that O O
the O O
CD4 B B_GENE/B_LOCATION
core I I_GENE/I_LOCATION
promoter I I_GENE/I_LOCATION
( O O
positions B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
-40 I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+16 I I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
lacks O O
a O O
classical O O
`` O O
TATA O O
'' O O
or O O
initiator B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positioning I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consensus I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
directs O O
precise O O
and O O
efficient O O
transcription O O
when O O
coupled O O
to O O
the O O
ubiquitously O O
active O O
simian B B_GENE/B_LOCATION
virus I I_GENE/I_LOCATION
40 I I_GENE/I_LOCATION
enhancer I I_GENE/I_LOCATION
. O O

Another O O
ETS B B_LOCATION/B_PERSON
consensus I I_LOCATION/I_PERSON
sequence I I_LOCATION/I_PERSON
is O O
located O O
1060 O O
nt O O
upstream O O
. O O

By O O
morphologic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
criteria O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O O
thymidine O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
incorporation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
the O O
fractions O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O O
separated O O
into O O
populations O B_LOCATION/B_ORGANIZATION
of O O
G0 O B_MEASURE/B_PROTEIN[GENE]
and O O
G1 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phase O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
S O B_DISEASE
and O O
post-S O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
cells O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O O

A O O
2- O B_MEASURE/B_LOCATION
to O O
3-fold O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
glucocorticoid O B_GENE/B_MEASURE
receptor O B_GENE/I_MEASURE
sites O B_GENE/I_MEASURE
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
, O O
for O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
S O B_OTHER/B_DISEASE
and O O
post-S O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
over O O
those O O
in O O
G0 O B_PROTEIN[GENE]/B_DISEASE
and O O
G1 O B_PROTEIN[GENE]
, O O
was O O
observed O O
with O O
both O O
nonstimulated O B_DISEASE_ADJECTIVE[DISEASE]
rat O I_DISEASE_ADJECTIVE[DISEASE]
lymph O I_DISEASE_ADJECTIVE[DISEASE]
node O I_DISEASE_ADJECTIVE[DISEASE]
cell O I_DISEASE_ADJECTIVE[DISEASE]
suspensions O I_DISEASE_ADJECTIVE[DISEASE]
and O O
concanavalin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
A-stimulated O O
human O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
observations O O
together O O
with O O
those O O
from O O
other O O
studies O O
indicate O O
that O O
formation O O
of O O
new O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
near O O
the O O
S O O
phase O O
may O O
be O O
a O O
general O O
phenomenon O O
in O O
proliferating O O
cells O O
. O O

We O O
propose O O
that O O
this O O
increase O O
in O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
during O O
the O O
cell O O
cycle O O
may O O
explain O O
the O O
increase O O
in O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mitogen-stimulated O O
lymphocytes O O
. O O

The O O
leukocyte O O
migration O O
inhibition O O
response O O
to O O
certain O O
breast B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cancer-related I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigens I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MCF-7 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
MuMTV B B_GENE/B_SPECIES[BIO]
) O O
: O O
their O O
potential O O
as O O
discriminants O O
. O O

Breast O O
cancer O O
patients O O
showed O O
significant O O
responses O O
to O O
MuMTV B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
( O O
49 O O
% O O
and O O
to O O
MCF-7 O O
( O O
50 O O
% O O
) O O
, O O
but O O
not O O
to O O
MPMV B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O O
29 O O
% O O
) O O
. O O

In O O
a O O
paired-antigen O O
study O O
using O O
MuMTV B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
MCF-7 B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
75 O O
% O O
of O O
the O O
breast O O
cancer O O
patients O O
responded O O
, O O
versus O O
18 O O
% O O
of O O
the O O
normal O O
women O O
( O O
P O O
less O O
than O O
0.0050 O O
) O O
. O O

The O O
overall O O
responses O O
to O O
MuMTV B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
and O O
MCF-7 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
analyzed O O
with O O
reference O O
to O O
certain O O
prognostic O O
factors O O
, O O
but O O
showed O O
no O O
relation O O
to O O
age O O
, O O
menstrual O O
status O O
, O O
estrogen O O
receptor O O
status O O
, O O
or O O
stage O O
of O O
disease O O
. O O

The O O
above O O
reactions O O
suggest O O
that O O
a O O
large O O
proportion O O
of O O
breast O O
cancer O O
patients O O
exhibit O O
presensitization O O
to O O
antigenfs O O
found O O
in O O
MuMTV B B_GENE/B_SPECIES[BIO]
and O O
MCF-7 B B_DISEASE/B_VIRUS[BIO]
, O O
which O O
may O O
be O O
cross-reactive O O
with O O
antigens O O
in O O
the O O
primary O O
cancer O O
. O O

On O O
the O O
other O B_PERSON/B_LOCATION
hand O B_PERSON/I_LOCATION
, O O
a O O
significant O B_MEASURE
difference O I_MEASURE
( O O
P O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less O B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O O
0.02 O B_MEASURE
) O O
was O O
found O O
between O O
stage O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
O O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
stage O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
III/IV O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
patients O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
terms O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
in O O
vitro O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O O
[ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uridine O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incorporation O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
human B B_PROTEIN[GENE]/B_LOCATION
TNF I I_PROTEIN[GENE]/I_LOCATION
promoter I I_PROTEIN[GENE]/I_LOCATION
contains O O
four O O
potential O O
nuclear B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
factor-kappa I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
B I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
NF-kappa I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
B I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
) I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
-binding I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
sites I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
with O O
the O O
strongest O O
binding O O
seen O O
for O O
the O O
-605 O O
motif O O
. O O

Stimulation O O
of O O
Mono O O
Mac O O
6 O O
cells O O
with O O
LPS O O
will O O
increase O O
complex B B_LOCATION/B_DISEASE
II I B_LOCATION/I_DISEASE
and O O
will O O
strongly O O
induce O O
a O O
second O O
specific O O
complex O O
( O O
complex B B_LOCATION/B_PERSON
I I I_LOCATION/I_PERSON
) O O
, O O
which O O
represents O O
the O O
p50/65 B B_GENE/B_SEQUENCE[MEASURE]
heterodimer I B_GENE/I_SEQUENCE[MEASURE]
. O O

Treatment O O
of O O
Mono O O
Mac O O
6 O O
cells O O
with O O
pyrrolidine-dithiocarbamate O O
( O O
PDTC O O
) O O
at O O
300 O O
microM O O
will O O
block O O
the O O
LPS-induced B B_GENE/B_LOCATION
complex I I_GENE/I_LOCATION
I I I_GENE/I_LOCATION
almost O O
completely O O
and O O
will O O
reduce O O
complex B B_LOCATION/B_DISEASE
II I B_LOCATION/I_DISEASE
to O O
the O O
constitutive O O
level O O
. O O

Binding O O
activity O O
of O O
other O O
nuclear B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O O
recognize O O
the O O
SP-1 O O
and O O
c/EBP O O
motifs O O
of O O
the O O
human B B_GENE
TNF I I_GENE
promoter I I_GENE
is O O
not O O
affected O O
by O O
such O O
treatment O O
. O O

Secreted O O
TNF B B_DISEASE_ADJECTIVE[DISEASE]
protein I I_DISEASE_ADJECTIVE[DISEASE]
as O O
detected O O
in O O
the O O
Wehi O O
164S/ActD O O
bioassay O O
and O O
in O O
a O O
sandwich O O
immunoassay O O
was O O
similarly O O
reduced O O
by O O
PDTC O O
. O O

These O O
regions O O
are O O
designated O O
YI B B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
amino B B_MEASURE
acids I I_MEASURE
[ I I_MEASURE
aa I I_MEASURE
] I I_MEASURE
1 I I_MEASURE
to I I_MEASURE
25 I I_MEASURE
) O O
, O O
YII B B_PROTEIN[GENE]/B_LOCATION
( O O
aa B B_MEASURE
51 I I_MEASURE
to I I_MEASURE
102 I I_MEASURE
) O O
, O O
and O O
YIII B B_PROTEIN[GENE]/B_LOCATION
( O O
aa B B_MEASURE/B_BIO
228 I I_MEASURE/I_BIO
to I I_MEASURE/I_BIO
245 I I_MEASURE/I_BIO
) O O
. O O

Two O O
of O O
the O O
three O O
regions O O
of O O
the O O
native O O
ZEBRA B B_GENE/B_LOCATION
protein I I_GENE/I_LOCATION
act O O
together O O
to O O
mediate O O
activation O O
when O O
assayed O O
on O O
ZEBRA B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

However O O
, O O
when O O
fused O O
to O O
the O O
DNA B B_GENE/B_LOCATION
binding I I_GENE/I_LOCATION
domain I I_GENE/I_LOCATION
of O O
GAL B B_GENE/B_BACTERIUM[BIO]
4 O O
and O O
assayed O O
on O O
GAL4 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
binding I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sites I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
regions B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
YII I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
and I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
YIII I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
were O O
each O O
sufficient O O
to O O
confer O O
activation O O
in O O
S. O O
cerevisiae O O
. O O

The O O
amino-terminal B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
region I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
ZEBRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
aa B B_PROTEIN[GENE]/B_MEASURE
1 I I_PROTEIN[GENE]/I_MEASURE
to I I_PROTEIN[GENE]/I_MEASURE
98 I I_PROTEIN[GENE]/I_MEASURE
) O O
was O O
required O O
for O O
activation O O
both O O
in O O
S. O O
cerevisiae O O
and O O
in O O
human O O
B O O
cells O O
; O O
deletion O O
of O O
the O O
carboxy-terminal B B_LOCATION/B_GENE
18 I B_LOCATION/I_GENE
aa I B_LOCATION/I_GENE
also O O
significantly O O
reduced O O
activation O O
in O O
both O O
cell O O
types O O
. O O

Thus O O
, O O
the O O
behavior O O
of O O
ZEBRA B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O O
B O O
cells O O
and O O
S. O O
cerevisiae O O
suggests O O
that O O
the O O
protein O O
contains O O
universal B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
activation I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
motifs I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
that O O
interact O O
with O O
conserved O O
components O O
of O O
the O O
transcription O O
machinery O O
. O O

The O O
discordant O O
mutants O O
may O O
reflect O O
interactions O O
with O O
a O O
variable B B_MEASURE/B_LOCATION
domain I I_MEASURE/I_LOCATION
of O O
a O O
conserved O O
component O O
or O O
unique O O
interactions O O
with O O
specialized O O
components O O
of O O
the O O
basal O O
transcription O O
apparatus O O
in O O
different O O
cells O O
. O O

Here O O
we O O
report O O
that O O
both O O
the O O
acidic O O
transcription O O
activation O O
domain O O
mapping O O
to O O
the O O
unique O O
C B B_LOCATION/B_BIO
terminus I I_LOCATION/I_BIO
of O O
chicken B B_GENE
c-Rel I I_GENE
and O O
the O O
F9 B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
cell-specific I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
activation I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
region I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
common O O
to O O
both O O
v-Rel B B_GENE
and O O
c-Rel B B_GENE
interact O O
with O O
the O O
TATA-binding B B_GENE
protein I I_GENE
( O O
TBP B B_GENE/B_LOCATION
) O O
and O O
transcription B B_GENE
factor I I_GENE
IIB I I_GENE
( O O
TFIIB B B_GENE/B_DISEASE
) O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

We O O
also O O
demonstrate O O
that O O
TPB B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
interaction O O
with O O
Rel B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activation I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
regions I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leads O O
to O O
synergistic O O
activation O O
of O O
transcription O O
of O O
a O O
kappa B B_GENE
B-linked I I_GENE
reporter I I_GENE
gene I I_GENE
. O O

Combined O O
with O O
the O O
observation O O
that O O
the O O
mouse B B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
c-Rel I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
and I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
human I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
RelA I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
also O O
interact O O
with O O
TBP B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
TFIIB B B_GENE
in O O
vitro O O
, O O
these O O
results O O
suggest O O
that O O
association O O
with O O
basal B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcription I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factors I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
is O O
important O O
for O O
the O O
transcriptional O O
activities O O
of O O
Rel B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
family I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

p21ras B B_GENE
and O O
calcineurin O O
synergize O O
to O O
regulate O O
the O O
nuclear B B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
factor I B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
activated O O
T O O
cells O O
. O O

In O O
T O O
lymphocytes O O
, O O
triggering O O
of O O
the O O
T B B_GENE
cell I I_GENE
receptor I I_GENE
( O O
TCR B B_LOCATION/B_ORGANIZATION
) O O
induces O O
several O O
signaling O O
cascades O O
which O O
ultimately O O
synergize O O
to O O
induce O O
the O O
activity O O
of O O
the O O
nuclear B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
activated O O
T O O
cells O O
( O O
NFAT O O
) O O
, O O
a O O
DNA B B_GENE
binding I I_GENE
complex I I_GENE
critical O O
to O O
the O O
inducibility O O
and O O
T O O
cell O O
specificity O O
of O O
the O O
T B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interleukin B I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
coexpression O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
activated O O
calcineurin O B_GENE
with O O
activated O O
p21ras O B_GENE
could O O
mimic O O
TCR O B_DISEASE_ADJECTIVE[DISEASE]
signals O I_DISEASE_ADJECTIVE[DISEASE]
in O O
NFAT O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
induction O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

The O O
two O O
major O O
types O O
and O O
their O O
principal O O
products O O
, O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
4 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
interferon B B_MEASURE
gamma I I_MEASURE
( O O
IL-4 B B_GENE
and O O
IFN-gamma B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
are O O
reciprocally O O
negatively O O
interactive O O
. O O

IL-4 B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
pretreatment O O
of O O
Jurkat O O
cells O O
prior O O
to O O
stimulation O O
resulted O O
in O O
a O O
decrease O O
in O O
transcription O O
of O O
the O O
IL2 B B_GENE
gene I I_GENE
. O O

Using O O
enhancer-reporter B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constructs I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IL-4 B B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O O
down-regulated O O
the O O
NFIL-2B B B_GENE
element I I_GENE
. O O

These O O
results O O
suggest O O
that O O
IL-4 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
regulate O O
development O O
and O O
function O O
of O O
T-cell O O
subsets O O
involved O O
in O O
cell-mediated O O
immunity O O
in O O
part O O
by O O
inhibiting B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
factors I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
required O O
for O O
transcription O O
of O O
the O O
IL2 B B_GENE
gene I I_GENE

We O O
have O O
explored O O
the O O
possibility O O
of O O
using O O
antibodies B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O O
purified O O
rat O O
liver O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
to O O
study O O
the O O
immunochemical O O
properties O O
of O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptors I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
from O O
murine O O
and O O
human O O
malignant O O
lymphocytes O O
. O O

For O O
this O O
purpose O O
, O O
purified B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
immune I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
immunoglobulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
G I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
covalently O O
linked O O
to O O
Sepharose B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
CL-4B I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Whereas O O
the O O
immunoaffinity O O
column O O
retained O O
70 O O
to O O
84 O O
% O O
of O O
the O O
58- O O
to O O
62-A O O
( O O
Stokes O O
radius O O
) O O
[ B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3H I B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
] I B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
triamcinolone I B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
acetonide-receptor I B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
complexes I B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
characteristic O O
of O O
the O O
CS O O
mouse O O
and O O
human O O
lymphocytes O O
, O O
it O O
failed O O
to O O
recognize O O
the O O
27- O O
to O O
28-A O O
( O O
Stokes O O
radius O O
) O O
glucocorticoid B B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I B_GENE/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
present O O
in O O
corticoid-resistant O O
mouse O O
lymphoma O O
P1798 O O
cells O O
. O O

In O O
leukocyte O O
population O O
freshly O O
isolated O O
from O O
the O O
blood O O
of O O
26 O O
patients O O
with O O
acute O O
leukemia O O
, O O
we O O
have O O
measured O O
several O O
parameters O O
including O O
glucocorticoid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
nucleoside O O
incorporation O O
, O O
percentage O O
of O O
cells O O
in O O
S O O
phase O O
, O O
and O O
steroid-induced O O
cell O O
lysis O O
. O O

The O O
association O B_MEASURE
constant O I_MEASURE
characterising O O
the O O
binding O B_GENE/B_MEASURE
of O O
cortisol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
cytosol O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
was O O
KA O B_LOCATION/B_PROTEIN[GENE]
= O O
3.5 O B_MEASURE
. O O
10 O B_MEASURE
( O O
9 O B_MEASURE
) O O
l/mol O B_MEASURE/B_BIO
. O O

The O O
apparent O O
paradox O O
of O O
heightened O O
adrenal O O
corticosteroid O O
levels O O
associated O O
with O O
reduction O O
in O O
the O O
competence O O
of O O
the O O
body O O
's O O
defensive O O
apparatus O O
to O O
cope O O
with O O
exposure O O
to O O
new O O
microbial B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigens I I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
considered O O
. O O

The O O
suggestion O O
is O O
offered O O
that O O
the O O
immunologic O O
response O O
to O O
self-antigens B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
exposed O O
by O O
disease O O
or O O
trauma O O
may O O
be O O
suppressed O O
by O O
corticosteroid O O
to O O
offset O O
the O O
likelihood O O
of O O
autoimmune O O
attack O O
. O O

Bacterial O O
LPS O O
induce O O
production O O
of O O
cytokines B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
such O O
as O O
IL-1 B B_GENE
, O O
IL-6 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
TNF B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
mononuclear O O
phagocytes O O
, O O
and O O
this O O
represents O O
a O O
central O O
component O O
in O O
the O O
pathogenesis O O
of O O
septic O O
shock O O
syndrome O O
. O O

It O O
is O O
shown O O
that O O
LPS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O O
a O O
12- O B_NUMBER[MEASURE]
to O O
16-fold O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
IL-1 O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
IL-6 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
TNF-alpha O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mRNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
this O O
was O O
completely O O
or O O
more O B_MEASURE
than O O
80 O B_TIME[MEASURE]/B_LOCATION
% O I_TIME[MEASURE]/I_LOCATION
blocked O O
by O O
the O O
protein O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
tyrosine O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
kinase O O
specific O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
herbimycin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
A O O
and O O
genistein O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O O
the O O
concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
1.7 O B_MEASURE
and O O
37 O B_MEASURE
microM O I_MEASURE
, O O
respectively O O
. O O

In O O
this O O
report O O
we O O
show O O
that O O
lipopolysaccharide O O
( O O
LPS O O
) O O
-induced O O
activation O O
of O O
B O O
or O O
pre-B O O
cells O O
results O O
in O O
loss O O
of O O
I B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kappa I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
NF-kappa B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
B I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
complexes I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
vivo O O
. O O

Some O O
liberated B B_LOCATION/B_ORGANIZATION
dimers I I_LOCATION/I_ORGANIZATION
were O O
retained O O
in O O
the O O
cytoplasm O O
, O O
however O O
, O O
through O O
binding O O
to O O
newly O O
synthesized O O
I B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kappa I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
B I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
a O O
finding O O
which O O
strongly O O
suggests O O
( O O
i O O
) O O
that O O
the O O
LPS-induced O O
signal O O
causes O O
dissociation O O
of O O
complexes O O
rather O O
than O O
preventing O O
their O O
association O O
and O O
( O O
ii O O
) O O
that O O
dissociation O O
results O O
from O O
modification O O
of O O
I B B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
not O O
of O O
c-rel B B_GENE
or O O
p65 B B_GENE
. O O

In O O
view O O
of O O
the O O
homology O O
between O O
the O O
NF-P B B_GENE/B_MEASURE
motif I I_GENE/I_MEASURE
and O O
other O O
Ets B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
proto-oncoprotein-binding I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
sites I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
it O O
is O O
postulated O O
that O O
NF-P1 B B_GENE
and O O
NF-P2 B B_GENE
belong O O
to O O
the O O
Ets B B_GENE/B_MEASURE
protein I I_GENE/I_MEASURE
family I I_GENE/I_MEASURE
. O O

The O O
role O O
of O O
NF-kappa B B_GENE
B1 I I_GENE
( I I_GENE
p50/p105 I I_GENE
) I I_GENE
gene I I_GENE
expression O O
in O O
activation O O
of O O
human O O
blood O O
T-lymphocytes O O
via O O
CD2 B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
CD28 I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
adhesion I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
transcription B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
NF-kappa I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
B I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
participates O O
in O O
the O O
regulation O O
of O O
both O O
IL-2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
IL-2R I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
as O O
well O O
as O O
multiple B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
cellular I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
genes I I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
involved O O
in O O
T-cell O O
proliferation O O
. O O

We O O
observed O O
a O O
transient O B_NUMBER[MEASURE]/B_LOCATION
4- O I_NUMBER[MEASURE]/I_LOCATION
to O O
5-fold O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
NF-kappa O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B1 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
expression O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
at O O
both O O
the O O
mRNA O B_GENE
and O O
protein O B_GENE
levels O I_GENE
, O O
lasting O O
for O O
at O O
least O O
24 O B_MEASURE
h O O
. O O

p50 O O
DNA-binding O B_GENE
activity O I_GENE
apparently O O
stays O O
highly O O
controlled O O
when O O
p105 O O
expression O B_GENE
is O O
enhanced O O
by O O
a O O
physiological O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
stimulus O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
peripheral O B_DISEASE/B_GENE
blood O I_DISEASE/I_GENE
T-cells O I_DISEASE/I_GENE
. O O

VDR O B_GENE
concentration O I_GENE
in O O
resting O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
not O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
three O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
represented O O
constitutive O B_DISEASE_ADJECTIVE[DISEASE]
receptor O I_DISEASE_ADJECTIVE[DISEASE]
expression O I_DISEASE_ADJECTIVE[DISEASE]
of O O
monocytes O B_GENE
. O O

Proliferation O B_MEASURE/B_GENE
, O O
as O O
assessed O O
from O O
[ O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
3H O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
] O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
thymidine O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
incorporation O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O O
inversely O O
correlated O O
with O O
serum O B_MEASURE/B_BIO
1 O I_MEASURE/I_BIO
, O O
25 O B_MEASURE
( O O
OH O B_LOCATION/B_PROTEIN[GENE]
) O O
2D3 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O O
was O O
significant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
R O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O O
-0.299 O B_MEASURE
, O O
p O O
= O O
0.048 O B_MEASURE
) O O
. O O

Influence O O
of O O
sex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
serum B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
albumin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O O
the O O
conversion O O
of O O
androstenedione O O
to O O
testosterone O O
by O O
human O O
erythrocytes O O
. O O

The O O
influence O O
of O O
human B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
serum I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
albumin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
sex B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
globulin I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
SHBG B B_GENE
) O O
on O O
the O O
enzymic O O
conversion O O
of O O
androstenedione O O
to O O
testosterone O O
in O O
human O O
erythrocytes O O
was O O
investigated O O
in O O
vitro O O
. O O

Recently O O
a O O
2- O O
to O O
3-fold O O
increase O O
in O O
the O O
number O O
of O O
glucocorticoid B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O O
peripheral O O
lymphocytes O O
has O O
been O O
noted O O
after O O
in O O
vitro O O
mitogen O O
stimulation O O
. O O

Despite O O
a O O
50 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
increase O I_MEASURE/I_LOCATION
in O O
the O O
number O B_MEASURE
of O O
glucocorticoid O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
receptor O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
sites O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
per O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
the O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
the O O
homolateral O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
controlateral O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
lymph O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
nodes O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
equally O O
sensitive O B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
inhibitory O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
effects O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O O
dexamethasone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
determined O O
by O O
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
incorporation O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
radiolabeled O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
precursors O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
protein O B_GENE/B_BACTERIUM[BIO]
, O O
RNA O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O O
and O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
or O O
measurements O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
in O O
vitro O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cell O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
survival O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Contrary O O
to O O
the O O
widely O O
held O O
view O O
that O O
mitogen-stimulated O O
cells O O
become O O
insensitive O O
to O O
glucocorticoids O O
, O O
our O O
experiments O O
show O O
that O O
with O O
respect O O
to O O
inhibition O O
of O O
thymidine O O
and O O
uridine O O
incorporation O O
and O O
glucose O O
uptake O O
, O O
the O O
cells O O
are O O
highly O O
sensitive O O
to O O
dexamethasone O O
at O O
24 O O
, O O
48 O O
, O O
and O O
72 O O
h O O
after O O
stimulation O O
with O O
concanavalin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
A I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
reliable O O
procedure O O
is O O
described O O
for O O
isolating O O
3H-triamcinolone B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acetonide I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
3H-TA I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
complexes I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
from O O
purified O O
chronic O O
lymphatic O O
leukemia O O
( O O
CLL O O
) O O
lymphocyte O O
nuclei O O
, O O
based O O
on O O
the O O
use O O
of O O
carbobenzoxy-L-phenylalanine O O
( O O
CBZ-L-phe O O
) O O
to O O
prevent O O
breakdown O O
of O O
hormone-receptor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
during O O
extraction O O
of O O
nuclei O O
with O O
0.6M O O
KCl O O
. O O

No O O
correlation O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
found O O
between O O
levels O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
nuclear-associated O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3H-TA O I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
peripheral O B_DISEASE_ADJECTIVE[DISEASE]
white O I_DISEASE_ADJECTIVE[DISEASE]
blood O I_DISEASE_ADJECTIVE[DISEASE]
cell O I_DISEASE_ADJECTIVE[DISEASE]
count O I_DISEASE_ADJECTIVE[DISEASE]
or O O
rosetting O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
circulating O O
lymphocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Analysis O O
of O O
de O O
novo O O
gene O O
activation O O
in O O
multinucleated O O
heterokaryons O O
has O O
shown O O
that O O
the O O
differentiated O O
state O O
, O O
although O O
stable O O
, O O
is O O
not O O
irreversible O O
, O O
and O O
can O O
be O O
reprogrammed O O
in O O
the O O
presence O O
of O O
appropriate O O
combinations O O
of O O
trans-acting B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
regulatory I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
molecules I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
have O O
tested O O
whether O O
breakdown O O
of O O
phosphatidylcholine O O
( O O
PC O O
) O O
initiated O O
by O O
exogenous O O
addition O O
of O O
a O O
PC-specific B B_ENZYME[GENE]/B_DISEASE
phospholipase I I_ENZYME[GENE]/I_DISEASE
C I I_ENZYME[GENE]/I_DISEASE
( O O
PC-PLC B B_LOCATION/B_ORGANIZATION
) O O
from O O
Bacillus O O
cereus O O
or O O
by O O
endogenous O O
overexpression O O
of O O
PC-PLC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
induces O O
functional O O
activation O O
of O O
NF-kappa B B_GENE
B I I_GENE
and O O
increases O O
human B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
immunodeficiency I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
virus I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
HIV I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
enhancer I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O O
. O O

Induction O O
of O O
NF-kappa B B_GENE/B_DISEASE
B I B_GENE/I_DISEASE
by O O
PC-PLC B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
not O O
depend O O
on O O
de O O
novo O O
synthesis O O
of O O
proteins O O
or O O
autocrine O O
secretion O O
of O O
either O O
tumor B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
interleukin B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
human O O
monocytic O O
and O O
lymphoblastoid O O
T-cell O O
lines O O
, O O
induction O O
of O O
NF-kappa B B_GENE
B I I_GENE
by O O
PC-PLC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
resulted O O
in O O
clear O O
induction O O
of O O
luciferase B B_GENE
expression O O
vectors O O
placed O O
under O O
the O O
control O O
of O O
synthetic B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhancers I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
wild O O
type O O
, O O
but O O
not O O
kappa O O
B-mutated O O
, O O
HIV B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
long I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
terminal I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
repeat I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
constructs I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

HIV O O
replication O O
was O O
increased O O
by O O
PC-PLC B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
chronically O O
infected O O
monocytes O O
and O O
T O O
lymphocytes O O
. O O

Interaction O O
of O O
IL-2 B B_GENE
with O O
its O O
high B B_GENE
affinity I I_GENE
membrane I I_GENE
receptor I I_GENE
complex I I_GENE
( O O
IL-2R B B_LOCATION/B_ORGANIZATION
) O O
present O O
on O O
activated O O
T O O
lymphocytes O O
induces O O
cell O O
proliferation O O
and O O
mediates O O
effector O O
functions O O
. O O

In O O
addition O O
, O O
Scatchard O O
plot O O
analysis O O
of O O
125I-labeled B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IL-2 I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
Dex O O
did O O
not O O
affect O O
the O O
binding O O
of O O
IL-2 B B_GENE
, O O
thus O O
suggesting O O
that O O
inhibition O O
is O O
due O O
to O O
a O O
postreceptor O O
effect O O
. O O

The O O
relationship O B_PERSON/B_MEASURE
between O O
human O B_DISEASE/B_VIRUS[BIO]
immunodeficiency O B_DISEASE/I_VIRUS[BIO]
virus O B_DISEASE/I_VIRUS[BIO]
type O B_DISEASE/I_VIRUS[BIO]
1 O B_DISEASE/I_VIRUS[BIO]
( O O
HIV-1 O B_DISEASE
) O O
infection O B_DISEASE/B_GENE
and O O
the O O
induction O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
NF-kappa O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
binding O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
activity O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
examined O O
in O O
a O O
myeloid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cell O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
HIV-1 O B_DISEASE
infection O I_DISEASE
derived O O
from O O
the O O
PLB-985 O O
cell O B_DISEASE/B_ORGANIZATION
line O I_DISEASE/I_ORGANIZATION
. O O

Chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infection O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
PLB-985 O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
led O O
to O O
increased O O
monocyte-specific O B_GENE/B_DISEASE
surface O B_GENE/I_DISEASE
marker O B_GENE/I_DISEASE
expression O B_GENE/I_DISEASE
, O O
increased O O
c-fms O B_DISEASE/B_GENE
gene O I_DISEASE/I_GENE
transcription O I_DISEASE/I_GENE
, O O
and O O
morphological O B_DISEASE_ADJECTIVE[DISEASE]
alterations O I_DISEASE_ADJECTIVE[DISEASE]
consistent O I_DISEASE_ADJECTIVE[DISEASE]
with O O
differentiation O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
along O O
the O O
monocytic O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
pathway O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

PLB-IIIB O O
cells O O
displayed O O
a O O
constitutive O O
NF-kappa O O
B-like O O
binding O O
activity O O
that O O
was O O
distinct O O
from O O
that O O
induced O O
by O O
tumor B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alpha I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O O
phorbol O O
12-myristate O O
13-acetate O O
treatment O O
of O O
the O O
parental O O
PLB-985 O O
cell O O
line O O
. O O

This O O
unique O O
DNA O O
binding O O
activity O O
consisted O O
of O O
proteins O O
of O O
70 B B_MEASURE/B_PROTEIN[GENE]
, I I_MEASURE/I_PROTEIN[GENE]
90 I I_MEASURE/I_PROTEIN[GENE]
, I I_MEASURE/I_PROTEIN[GENE]
and I I_MEASURE/I_PROTEIN[GENE]
100 I I_MEASURE/I_PROTEIN[GENE]
kDa I I_MEASURE/I_PROTEIN[GENE]
with O O
a O O
high O O
degree O O
of O O
binding O O
specificity O O
for O O
the O O
NF-kappa B B_PROTEIN[GENE]/B_LOCATION
B I I_PROTEIN[GENE]/I_LOCATION
site I I_PROTEIN[GENE]/I_LOCATION
within O O
the O O
PRDII B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
domain I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
beta B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Virus O O
infection O O
does O O
not O O
appear O O
to O O
alter O O
the O O
amount O O
of O O
RelA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
p65 B B_GENE/B_MEASURE
) O O
or O O
NFKB1 B B_GENE
( O O
p50 B B_MEASURE
) O O
but O O
rather O O
affects O O
the O O
capacity O O
of O O
I B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kappa I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
sequester O O
RelA B B_GENE
( I I_GENE
p65 I I_GENE
) I I_GENE
, O O
therefore O O
leading O O
to O O
constitutive O O
levels O O
of O O
RelA O O
DNA O O
binding O O
activity O O
and O O
to O O
increased O O
levels O O
of O O
NF-kappa O O
B-dependent O O
gene O O
activity O O
. O O

The O O
virally O O
induced O O
90- B B_GENE
to I I_GENE
100-kDa I I_GENE
proteins I I_GENE
have O O
a O O
distinct O O
binding O O
specificity O O
for O O
the O O
PRDII B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
domain I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
an O O
AT-rich B B_GENE/B_LOCATION
sequence I I_GENE/I_LOCATION
but O O
do O O
not O O
cross-react O O
with O O
NF-kappa O O
B O O
subunit-specific O O
antisera O O
directed O O
against O O
NFKB1 B B_GENE
( O O
p105 B B_MEASURE/B_GENE
or O O
p50 B B_MEASURE
) O O
, O O
NFKB2 B B_GENE
( O O
p100 B B_MEASURE/B_GENE
or O O
p52 B B_GENE/B_MEASURE
) O O
, O O
RelA B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
p65 B B_GENE/B_DISEASE
) O O
, O O
or O O
c-rel B B_GENE
. O O

Presence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
estrogen-binding O O
sites O B_LOCATION/B_BIO
on O O
macrophage-like O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synoviocytes O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
CD8+ O B_GENE
, O O
CD29+ O B_GENE/B_DISEASE
, O O
CD45RO+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
in O O
normal O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
rheumatoid O B_DISEASE/B_LOCATION
synovium O I_DISEASE/I_LOCATION
. O O

To O O
study O O
the O O
presence O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
estrogen-binding O O
sites O B_LOCATION/B_BIO
( O O
EBS O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
in O O
the O O
synovial O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
tissues O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
male O B_PERSON
and O O
female O B_PERSON
patients O I_PERSON
with O O
rheumatoid O B_DISEASE
arthritis O I_DISEASE
( O O
RA O B_LOCATION/B_ORGANIZATION
) O O
and O O
in O O
age- O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O O
sex-matched O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
healthy O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
controls O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Both O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
1 O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O O
high O B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
affinity O B_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
, O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
binding O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
capacity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O O
and O O
type O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
2 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
reduced O O
affinity O B_GENE/B_MEASURE
, O O
higher O B_DISEASE_ADJECTIVE[DISEASE]
binding O I_DISEASE_ADJECTIVE[DISEASE]
capacity O I_DISEASE_ADJECTIVE[DISEASE]
) O O
EBS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O O
investigated O O
in O O
both O O
soluble O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
and O O
nuclear O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
fractions O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
of O O
homogenized O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synovial O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissue O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
a O O
dextran-coated O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
charcoal O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

To O O
determine O O
what O O
type O O
of O O
synovial O O
cell O O
was O O
positive O O
for O O
EBS O O
, O O
cryosections O O
of O O
synovial O O
tissues O O
were O O
immunostained O O
with O O
a O O
specific O O
monoclonal B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti-estrogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibody I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
anti-ER B B_LOCATION/B_ORGANIZATION
MAb I I_LOCATION/I_ORGANIZATION
) O O
using O O
both O O
immunofluorescence O O
and O O
immunoperoxidase O O
techniques O O
. O O

Double O O
immunostaining O O
with O O
the O O
anti-ER B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MAb I B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
with O O
specific B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
MAb I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
detect O O
different O O
macrophage B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
antigens I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Ber-MAC3 B B_GENE
, O O
MAC387 B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
CD68 B B_GENE
) O O
and O O
CD8+ O O
T O O
cell O O
subsets O O
( O O
CD29+ O O
, O O
CD45RO+ O O
and O O
CD29- O O
, O O
CD45RO- O O
) O O
was O O
performed O O
. O O

Immunostaining O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O O
the O O
estrogen O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
receptor-positive O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
the O O
macrophage-like O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synoviocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
CD8+ O B_GENE/B_PERSON
, O O
CD29+ O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
T O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
both O O
in O O
RA O B_DISEASE/B_LOCATION
and O O
in O O
control O B_DISEASE/B_PROTEIN[GENE]
synovial O B_DISEASE/I_PROTEIN[GENE]
tissues O B_DISEASE/I_PROTEIN[GENE]
. O O

Higher O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nuclear O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
content O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
EBS O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
more O O
intense O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
nuclear O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
staining O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
synoviocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
T O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

It O O
is O O
conceivable O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
that O O
the O O
immunomodulatory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exerted O O
by O O
estrogens O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O O
at O O
least O O
partly O O
mediated O O
through O O
their O O
interaction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O O
EBS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
that O O
are O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O O
macrophage-like O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synoviocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
functioning O O
as O O
antigen-processing O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
antigen-presenting O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
, O O
and O O
on O O
antigen-experienced O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
memory O B_DISEASE_ADJECTIVE[DISEASE]
) O O
CD8+ O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
T O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
lymphocytes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
( O O
CD29+ O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
CD45RO+ O B_GENE/B_LOCATION

